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Abstract
Chronic heart failure (CHF) is an increasingly commoncondition. Over the past 10
years the treatment options for heart failure have improved dramatically however
despite this many patients remain significantly limited. A proportion of these patients
suffer from dyssynchronous ventricular contractions, which lead to further limitation
in cardiac function and neurohormalstimulation causing increased symptoms and a
worse prognosis. Cardiac resynchronisation therapy (CRT) has been shownto be of
benefit in this patient group and leadsto a significant improvement in morbidity and
mortality. This thesis uses non-invasive methods of measuring functional capacity to
investigate several hypothesesin patients suitable for CRT.
The first study evaluated the longitudinal impact of CRT on functional capacity,
haemodynamic measures and skeletal muscle function in 40 patients. The study
showed cardiopulmonary exercise testing could be safely performed in patients
suitable for CRT. It was found that CRT led to significant improvements in
symptomatic status, aerobic exercise capacity and cardiac pumping capability. The
improvements in most measures were significant 2 weeks after CRT and were
maintained untill 3 months. Despite the significant improvements there was no
significant changes in peak skeletal muscle function or anaerobic exercise capacity.
The second study was performed in 50 patients to assess whether exercise training in
addition to CRT could lead to further improvements. The subjects were followed for 3
months following CRT implantation and then randomisedto either a exercise training
or a control group. Three months following CRT there were significant improvements
in exercise capacity and exercise haemodynamic measures. However there was no
significant change in peak skeletal muscle function. The addition of exercise training
led to further improvements in exercise capacity, exercise haemodynamic measures
and also peak skeletal muscle function. The control group did not showsignificant
changes during this period. The results from this study allow us to achieve the
maximum patient benefit following CRT throughthe addition of exercise training.
The third study was designed to assess the effectiveness of surgically placed CRT in
23 patients with unsuccessful transvenous placement. The results were compared to a
control group with successful transvenous CRT. This study showedthat both groups
showedsimilar significant improvements at 6 months. The improvement was delayed
and of a smaller magnitude in the mini thoracotomy group. Therefore while CRT via
a mini thoracotomyis a viable option for patients it could not be regarded asa first
line option.
The findings from this thesis help to improve our understanding of the mechanisms
behind improvements following CRT and will allow us to maximise the benefit for
patients following CRT. This information can be used to help clinical decision-
making and improvethe quality of care provided in the future.
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CHAPTER1: INTRODUCTION
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1.1 Congestive cardiac failure
1.1.1 Epidemiology
Chronic heart failure (CHF) is an increasingly common condition, which has now
reached epidemic proportions. In the United kingdom heart failure affects between 1-
3% of the general population (Davieset al., 2001;McMurray and Stewart, 2002) and
increases with age to affect 10% of those over 70 (McMurray and Stewart, 2002).
This represents only those patients who are symptomatic. In a population based study
in England it was shown that the prevalence of left ventricular (LV) systolic
dysfunction (defined as an ejection fraction (EF) <40%) in patients aged 45 years and
above was 1.8%, and of these 47% had no symptoms (Davieset al., 2001). As the
population ages and survival from ischaemic heart disease improvesthe prevalence is
likely to increase further. In a simulation model it was shownthat between 1985 and
2010 there was likely to be a 70% increase in absolute numbers of heart failure
patients (Bonneuxet al., 1994). This hypothesis has been shownto be accurate in a
long term study of the Framingham cohort. In this study the 5 year event rate was
calculated following a myocardial infarction. The authors showed that the overall
rate of chronic heart failure and death combined had stayed similar from 1970 to
1999 (p=0.25). This has occurred as the rate of death following a MI has
significantly reduced in that time (p<0.0001) whilst the risk of developing heart
failure has significantly increased (p=0.02)(see table 1.1) (Velagaleti et al., 2008).
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Table 1.1: Long term trends in chronic heartfailure following myocardial infarction (adapted
from “Long-term trendsin the incidence of heart failure after myocardial infarction” Velageleti
et al Circulation 2008)
5-Year events (including 30-day 1970-1979 1980-1989 1990-1999 pp for
events) Trend
Chronic heart Failure (CHF)
No.of events/No. at risk (%) 45/230(19.6) 54/251 (21.5) 66/195 (33.9) 0.02
Death without CHF
No. of events/No.at risk (%) 66/230 (28.7) 47/251 (18.7) 26/195 (13.3) <0.01
CHFordeath
No. of events/No.at risk (%) 111/230 (48.3) 101/251 (40.2) 92/195 (47.2) 0.25
 
1.1.2 Aetiology
The most common cause of chronic heart failure has changed over the past five
decades. In the Framingham study the most common aetiology of chronic heart
failure was hypertension. Hypertension (HT) preceded almost 75% of all cases of
chronic heart failure whereas coronary artery disease (CAD) not accompanied by
hypertension was only responsible for 10% of cases. Other causes identified were
rheumatic heart disease (RHD)and a miscellaneous group including congential heart
disease, thyrotoxic heart disease, atrial fibrillation and inherited cardiomyopathies
(see figure 1.1) (McKeeetal., 1971). Levy et al assessed the temporal trends in the
incidence of heart failure over a 40 year period spanning 1950-1990. They showed
no change in annual incidence of cardiac failure in men over that period but showed
a 30-40% decline in annual incidence in womenoverthat period. The explanation for
this was that the most common aetiology in men was CAD and the improved
survival from acute myocardial infarction due to thrombolysis and revascularisation
treatments means that there are more people highly susceptible to cardiac failure. In
womenthe most commonaetiology was hypertension and whilst this was a common
cause in the 1950’s medical therapy has declined its importance by the 1990’s (Levy
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et al., 2002). In one British study from the 1990’s only 6% of cases of heart failure
were secondary to hypertension whereas 41% were secondary to CAD (Sutton, 1990)
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Figure 1.1: Aetiology of chronic heart failure in the Framingham study (adapted from “The
naturalhistory of congestive heart failure” Mckee et al NEJM 285(26): 1441-1446)
1.1.3 Pathophysiology of cardiac failure
Chronic heart failure is a progressive syndromethat starts with a left ventricular
insult and progresses at variable speed to end stage cardiac failure. The
pathophysiology behind this progression has been widely described and treatments
aimed at modifying the neurohormonal adaptations have been shownto significantly
improve the outcomein patients with heart failure. The initial insult leading to left
ventricular dysfunction can be varied and include myocardial infarction,
inflammatory myocardial disease and chronic volume or pressure overload. This
initial insult increases myocardial wall stress which has a major impact on the
expression of local neuroendocrine systems such as the renin angiotensin
aldsosterone system. Wall stress also causes a change in baroreceptor mechanisms
that impact on the sympathetic parasympathetic balance leading to sympathetic
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activation and therefore peripheral vasoconstriction. Sympathetic induced
vasoconstriction potentially causes endothelial dysfunction, vascular smooth muscle
proliferation and ischaemia. Simultaneously the increased expression of angiotensin
II, via the renin angiotensin aldsoterone system, has been shown to trigger myocyte
apoptosis (Tan et al., 1991) leading to myocardial thinning anddilation. The above
mechanisms cause “forward failure” leading to reduced organ function and
“backward failure” leading to oedema and pulmonary congestion (see figure 1.2)
(Bohm et al., 2003). The deleterious effects of over activation of the renin
angiotensin and the sympathetic nervous systems are the main mechanisms by which
the clinical syndrome of heart failure develops. Therefore these are the main target
for the medical managementofheart failure.
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Figure 1.2: The progression from left ventricular dysfunction to advanced heart failure
(adapted from Mechanisms contributing to the progression of left ventricular dysfunction to
end-stage heart failure Bohm et al EHJ Suppl 2003 5(1);114-21)
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1.1.4 Presentation and Morbidity
Unlike most cardiovascular condition cardiac failure is becoming a more common
condition over time. Currently improved survival from CAD has meantthat there are
nearly 1 million new cases diagnosed annually worldwide. This makes cardiac
failure the most rapidly growing cardiovascular disorder. Cardiac failure impairs
quality of life significantly, in multiple surveys it has been shownthat cardiac failure
impairs quality of life more than almost any other chronic medical problem
(McMurray and Stewart, 2002). The medical outcomes study (Stewart et al., 1989)
showedthat self reported quality of life was more impaired by heart failure than by
hypertension, diabetes, arthritis, chronic lung disease or angina. In another study
nearly half of all the patients with heart failure felt that their quality of life was so
poor that they would be willing to trade at least half of their remaining life
expectancyin orderto feel better (Lewis etal., 2001).
1.1.5 Progression and Mortality
In the last decade there have been many advancesin the pharmacological treatment
of heart failure, however the condition continues to exact a heavy burdenin terms of
mortality and morbidity (Cleland et al., 1999). Death due to heart failure may be
sudden (usually arrhythmic) or due to progressive heart failure with gradual
deterioration in symptoms (MERIT-HF Study Group, 1999). The 1-year mortality
has been shownto increase with worsening symptomatic heart failure from 5-15%
for NYHA class II and 20-50% for class III to >50% for class IV (Uretsky and
Sheahan, 1997;Stellbrink et al., 1999a;Farwell et al., 2000). Despite advancesin the
treatments available around 38% of patients diagnosed with heart failure die within a
year of diagnosis (Cowieet al., 2000). The 5-year mortality following the diagnosis
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of heart failure has remained approximately 50% (McKeeetal., 1971;Johnson and
Palacios, 1982;Levy et al., 2002) and is therefore similar to those from cancerof the
colon, and worse than those from cancer of the breast or prostate (Quinn etal.,
2001).
Long term follow up data from the Framingham study has shownthat whilst there
has been improvementin survival from heart failure in both men and womensince
the 1950 the 5 year survival wasstill less than 50% (see figure 1.3) (Levy et al.,
2002). In the UK heart failure has been reported to consume more than 2.5% ofthe
total health care expenditure (McMurray and Stewart, 2002). With such continued
impact from heart failure we require new modes of treatment in addition to those
currently available to improve mortality and morbidity.
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Figure 1.3: Temporal trendsin survival from heart failure (adapted from “Long-term trends in
the incidence of and survival with heart failure” Levy D NEJM,v. 347, no. 18, p. 1397-1402)
1.1.6 Assessment of cardiac failure
Heart failure is primarily a clinical diagnosis. Patients with heart failure may have a
number of symptoms, the most common being breathlessness, fatigue, exercise
intolerance, and fluid retention. The degree of exertion required to elicit symptoms
such as breathlessness is used to grade the severity of symptoms into one of four
functional classes (New York heart association (NYHA)classes see Table 1.2) (New
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York Heart Association Criteria Committee, 1979). There is a close relationship
between NYHAclass and mortality. Ahmed et al showedthat as patients functional
class worsened so did their prognosis (see figure 1.4) (Ahmedetal., 2006). However
none of the symptoms discussed aboveis specific to heart failure, and several other
disorders may present in a similar manner. Therefore, symptoms alone cannot be
relied upon to make the diagnosis which depends upon a combination of good
clinical skills with history taking and physical examination, supplementedbytests.
Table 1.2:NYHAclassification (adapted from Nomenclature andcriteria for diagnosis of
disease of the heart and greatvessels, criteria committee of the New Yorkheart association
1979.)
 
I No limitations. Ordinary physical activity does not cause fatigue, breathlessness or
palpitation. (Asymptomatic left ventricular dysfunction is included in this category.)
Slightlimitation of physical activity. Such patients are comfortable at rest. Ordinary
 
ul physicalactivity results in fatigue, palpitation, breathlessness or angina pectoris
(symptomatically ‘mild’ heart failure).
Wt Markedlimitation of physicalactivity. Although patients are comfortable at rest, less
than ordinary physical activity will lead to symptoms (symptomatically ‘moderate’
heart failure).
IV Inability to carry on any physical activity without discomfort. Symptoms of congestive
cardiac failure are present evenat rest. With any physical activity increased discomfort
is experienced (symptomatically ‘severe’ heart failure). 
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Figure 1.4: NYHA class and mortality (adapted from "Higher New York heart association
classes and increased mortality and hospitalization in patients with heart failure" AhmedA etal
Am Heart J 151(2): 444-450.)
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There are multiple guidelines on the ideal diagnostic path to an accurate diagnosis of
heart failure. The diagnosis of heart failure is initially suspected on clinical grounds.
Oncethere is a suspicion of a diagnosis of heart failure the ideal first two tests are a
12 lead electrocardiogram and measurement of Brain Natriuretic Peptide (BNP) or N
terminal pro-Brain Natriuretic peptide (NT-proBNP). A diagnosis of heart failure is
very unlikely in a patient with a normal ECG and a normal plasma concentration of
BNP or NT-proBNP, given the high sensitivity of these tests (Cowie et al., 2003).
Normalresults in both tests may therefore indicated that alternative diagnoses need
to be considered. If either of these tests is abnormal then a heart failure diagnosis is
possible however neither of these tests is a 100% sensitive and therefore further
investigation is warranted.
The current gold standardtest is a transthoracic echocardiographic examination. This
can, in the hands of a good operator, provide detailed views of the heart andleft
ventricular systolic function (ejection fraction (EF)) can be assessed with either the
“eyeball” method or by using mathematical models such as the apical biplane
formulae. The latter uses a Simpsons rule assumption based on stacked disks to
calculate ejection fraction (Otto, 2004). If there is reduction in ejection fraction seen
then the combination of an abnormal echocardiogram, symptomsandsigns of heart
failure and abnormal ECG and BNP measurementprovides strong evidence towards
a diagnosis ofheart failure. In people whose transthoracic echocardiographic window
is poor alternative imaging modalities should be considered including
transoesophageal echocardiogram, cardiac magnetic resonance imaging (MRI) and
multi gated acquisition (MUGA)scan (full algorithm shownin figure 1.5) (National
Institute for Clinical Excellence, 2003)
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Suspected heart failure
because ofhistory, symptoms, and
signs  
 
-
Seek to exdude heart failure
through:
* 12-lead ECG
* and/or natriuretic peptides
(BNP or NTproBNP) - where
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Other recommended tests:
(mostly to exclude other
conditions)
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Blood tests: U&Es, creatinine, FBC,
TFTs, LFTs, glucose, and lipids
Urinalysis, peak flow or spirometry  
 Ww Vv
Both normal-
heart failure unlikely
consider alternative diagnosis 
 Oneor more abnormal  
 ww
 Imaging by echocardiography*    v ww No abnormality detected
Heart failure unlikely, but if
diagnostic doubt persists consider
diastolic dysfunction and consider
referral for specialist assessment  
resonance imaging 
 
Abnormal
Assess heart failure severity,
aetiology, precipitating and
exacerbating factors and type of
cardiac dysfunction
Correctable causes must be
identified
Considerreferral  
* Alternative methods of imaging the heart should be considered when a poor imageis
produced bytransthoracic Doppler 2D echocardiography — alternatives include
transoesophageal Doppler 2D echocardiography, radionudide imaging or cardiac magnetic
Key: ECG: electrocardiogram, BNP: B-type natriuretic peptide, NTproBNP: N-terminal proB-type natriuretic peptide,
U&Es: urea and electrolytes, FBC: full blood count, TFTthyroid function tests, LFTs: liver function tests
  
 
Figure 1.5: Diagnostic alogrithm for heart failure (adapted from the NICE guidelines for
chronic heart failure 2003)
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1.2 Treatmentof cardiac failure
The treatment options available for patients are now extensive and detailed below.
The ideal treatment regime would need to be tailored to the individual patient.
Treatments are designed to improve symptoms, reduce progression and increaselife
expectancy. The importance of each of these components will depend onthe stage of
the disease in any one specific case. The latest American Heart Association
guidelines suggested 4 sub groups of patients with heart failure- a group who are
currently well but at risk of developing structural heart disease, a group with
asymptomatic structural heart disease, a group with symptomatic heart failure and a
group with refractory heart failure. The treatments recommended for each group are
shownin figure 1.6 (Huntet al., 2005)
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Figure 1.6: Stages in the development of heart failure (adapted from the American heart
association guidelines for the managementof heartfailure (2005))
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1.2.1 Lifestyle
Changes in lifestyle are an important treatment aimed at slowing down disease
progression. They are particularly important in patients at risk of structural heart
disease and patients with asymptomatic structural heart disease. Lifestyle changes are
primarily focussed on reducing the risk of ischaemic heart disease, including
smoking cessation and goodlipid control, and preventing excess fluid accumulation
by reducing salt and fluid intake. Patients are also advised to perform regular
exercise and if appropriate lose weight to achieve better control of the metabolic
syndrome. Good control of hypertension is important and advice is also given to
reduce alcohol consumption. Regular innoculations to avoid pneumococcal
infections is also important to reduce concomitantillness. Whilst these changes are
not specifically designed to improve symptomsthey are a very importantfirst step in
reducing disease progression (Huntet al., 2005).
1.2.2 Treatmentof reversible causes
The most common cause of heart failure in the modern era is ischaemia (Sutton,
1990). In patients with symptoms of heart failure and reversible ischaemia on
functional testing revascularisation may be considered. If the heart failure is
secondary to hypertension then adequate treatment may improve symptoms. In
patients with valvular heart disease causing heart failure, valve repairs or
replacement may improve outcomes. Heart failure can also be secondary to any high
output states including hyperthyroidism, Pagets syndrome and atrioventiricular
fistulae. In these cases treatment of the underlying condition is paramount in improve
the symptomsofheart failure
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1.2.3. Exercise training in heart failure
1.2.3.1 Central and peripheral therories of heart failure
The primary initial abnormality in heart failure is the failure of the heart to provide
an adequate output. Howeverthis central haemodynamic impairmentis not the sole
cause of the symptoms seen in patients with heart failure. When central cardiac
function is suddenly improved (e.g. following cardiac transplantation) there is no
immediate improvement in exercise performance but rather a gradual improvement
occurs over weeks to months (Savin et al., 1980;Sinoway et al., 1988). This
observation has led to the “muscle hypothesis of cardiac failure”. This proposesthat
skeletal muscle is abnormal in CHF. During exercise, muscle has a limited capacity
for aerobic metabolism, resulting in fatigue and ergoreflex activation, which causes
an increase in the ventilator response to exercise and the sensation of dysopnea.
Ergoreflex activation also causes sympathetic nervous system activation, with a
consequent increase in afterload and a decrease in blood flow to the periphery,
further exacerbating skeletal muscle abnormalities (Clarket al., 1996).
Muscle wasting has been recognised in heart failure. Mancini et al showed that
muscle wasting occurs even in mild heart failure and that peak exercise capacity
correlated with calf muscle volume (Manciniet al., 1992). Further evidence towards
the importance of the peripheries in heart failure was shownin a study by Jondeauet
al. In this study the authors performed maximal lowerlimb cardiopulmonary exercise
testing and then added in upper limb exercise in addition, thus increasing the
exercising muscle bulk. In normal subjects increasing the exercising muscle bulk led
to no further increase in peak VO. suggesting that exercise capacity was limited by
cardiac function. However in the heart failure group the increase in exercise muscle
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bulk led to a further increase in peak VO. suggesting that the limitation wasat least
partly at the skeletal muscle level (Jondeauet al., 1992). The histological appearance
of skeletal muscle in chronic heart failure patients has been reported in numerous
trials. The majority of these have a shown a reduction in Type | (slow twitch,
aerobic) fibres and a increase in Type 2 (fast twitch, anaerobic fibres) (Lipkinetal.,
1988;Manciniet al., 1989;Sullivan et al., 1990;Drexler et al., 1992). Biochemically
there was a reduction in the oxidative capacity of the muscle (Mancini et al.,
1989;Drexleret al., 1992). Taken together, the histological and biochemical changes
suggest a switch, from aerobic to anaerobic metabolism in the skeletal muscle of
patients with chronic heart failure, and a reduction in the activity of oxidative
enzymes(Clarket al., 1996).
1.2.3.2 Benefical effects of exercise training
Exercise training is not routinely offered to patients following cardiac
resynchronisation therapy in the United Kingdom. However it is now widely
accepted that in patients with chronic heart failure a period of exercise training can
lead to improvements in exercise capacity, peak VOz, quality of life and in onetrial
mortality (Piepoli et al., 2004;van Tol et al., 2006). The mechanism behind the
improvementin peak VO;is likely to be a combined improvementin central cardiac
output and skeletal muscle function. However, the majority of trials evaluating
exercise training have focussed on patients with mild heart failure (New York Heart
Association (NYHA)I-II). Most recently HF-Action showed that exercise training
was safe in patients with more severe heart failure (NYHA II-IV) and led to an
improvement in peak VO2. Despite this there were no significant improvements in
mortality or morbidity in this group (O'Connoret al., 2008). Patients suitable for
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CRTare of a comparable functional status to those in HF-Action. The combination
of exercise training and CRT has not been well investigated with only one small
scale study suggesting possible benefit (Conraads et al., 2007). Previous trials
looking at exercise in CHF have had varying intensity and frequency. In the
ExtraMatch meta analysesthe trials varied from 2 to 7 times a week and 50% to 80%
of the peak heart rate (Piepoli et al., 2004) and in HF-Action, the largest trial of
exercise training in heart failure so far, the exercise programme was 30 minutes 3
times a week in the supervised stage. However, by the end ofthe trial the average
duration of exercise was only 50 minutes per week (O'Connor et al., 2008).
Therefore it is still unclear what the ideal training programme should be and whether
the addition of exercise training to CRTis beneficial.
1.2.4 Medical therapy
In heart failure there is compensatory up regulation of components of the renin-
angiotensin-aldosterone and sympathetic nervous systems due to a reduced cardiac
output. This has been shown to suppress myocardial function, cause myocardial
hypertrophy and myocyte apoptosis leading to mural thinning and progressive
dilation (Bohm etal., 2003). Therefore modulation of these neurohormonal changes
has become the cornerstone of treatment. Three main classes of drugs have been
shown to improve mortality and symptoms namely drugs blocking the over
expression mechanisms(including angiotensin-converting enzyme (ACE) inhibitors
and angiotensin II type 1 receptor blockers (ARB)), beta-adrenoceptor blockers and
aldosterone antagonists.
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There have been 34 trials assessing ACE inhibitors in heart failure. A review ofall
34 trials showeda statistically significant reduction in total mortality (p<0.001) and
combined endpoint of mortality or hospitalisation (p<0.001) (Garg and Yusuf, 1995).
In animal models it has been shown that despite adequate ACE inhibition there is
still near normal production of angiotensin II, via ACE independent pathways, within
the myocardium (van Katset al., 1998). It was therefore postulated that blockade of
the renin-angiotensin system at the angiotensin II type 1 receptor level would be
more beneficial than ACE inhibition. Howeverthis has not been borneoutin clinical
trials. In a meta-analysis of 17 trials looking at ARBs the results showed that when
ARB were comparedto placebo there was a non-significant trend towards improved
survival (p=0.19) and decreased hospitalisation (p=0.33) with ARB treatment. When
ARB were compared to ACE Inhibitors there was no difference in survival or
hospitalisation and when ARB were added to ACEinhibitors and compared to ACE
inhibitors alone there was no difference in mortality but there was statistically
significant reduction in hospitalisation (p<0.0001) (Jongetal., 2002).
Beta-adrenoceptor blockers have been shownto significantly improve the functional
status (p=0.04) (CIBIS Investigators, 1994), reduce hospitalisation ((p<0.01) (CIBIS
Investigators, 1994), (p=0.036) (Packer et al., 1996)), reduce all cause mortality
((p=0.0062) (MERIT-HF Study Group, 1999), (p<0.001) (Packer et al., 1996),
(p<0.0001) (CIBIS-II Investigators, 1999)) and reduce sudden death ((p=0.0002)
(MERIT-HFStudy Group, 1999), (p=0.0011) (CIBIS-II Investigators, 1999)).
Two main aldosterone antagonists, namely Spironolactone and Eplerenone, have
been studied in addition to standard therapy, and both produced a significant
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reduction in mortality ((p<0.001) (Pitt et al., 1999), (p=0.008) (Pitt et al., 2003)) and
morbidity ((p<0.001) (Pitt et al., 1999), (p=0.002) (Pitt et al., 2003)). Further
symptomatic treatment is achieved using diuretics and digoxin (The Digitalis
Investigation Group, 1997), however neither of these treatments have any impact on
mortality.
A combination of the above drugs is now widely accepted as being the optimum
medical therapy for heart failure however it has been shownthat full implementation
of evidence-based doses is rarely achieved in clinical practice (Packer et al.,
1996;Philbin et al., 1996;Smith et al., 1998). This is despite the fact that clinical
studies have shown that ACE inhibitors at maximum doses are well tolerated by
around 80-90% of patients with chronic heart failure (Kjekshus and Swedberg,
1988;O'Connell and Bristow, 1994). The ATLAStrial showed the importance of
achieving the maximum tolerated dose, in this large-scale trial it was shown that
there was a greater benefit to be gained from high dose (32.5-35mg) versus low dose
(2.5-5mg) Lisinopril in patients with heart failure (Packer et al., 1999).
Unfortunately in a substantial number of patients despite being on optimal medical
treatment they continue to suffer with poorly controlled symptomsanda highrisk of
death (Cohn et al., 1986;The CONSENSUSTrial Study Group, 1987;Cohn et al.,
1991;Packeret al., 1996;Bradley, 2003).
1.2.5 Device based treatments
The mechanism of sudden death in heart failure patients was assessed in a sub-study
of the ATLAStrial. In this study 51% of patients with sudden death were thought to
have had a primary arrhythmic event (Uretsky et al., 2000). In view of this high
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incidence of potentially reversible arrhythmia manytrials have evaluated ways of
preventing sudden death.
Initially anti-arrhythmic drugs were used in post myocardial infarction (MI) patients
with impaired LV function. CAST and CASTII used classI anti-arrhythmic agents
(encainide, flecainide or moricizine) versus placebo. Both trials were terminated
prematurely due to increased mortality ((p=0.0004) (Echtet al., 1991) (p=0.40) (The
Cardiac Arrhythmia Suppression Trial II Investigators, 1992)) in the anti-arrhythmic
group. In view of these results the focus switched to amiodarone, and to date there
have been 13 randomised trials performed (Hockings et al., 1987;Hamer et al.,
1989;Burkart et al., 1990;Cairnset al., 1991;Nicklas et al., 1991;Ceremuzynski etal.,
1992;Navarro-Lopezet al., 1993;Dovalet al., 1994;Garguichevichet al., 1995;Singh
et al., 1995;Julian et al., 1997;Cairnset al., 1997;Elizari et al., 2000). Only three of
these have reported a significant reduction in overall mortality (Burkart et al.,
1990;Dovalet al., 1994;Garguichevich et al., 1995). A meta-analysis of all 13 trials
showedthat there was a 13% reduction in mortality with amiodarone (p=0.03) and a
29% reduction in arrhythmic death (p=0.0003). There was virtually no effect of
amiodarone on non-arrhythmic death (Connolly, 1999).
1.2.6 Implantable cardioverter defibrillator
In the mid 1990’s attention began to switch towards implantable cardioverter
defibrillators (ICD). Initially ICDs were compared against anti-arrhythmic agents
(mainly Amiodarone) in patients who had been resuscitated from ventricular
arrhythmias. Three large scale multi-centre trials were carried out in this patient
group. The antiarrhythmics versus implantable defibrillators (AVID) trial found a
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significant reduction in mortality in the ICD group (p<0.02) (The Antiarrhythmics
versus Implantable Defibrillators (AVID) Investigators, 1997), the Canadian
implantable defibrillator study (CIDS) found a non-significant 19.7% reductionin all
cause mortality (p=0.142) and a non-significant 32.8% reduction in the risk of
arrhythmic mortality with ICD therapy (p=0.094) (Connolly et al., 2000b), and the
cardiac arrest study Hamburg (CASH) which found a non-significant 23% reduction
in all cause mortality in the ICD group (p=0.081) (Kuck et al., 2000). A meta-
analysis showedthat there was an overall 28% reduction in mortality (p=0.0006) and
that this was entirely due to a 50% reduction in arrhythmic deaths (p<0.0001). The
meta-analysis also showed that patients with a LVEF >35% had significantly less
benefit from ICD than those with a EF <35% (p=0.011) (Connolly et al., 2000a).
ICDs were thusestablished as the treatment of choice in preventing sudden death in
patients post resuscitation for ventricular arrhythmias. The next step was to decide
whether high-risk patients who had not yet suffered a cardiac arrest would benefit
from ICD’s. The high-risk group initially identified were patients with LV
dysfunction post MI with a history of non-sustained ventricular tachycardia (at least
3 beats) and a positive electrophysiological study (EPS) (defined as inducible non-
suppressible ventricular tachy-arrhythmias). The two trials looking at this were the
multicenter automatic defibrillator implantation trial (MADIT) I and the multicenter
unsustained tachycardia trial (MUSTT). Both studies randomised patients to
treatment with either an ICD or conventional treatment (including amiodarone).
MADITI found a 54% reduction in mortality with ICD treatment (p=0.009) (Mosset
al., 1996) whilst MUSTT showed a 76% reduction in cardiac arrest or death from
arrhythmia in patients treated with an ICD (p<0.001) (Buxton et al., 1999). The
42
MUSTTtrial also showed treatment with serial electrophysiologic drug testing
without ICD back up, even when a drug was foundthat effectively suppressed VT
induction, had no significant benefit compared to no treatment (Klein and Reek,
2000).
In the MUSTTtrial the patients who were not inducible at baseline (and hence not
entered into the trial) were entered into a MUSTTregistry. These patients had lower
death rates than the randomised, inducible patients. The effect of EF on mortality and
inducibility over the course ofthetrial in both groups of patients (inducible and non
inducibility) was examined. The subgroup with the worst mortality rates had low EF
and inducibility, followed by the subgroup with low EF and non inducibility and then
the group with a normal EF and inducibility. The group with a normal EF and non
inducibility VT had the best prognosis. Thus, in MUSTT, EF was a more important
predictor of sudden death than inducibility (Buxtonet al., 2007).
The MADITIItrial researchers therefore reasoned that in patients with a prior MI
and advanced LV dysfunction, the scarred myocardium would serve as a substrate
for ventricular arrhythmia, and therefore EPS testing or 24 hour holter monitoring
would not be required for risk stratification (Mosset al., 2002a). They therefore took
1232 patients with a history of a previous myocardial infarction and an EF <30% and
randomised them, without any further testing, to either implantation of a ICD or
conventional treatment. In the group with an ICD there was a 31% relative reduction
in mortality compared to optimal conventional treatment (p=0.016). The greatest
reduction was seen in a sub group of patients whose QRS width was greater than
150ms (Mosset al., 2002b). Despite EPS inducibility not being an inclusion criteria
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593 patients in the ICD arm underwent EPStesting at the time of ICD implantation.
EPSinducibility at baseline did notdifferentiate between those who were morelikely
to require ICD therapy for termination of ventricular tachycardiaor fibrillation from
those who were not (Moss, 2003).
Morerecently the results from Sudden Cardiac Death in Heart Failure trial (SCD-
HeFT) were reported. This study took 2521 patients with ischaemic and non-
ischaemic NYHA classII and III chronic heart failure and EF <35%. Patients were
randomised to an ICD versus amiodaroneversus placebo with a primary end-point of
all-cause mortality. There was nostatistically significant difference between the
placebo and amiodarone group, however the ICD group had a significant 23%
reduction in mortality (p=0.007). The improvement in mortality was independent of
the heart failure aetiology and the benefit was greater in the group with NYHAclass
Il, rather thanclass III, heart failure (Bardyet al., 2005).
ICD therapy has therefore becomethe treatment of choice in primary and secondary
prevention of ventricular arrhythmias. However whilst it is known that ICDs reduce
sudden death, it has now been shownthat recurrent ICD discharges are associated
with psychological disturbances (Dougherty, 1995). Therefore the combination of
anti-arrhythmic drugs and ICDsare currently being investigated. In the only double
blinded trial looking at the addition of an anti-arrhythmic to an ICD, it was shown
that the addition of Sotalol led to a 48% reduction in death or first ICD shock
(p<0.001) (Pacifico et al., 1999). The evidence for amiodaroneis less robust, the
conventional versus amiodarone drug evaluation (CASCADE)study was designed to
compare amiodaroneversus EPS guided drug therapy. However during the course of
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the trial ICD placement becamestandard to both groups and in the amiodarone group
there were significantly fewer shocks associated with syncope (p=0.032) and a non-
significant reduction in total number of shocks (p=0.14) (The CASCADE
Investigators, 1993)
1.2.7. Cardiac resynchronisation therapy
Conduction system delay (evidenced by QRS prolongation) occurs as a consequence
of the underlying pathophysiological disease in patients with chronic heart failure
and results in dyssynchronous ventricular contractions. This triggers adaptive
chamber dilation and neurohormal stimulation (Kass, 2003) leading to diminished
contractile reserve of the heart (Nelson et al., 2000) and inefficient myocardial
contraction (Hare, 2002). The mean QRS duration increases as the severity of
chronic heart failure increases. The percentage of people with a QRS >120ms has
been shownto be 9.7% for New York Heart Association (NYHA)class 0-I, 32% for
NYHA class II and 53% for NYHAclass III (Cohn etal., 1986). In a sub-study of
the VESTtrial increased QRS width was a independent predictor of mortality
(p<0.0001) (Gottipaty et al., 1999) (see figure 1.7).
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Figure 1.7: QRS duration predicts mortality (adapted from Gottipaty et al 1999)
Studies were devised to reverse LBBB using temporary pacing wires connected to an
external pacemaker box,delivering right ventricular (RV), left ventricular (LV) or
biventricular (BiV) pacing. These studies showed RV pacing led to no significant
improvement over no pacing (Cazeau et al., 1996;Blanc et al., 1997;Kasset al.,
1999). BiV and LV pacing was shown to increase the mean cardiac index (p<0.006)
(Cazeau et al., 1996), decrease the pulmonary capillary wedge pressure (p<0.01)
(Cazeauet al., 1996;Blanc etal., 1997), decrease mean V wave ((p<0.004) (Cazeau
et al., 1996), (p<0.001) (Blanc et al., 1997)), increase the systolic blood pressure
((p<0.03) (Blanc etal., 1997), (p<0.0001) (Auricchio etal., 1999b)) and increase the
maximum LV pressure derivative ((p<0.01) (Kass et al., 1999), (p<0.0001)
(Auricchio etal., 1999b)). In someof these studies LV pacing had a morebeneficial
effect than BiV pacing ((p<0.05) (Kass et al., 1999), (p<0.01) (Auricchio et al.,
1999b)). This may have been due to the fact that in the BiV pacing group there was
synchronous stimulation of both ventricles however this does not recapture the
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 normal activation of the two ventricles and therefore may be sub-optimal. However
the studies had small patient numbersthus preventing firm conclusions (Leclercq and
Kass, 2002).
In view of these acute haemodynamic changes CRT devices were developed with
right atrial and ventricular leads as seen in a dual chamber pacemaker and an
additional lead which is passed through the coronary sinus to the LV free wall (see
figure 1.8). The pacemaker can then mimic the intrinsic conduction system and
ensure that atrial and synchronised ventricular contractions occur in order to achieve
optimal cardiac function and thereby improve symptoms.
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Figure 1.8: Xray showing lead position in a CRT pacemaker
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Initially small-scale observational studies, including the pacing therapies for
congestive heart failure (PATH-CHF) (n=41) (Auricchio et al., 2002), multisite
stimulation in cardiomyopathies (MUSTIC) (n=67) (Cazeau et al., 2001) and the
multicenter insync (InSync) study(n=103) (Gras et al., 2002), were carried out to
assess the effects of CRT on symptomsandfunctional capacity. All the patients were
on optimal medical treatment butstill had severe persistent symptoms (NYHAIII-
IV), a prolonged QRS duration (>120ms in PATH-CHF, >150ms in MUSTIC and
InSync) and a dilated LV (>60mm in InSync). Treatment with a CRT device led to
an improvement in quality of life scores (p<0.001) (Cazeau et al., 2001;Auricchio et
al., 2002;Gras et al., 2002), NYHA class (p<0.001) (Auricchio et al., 2002;Gras et
al., 2002), 6 minute walk test distance (p<0.001) (Cazeau et al., 2001;Auricchio et
al., 2002;Gras et al., 2002), peak VO2 ((p<0.001) (Auricchio et al., 2002), (p<0.03)
(Cazeauet al., 2001)) and decreased hospitalisations (p<0.05) (Cazeauet al., 2001).
In addition CRT therapy was shown to reduce myocardial oxygen consumption
(Nelson et al., 2000), which is most likely due to decreased LV wall stress through
improved co-ordination of the wall contractions (Toussaint et al., 1999;Curry etal.,
2000). This is significant as most heart failure therapies directly enhancing systolic
function do so whilst also increasing myocardial oxygen consumption. The only
other therapy shownto reduce myocardial oxygen consumption but improve systolic
function is beta-blockade (Nelson et al., 2000). Corresponding to these
haemodynamic and functional benefits, studies have also shown that CRT leads to a
reduction in the LV end-diastolic and end-systolic volumes and also to improved
myocardial performance index (Breithardtet al., 1999;Stellbrink et al., 1999b;Gras et
al., 2002).
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The multicenter insyne randomisedclinical evaluation (MIRACLE)trial wasthe first
large scale randomisedclinicaltrial looking at CRT in heart failure. 453 patients with
moderate to severe heart failure, ejection fraction <35%, and QRSdurations >130ms
wererecruited following successful implantation of a CRT device. The patients were
randomised to have the device switched on or off to act as controls. In the active
treatment group there wasa statistically significant improvement in the 6-minute
walk distance (p=0.005), the functional class (p<0.001), quality of life scores
(p=0.001), treadmill exercise time (p=0.001) and ejection fraction (p<0.001). The
active treatment group also required less hospitalisation or intravenous medication
(p<0.05) (Abraham etal., 2002). In a sub-study echocardiograms were performed pre
and post treatment with a CRT device. In the active treatment group the
echocardiograms showed reduced enddiastolic and end systolic volumes (p<0.001),
decreased LV mass (p<0.01), reduced mitral regurgitation (p<0.001), improved
ejection fraction (p<0.001), and improved myocardial performance index (p<0.001)
(St John Sutton et al., 2003). Therefore the MIRACLEtrial showed that CRT
treatment improved both symptoms and echocardiographic appearance in patients
with moderate to severe heart failure.
It was hypothesised that CRT might improve prognosis in patients with chronic heart
failure. The largest trial to date to assess this was the cardiac resynchronisation in
heart failure (CARE-HF)trial. This trial enrolled 813 patients and randomised them
to either medical treatment or a CRT device. There was a 36% reduction in death
from any cause (p<0.002) and 52% reduction in hospitilisation from heart failure
(p<0.001). The CRT group also had a decreased incidence of death from worsening
heart failure. This suggests that the improvementin all cause mortality is most likely
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due to an improvementin cardiac function following CRT. Howeverinthis trial 35%
of the deaths occurring in the CRT arm were due to sudden cardiac death (Clelandet
al., 2005b). It was therefore postulated that a combination device with CRT and ICD
functions may improve outcomesfurther.
Whena meta-analysis ofthe initial trials (not including CARE-HF)wascarried outit
showed that CRTled to a significant 51% reduction in deaths from progressive heart
failure (Odds Ratio (OR) 0.49, 95% Confidence Intervals (CI) 0.25-0.93), a
significant 29% reduction in heart failure hospitalisations (OR 0.71, 95%CI 0.53-
0.96) and a non-significant 23% reduction in all cause mortality (OR 0.77, 95%CI
0.51-1.18). It also showed that CRT had noeffect on non-heart failure mortality (OR
1.15, 95%CI 0.65-2.02) and was not associated with a reduction in ventricular
tachycardiaorfibrillation (OR 0.92, 95%CI 0.67-1.27) (Bradley et al., 2003).
Attention thus began to focus on combination devices with both CRT and ICD
functions, the latter having been shownto have the greatest impact on mortality in
patients fitting selection criteria for the former in MADIT II. Two multicenter
randomised trials have evaluated the effect of a combination cardiac
resynchronisation and defibrillator device in patient with heart failure, namely the
comparison of medical therapy, pacing, and defibrillation in heart
failure (COMPANION)trial and the multicenter insync ICD randomised clinical
evaluation (MIRACLEICD)trial.
The COMPANIONtrial was a three-arm study of 1520 patients with NYHAclass
III/IV heart failure despite optimal treatment. The inclusion criteria were evidence of
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a conduction system delay on 12 lead ECG (with a PR interval >150ms and a QRS
interval >120ms), LVEF <35%, end-diastolic LV size >60mm, and hospitalisation
for heart failure in the past year. The patients were randomised to drug treatment
only, insertion of a CRT device, or insertion of a combination (CRT+ICD) device
(Bristow et al., 2000). The results showed that the primary end-point (all cause
mortality andall cause hospitalisation) was reduced by 19% in the CRT only group
(p=0.014) and by 20% in the CRT+ICD group (p=0.01). Total mortality was reduced
by a non-significant 24% in patients receiving CRT alone (p=0.059) and by a
significant 36% in the CRT+ICD group (p=0.003) (Bristow et al., 2004). The rate of
sudden death in the CRT only group was 36% in the COMPANIONtrial, which is in
keeping with the CARE-HFstudy wherethe rate was 35% (Clelandetal., 2005b).
Interestingly the rates of sudden death were higher in both the CARE-HF and
COMPANIONtrials when compared to the SCD-HEFTtrial. In SCD-HEFT, where
the inclusion criteria required symptomatic heart failure (NYHAclassII orIII) and a
low left ventricular ejection fraction (EF<35%) but no need for conduction system
delay, the sudden death rates were 29% in the placebo group and 28% in the group
receiving amiodarone treatment alone (Bardy et al., 2005). This is in keeping the
previously mentioned VEST substudy which showed that QRS duration is a
independentpredictor of mortality (Gottipaty et al., 1999). The addition of an ICD
improved sudden deathrates in both the SCD-HEFTtrial (22%) (Bardyet al., 2005)
and also in the COMPANIONtrial (16%). Therefore in all the trials the lowest
sudden death rate achieved was in the CRT+ICD group in the COMPANIONtrial
(Bristow et al., 2004). However with a rate of 16% it must be noted that an ICD
therefore does not guarantee a non suddendeath.
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The MIRACLEICDtrial also assessed a combination CRT and ICD device . This
trial assessed 369 patients with NYHAIII/IV heart failure on optimal treatment, with
an EF <35% and a QRSinterval >130ms. All the patients had a combination device
placed, in the control group (n=182) the CRT portion of the device was switchedoff,
in the active treatment group (n=187) the CRT portion was switched on. All of the
patients had the ICD facility switched on. At 6 months post device implantation, the
active treatment group showed improved quality of life scores (p=0.02), improved
functional class (p=0.007), improved peak O2 consumption (p=0.04) and improved
exercise function on a treadmill (p<0.001). No pro-arrhythmiathic tendencies were
observedin the active treatment group.In this group there was also no impairment of
arrhythmia termination capabilities by the ICD portion. However the MIRACLE ICD
trial was not powered or designed to evaluate an effect on mortality (Younget al.,
2003).
These trials therefore showed that combination devices could be used safely to
provide a significant improvement in both symptomsand mortality. CRT is now an
accepted treatment for suitable patients with a wide QRS and severe symptoms of
heart failure on stable optimal medical treatment. There is now interest in exploring
the effects of CRT in a wider population. Initially a study (RethinQ) was performed
to see if patients with severe heart failure and a normal QRS duration would benefit
from CRT. In this study there was no significant benefit following CRT in patients
with a normal QRS (Beshaiet al., 2007). Interest has therefore turned to patients with
a wide QRSbut only mild symptoms ofheart failure. Preliminary results from two
recent trials, resynchronisation reverses remodelling in systolic left ventricular
dysfunction (REVERSE) and the multicenter automatic defibrillator implantation
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trial with cardiac resynchronisation therapy (MADIT CRT), have shown that in
patients with a low ejection fraction and a wide QRS but with mild symptoms of
heart failure (NYHA I or II) CRT reduces the risk of future heart failure
hospitalisation and improved echocardiographic parameters but did not have any
effect on mortality (Lindeet al., 2008;Mosset al., 2009). CRT pacemakers (CRT-P)
and combination devices with CRT and ICD functions (CRT-D) have now been
included in the NICE guidelines (National Institute for Clinical Excellence, 2007)
and are now routine treatments for suitable patients.
1.2.7.1 Technical aspects of CRT implanation
For patients in sinus rhythm successful implantation of CRT devices requires three
transvenousleadsin the right atrium, right ventricle and on the epicardial surface of
the posterolateral wall of the left ventricle. Patients with atrial fibrillation have a
similar procedure but with only right ventricular and left ventricular leads. Initial
studies evaluating CRT placed the epicardial left ventricular leads via a full
thoracotomy. These patients exhibited significant improvements in peak VOz,
functional class and quality of life scores (Auricchio et al., 2002). However during
these studies there were significant complications related to the thoracotomy
procedure and subsequent studies therefore used transvenousleft ventricular leads.
Transvenous leads have the advantage of being done undera local anaesthetic and
without a thoracotomy, leading to a significantly reduced peri-operative risk. The
epicardial surface of the left ventricle is accessed retrogradely via the coronary sinus.
Different areas of the left ventricle can be accessedvia the tributaries to the coronary
sinus.
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Several multi-centre trials have shown that CRT via the transvenous route is an
effective procedure (Abraham etal., 2002;Bristow et al., 2004;Cleland et al., 2005b).
Howevera significant operator learning curve exists in all the major trials which
exhibit a historic 8-10% failure rate for placementof the left ventricular lead via the
transvenous route (Abraham et al., 2002;Cleland et al., 2005b). This failure of
implantation can be due to multiple factors including operator inexperience, failure
to cannulate the coronary sinus, diaphragmatic stimulation and_ recurrent
displacements due to low stability of some leads. As transvenous CRT has evolved
there has been a vast improvementin the delivery catheters, and a wider variety of
left ventricular leads, which should mean an improvedsuccessrate in the future.
There is also an overall 30% non-responder rate which may reflect compromised
lead positioning, for example dueto high thresholds, diaphragmatic twitching or lack
of an appropriate target vein (Young et al., 2003;Rivero-Ayerza et al., 2003).
Transvenous left venticular lead position is limited by the fact the final postion is
dependent on the coronary sinus venous anatomy. In multiple studies it had been
showedthat the ideal pacingsite for the left ventricular lead was the midlateral wall
accessed via a posterolateral branch of the coronary sinus (Auricchio et al., 1999a)
(Butter et al., 2001) (see figure 1.9), whilst this is the first choice when implanting
CRT devices, some patients do not have an appropriate vein goingto this site. In this
circumstance an alternative less haemodynamically beneficial site may be used
which mayleadto clinical non response.
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Figure 1.9: Average percentage change from baseline in systolic parameters at different left
ventricular pacing sites (adapted from Auricchio et al 1999a)
The options for patients in whom suitable target vein is not available are unclear
and may include epicardial placement of the left ventricular lead on to the lateral
wall (see section1.2.7.2). Following successful implantation there is currently no
consensus on whether optimisation is beneficial and no standard guidelines exist on
the best method to optimise patients following CRT.
1.2.7.2 Non responders to CRT
The rate of responders and non-responders to CRT is hard to define accurately as
currently no consensusis held on the definition of a non-responder to CRT. Multiple
trials have reported results from CRT and assessed predictors of response.
Unfortunately each of these have used different criteria for response. Alonso et al
used a improvement of | NYHAclass and a 10% increase in peak VO(Alonso et
al., 1999), Oguz et al used only a improvement of 1 NYHAclass (Oguzet al., 2002)
and Stellbrink et al suggested a left ventricular end stroke volume decrease of greater
than 15% (Stellbrink et al., 2001) . From a device perspective the primary role of
resynchronisation therapy is to provide a more co-ordinated ventricular contraction,
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therefore it could be argued that the purest response to CRT would be to show an
improved contraction suchasa increased ejection fraction. However from a patients’
perspective response can only be defined if the improved ventricular contraction
leads to an improvement in exercise capacity and symptoms. Therefore using only
one variable to assess responseis likely to be inaccurate. A combination of variables
which takes both the more co-ordinated ventricular contraction and an improved
exercise performance may therefore provide a more accurate basis for assessing
response. This may be achieved by defining a postive response as being an
improvementin both peak VOzandejection fraction.
It is also important to rememberthat advanced heart failure is often a progressive
disease and that maintaing the patients current level may still be an improved
outcome. The cause behind non-response is likely to be multifactorial and may
include poor patient selection and technical compromise of left ventricular lead
implantation.
1.2.7.3 Implanation of the left ventricular lead via a thoracotomy
The initial studies evaluating the acute response to CRT placed the epicardialleft
ventricular lead via a thoracotomy. The mid-lateral wall was shown to bethe ideal
pacing site in the LV (Butteret al., 2001;Auricchioet al., 2002). The lateral wall was
accessed via a full thoracotomy. These studies showed signficant improvements in
functional class and exercise haemodynamic measures. However there was a
signficant complication rate related to the thoracotomy procedure and a concern
about long term lead performance (Butteret al., 2001;Auricchio et al., 2002). At that
time therefore interest shifted towards transvenous leads which were associated with
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lower procedural complications. As described in section 1.1.11 transvenous lead has
been shown to lead to signficant improvements however in a small percentage of
people the coronary venous anatomyis not ideal for a transvenous approach. The
options for this grouptill recently were either a compromised transvenous placement
or a full thoracotomy with the attached higher procedural risks. Recently case
reports and case series have suggested epicardial lead placementvia a lateral mini
thoracotomy as an alternative to allow delivery of CRT (Mair et al., 2005). This
potentially has the advantage of reducing operative risk compared to a full
thoracomy and therefore may be a viable option for patients in whom transvenous
implanation is not ideal. However the published case series looking at epicardial
placement via a minin thoracotomy have involved small numbers and there is no
long term data on the haemodynamic effects compared to standard transvenous lead
implantation.
1.3 Exercise testing in the evaluation of cardiac failure patients
There is no universally accepted definition of chronic heart failure. A broad
definition is that chronic heart failure is the inability of the heart to provide the
required cardiac output to meet the metabolic requirements (Denolin et al., 1983).
The primary goal of chronic heart failure managementis therefore to improve the
cardiac function and hence allow better physical performance. Exercise testing is
now an accepted investigational tool for patients suffering from heart failure. Its
major advantage over traditional cardiac tests is that it assesses the heart at exercise
rather than just at rest. Exercise testing provides a objective functional assessment of
a patient’s condition and has been shown to be accurate at predicting prognosis. In
one study (Myerset al., 2002) peak exercise capacity was shownto bethestrongest
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predictor of all-cause mortality amongst both normal subjects and those with
cardiovascular disease. Exercise capacity outperformedothertraditional markers of
cardiovascular risk, including smoking, hypertension, diabetes, previous history of a
myocardial infarction or chronic heart failure and hyperlipidaemia. The authors
concluded that, in terms of reducing mortality from any cause, improving exercise
tolerance warranted at least as much attention from physicians as other traditional
risk factors (Myers et al., 2002). Serial exercise testing is also a very useful tool to
assess response to treatment.
Exercise tests are conducted on either a treadmill or bicycle ergometer and there is
considerable debate as to which best suits patients with heart failure. It is important
to take into account the exercise protocol as this can significantly affect the results.
Whendifferent protocols are used peak VO> varies considerably whereas VO>at the
anaerobic threshold remains reproducible (Pina and Karalis, 1990). Patient
motivation is another factor that can significantly affect the overall VO2 measured.It
is important to reduce the effect of external variables on the measurement of
haemodynamic measures. To ensure reliable results repeated testing should be
performed at same time of the day and should be at a controlled temperature.It is
also important to ensure that food and caffeine intake are kept to a minimum for at
least 4 hours prior to testing. A separate familiarisation test is usually performed to
ensure that familiarisation bias is eliminated. Treadmill testing produces a 10-15%
higher peak VO,and ventilation threshold compared to bicycle testing. This is due to
the greater mass of skeletal muscle used (Pageet al., 1994). The protocol used is of
equal importance to the method of exercise testing. When performing exercise
testing in patients with severe heart failure, such as those being investigated in this
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thesis, it is generally considered safer to investigate patients using gentle protocols
with small increments in speed andincline, for example the modified Bruce or
Naughtonscale.
1.3.1 Peak VO,
Oxygen consumption (VO7) (mls/min) is a measurementof an individual’s ability to
transport and utilize oxygen during exercise. For a given individual the relationship
between work and oxygen consumption is linear until a level after which further
increases in work load do not lead to further increases in oxygen consumption. This
plateau is defined as the maximal oxygen consumption (VO2max). To achieve a
reproducible plateau VO2max requires significant subject determination and is often
impossible to achieve in patients with significant cardiac dysfunction. In these
patients a peak VOz, defined as the highest oxygen consumption measured at peak
exercise, is a more reproducible measure. The measured value of VO. is dependent
on a combination of factors including pulmonary ventilation and gas diffusion,
cardiac output and skeletal muscle oxygen utilisation.
Peak VO>is a morereliable index of functional capacity than exercise duration or
workload as it represents a more precise, reproducible and physiological measure of
cardiopulmonary function (Myers and Gullestad, 1998;Francis et al., 2001).
Numerousstudies published in the last two decades demonstrate peak VO> to be an
independentpredictor of mortality (Szlachcic et al., 1985;Cohn et al., 1993;Myers et
al., 1998;Pardaenset al., 2000). Szlachcic et al were the first group to suggest a cut
off value, of 10mls/min/kg, that was useful in risk stratisfication of patients with
severe heart failure. Subsequently a cut off value of 14mls/min/kg has been shownto
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confer an equal 1 year mortality compared to cardiac transplantation (Mancinietal.,
1991). This value is currently accepted as a threshold for consideration of cardiac
transplantation however there is currently some debate as to whether this cut off is
helpful. Wilson et al tested a group of patients being referred for cardiac
transplantation. They showed that there was a poorcorrelation between peak VO»
and invasive cardiac haemodynamic measurements. In fact 44% of patients with mild
to moderate haemodynamic abnormalities had a peak VO2 <14mls/min/kg and 25%
of patients with severe haemodynamic impairment had a peak VO, >14mls/min/kg
(Wilson et al., 1995). Following this study it was suggested that a peak VO>
<10mls/min/kg was associated with a poor prognosis and should be considered for
transplantation, a peak VO2 >18mls/min/kg was associated with a good pronosis and
transplantation should be deferred and further haemodynamictesting is required for
the group with a peak VO» between 10 and 18mls/min/kg (Pina, 1995).
1.3.1.1 Limitation of peak VO,
Peak VO> is widely used in manyofthe clinical trials assessing cardiacpatients.It is
often described as being indicative of cardiac function. However peak VOz can be
influenced by many non-cardiac factors including skeletal muscle function, physical
size and hyperventilation (Fleg and Lakatta, 1988;Wilson et al., 1995;Coats, 2001).
A recent study showed that peak VO. reproducibility within subjects is poor, and
therefore different tests done on different days are likely to give different values
(Bensimhonetal., 2008). This has implications on testing for heart failure especially
when using a cut off value of 14mls/min/kg for transplantation. It would therefore be
morereliable to use peak VO> as continuous variable rather than having a discrete
cut off. A large study consisting of 664 patients during a 10-year period of follow up
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showed that peak VO, wasan independentpredictor of mortality above and below a
range of 10-17 mls/min/kg,rather than at a cut-off point of 14 mls/min/kg (Myers et
al., 2000). These limitations have encouraged researchers to move to more cardiac
specific markers such as cardiac power output and cardiac reserve (Tan, 1987;Tan
and Littler, 1990).Williams et al showed cardiac output reserve to be the best
prognostic indicator of all cardiopulmonary variables at predicting mortality at 10
years (Williamset al., 2005) and also in a separate study peak cardiac power output
was the only independent predictor of prognosis in chronic heart failure patients
(Williamset al., 2001)
1.4 Cardiac power output and cardiac reserve
1.4.1 Theoretical model of cardiac power output and cardiac reserve
Theheart is, at its most basic, the pump responsible for generating flow and pressure
around the body. In chronic heart failure the symptomsseen are dueto failure of the
pressure and flow generating capabilities. The cardiac pump has a potential output
between zero and infinity. To adequately describe the capabilities of the heart both
the resting and peak cardiac function have to be assessed. For most patients with
heart failure the symptoms are mainly related to exertion and therefore resting
cardiac output maybefairly normal.If only resting cardiac output is measured then it
is possible to get a false impression in this scenario. Therefore two important terms
can be applied to cardiac performance:
(a) Cardiac pumping capability — the maximum performancethat can be achieved.
(b) Cardiac pumping reserve — the difference in performance betweenresting and
maximalstates.
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This concept wasinitially proposed by in 1916 (Barringer, 1916) and has since been
re-evaluated and modified (Tan, 1986;Tan, 1987;Tan, 1991). The primary job of the
heart is to deliver oxygen to organs andperipheral tissues. The delivery of oxygenis
dependenton the rate of blood flow into the vascular bed of an organ. Therefore the
first demand placed on the heart is the production of an adequate cardiac output
(CO). The blood flow to the tissues can also be increased by reducing the systemic
vascular resistance or by increasing the arterial perfusion pressure. Increasing the
arterial perfusion pressure assumes greater importance in skeletal muscle during
exercise because of higher tissue pressure during muscular contraction, in particular
during isometric exercise. Hence, the second demand imposed on the heart is the
maintenance of an adequate arterial pressure. The product of cardiac output and
arterial pressure is defined as cardiac power output (CPO). This term represents the
demand imposed by metabolising tissues on the cardiac pump.
Cardiac pumping capability can thus be defined as the maximum cardiac power
output achieved by the heart’s during maximalstimulation, and cardiac reserve as the
increase in power output as the hearts performanceis increased from theresting state
to the maximally stimulated state. It is important to distinguish between direct and
indirect measurements of cardiac function. Cardiac output is by its very nature a
direct measurement of cardiac function. Other commonly used measures such as
peak VO> and exercise duration are strongly affected by cardiac function, however
they are also affected by non cardiac factors such as skeletal muscle function, and
therefore have to be classified as indirect measures. Schlosshan et al suggested a
hierarchy of cardiac function measures ranging from resting measures such as
ejection fraction to peak cardiac power(Schlosshan, 2007)(see figure 1.10)
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Figure 1.10: Hierarchy of indices of cardiac function (adapted from D. Schlosshanet al
2007)
CRTaimsto improve both the flow and pressure generating capabilities of the heart
by resynchronisation of the ventricular contractions. Resynchronisation is the
mechanism of action of CRT but cannot be viewed as the end goal. Electrical
resynchronisation in a heart that is scarred from previous myocardial infarction and
therefore non-contractile, would not lead to any significant increase in
haemodynamic function. Therefore to assess patients fully following CRT both the
pressure and flow generating capabilities have to be tested. The majortrials to date
have used peak VO2 as the main outcome measure, however peak VO) is
significantly affected by both pulmonary and skeletal muscle function and is
therefore not a ideal marker of cardiac function. When assessing the effect of CRT
on cardiac function direct measurementof cardiac function should be considered the
gold standard.
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1.4.2 Clinical application of Cardiac power output and Cardiac Reserve
Cardiac poweroutputis defined as the product of cardiac output (CO), meanarterial
pressure (MAP) and conversion factor of 2.22 x10° (Tan, 1986) (see appendix 1).
It is expressed in watts (W). Cardiac power output (CPO) can be calculated at a
resting state and maximal exercise. The difference between resting cardiac power
output and peak cardiac poweroutputis the cardiac reserve (CR)(see figure 1.11).
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Figure 1.11: Relationship of peak CPO and cardiac reserve
Theinitial studies looking at cardiac power output and cardiac reserve were carried
out using invasive catheters to measure cardiac output and meanarterial pressure.
Thefirst such study was done by Tan in 1986. In this study sixty three patients with a
mean left ventricular ejection fraction of 24.2% and severe heart failure (NYHA II-
IV) were studied. Invasive haemodynamic measurements were recordedat rest.
Dobutamine was then infused as a stress agent increasing in increments of
S5mcg/kg/min to a maximum of 40mcg/kg/min. The hypothesis tested was that a
maximal CPO of <1 watt (assumed to be normal resting value for average sized
male) could discriminate between survivors and non-survivors at one year follow up.
Of the 23 patients with a maximal CPO <1 watt, 19 died of progressive heart failure.
Fourpatients died in the group of 40 with a maximal CPO of>1 watt. No pattern was
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seen with any resting haemodynamic parameter. Conclusions were drawn therefore
that a maximal CPO <1 watt wasindicative of a poor 1-year survival (Tan, 1986).
Two further studies done using invasive measurement and dobutamine stress were
subsequently carried out. Thefirst studied the application of cardiac power output in
patients with acute cardiogenic shock. The study showed differences between
survivors and non-survivors in resting and maximalleft ventricular stroke work
index (LVSWI), maximalcardiac index (CI) and maximum CPO.All patients with a
resting CPO <0.35 watts died, as did all patients with a maximum CPO of <1 watt or
a LVSWI <0.25 J/m? (Tan and Littler, 1990). In the second study a group of
critically ill patients on an intensive care unit were studied. No patient with a
maximal CPO <1.5 watts survived. Survivors also had considerably higher values of
LVSWI(resting andstress) and resting CPO (Timminset al., 1992). These 3 studies
helped to establish cardiac power output and cardiac reserve as useful measures in
the assessmentof cardiacpatients.
All the above studies were performed using dobutamineas the stressor agent. Tan et
al showed that exercise induced stress produced comparable maximal CPO to
dobutamine testing (Tan et al., 1989). However dobutamine has peripheral effect in
addition to its inotropic and chrontropic effects. Therefore a more physiological
method of stress would be exercise. Roul et al were the first group to evaluate the
prognostic value of peak CPO during maximal exercise testing in patients with CHF.
This group assessed 50 patients with NYHA class II-III CHF using invasive
measurements of haemodynamic parameters during maximal supine exercise with a
mean follow up of 21.2 + 1.2 months. Multivariate analysis revealed peak CPO to be an
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Statistically significant independent predictor of death or a major cardiac event
(p<0.00001) and a peak CPO <2 watts was found to accurately identify patients with a
poorshort term prognosis (p<0.003) (Roulet al., 1995).
1.4.3 Non-invasive assessment of cardiac power output and cardiac reserve.
The initial trials using cardiac power output had shown it to be a useful prognostic
markerin patients. The trials had so far used invasive methodsto calculate cardiac
output using the direct Fick method (see figure 1.12). However invasive
haemodynamic measurementis not without its risks and is not suitable for routine
clinical use or forserial testing. The major difficulty in measuring CPO and CR non-
invasively is the need for accurate cardiac output measurement. Mean arterial
pressure can be accurately measured using a standard sphygmomanometer.
Oxygen absorbed per minute by the lungs (mls/min)
= (mls oxygen consumed/litres air expired) x (litres air expired/min of collection)
Inspired room air eg Oxygen used = 200 ml/min
Oxygen content of room air Expired air
Corrected for barometric pressure Collected over 3 minutes
Disappearance of oxygen measured  
Arterial blood
Oxygensaturation of
haemoglobin
measured by
reflectance oximetry
eg 02200 mI/L
Mixed venous blood
from the pulmonary
artery catheter
Oxygensaturation of
haemoglobin measured
by reflectance oximetry
eg 02160 mI/L
 
Arteriovenous O> difference across the
lungs (mls/litre of blood)
Measured as difference between
arterial blood and mixed venous blood
From the oxygen saturations,
eachlitre of blood picks up
40 ml/ O2 andsince total Oz
leaving lungs each minuteis
200 ml, a total of 5 litres of
blood must pass through
pulmonary circulation each
ArteriovenousO> difference (mls/litre of blood) minute CO= 5 L/min
Cardiac output(litres/minute)=
Oxygen absorbed per minute bythe lungs (mls/min)
 
Figure 1.12: Schematic example of cardiac output calculation from the direct Fick method
(Guyton, Medical Textbookof Physiology, 1991)
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Several techniques have been previously used to measure cardiac output non
invasively and these included impedance cardiography (Kinnen et al., 1964),
transcutaneous doppler (Feigenbaum etal., 1967) and radionuclide ventriculography
(Slutsky et al, 1979). However, these techniques are impractical for the
measurement of CO at peak exercise. The current versions of cardiopulmonary
exercise test machines now come with the capabilities to measure cardiac output.
These use the indirect Fick equation (Cardiac output (L/min) = CO, production
(L/min) / (venous- arterial CO2 concentration) to work out cardiac output. During
cardiopulmonary exercise testing, CO» production is measured directly, along with
O2 consumption. Thearterial COpartial pressure can be extrapolated from the end-
tidal pressure of CO2 (PETCOz2), assuming that equilibrium exists between the gas in
the alveolar space and the pulmonary vein capillary bed (Campbell and Howell,
1960). Computerised dissociation tables then convert partial pressure to
concentration (McHardy, 1967). To complete the indirect Fick equation required the
calculation of venous CO> concentration. This involves re-breathing gas containing
pre-determined concentrations of CO, using the lung as a tonometer for the
equilibrium of CO2. The two most widely reported methods of calculating venous
CO> concentration are Defares’s (Defares, 1958) and Collier’s (Collier, 1956). Both
these use rebreathing of a constant concentration of CO, to estimate venous CO,
concentration. Initial comparison showed good agreement between the methods
(r=0.97, p<0.001), and a good correlation between Colliers method and direct dye-
dilution (r=0.94, p<0.001) at rest (Muiesan et al., 1968). Comparison of Defares
method and dye-dilution at rest was disappointing (r=0.22) though the correlation
gradually improved with increasing workload (r=0.87) at maximum exercise
(Fergusonetal., 1968).
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Following this early work further studies have evaluated both these methods in
different patient groups. Wilmore et al, employed the automated “Beckman
metabolic measurement cart” to measure cardiac output by the Collier method in 6
healthy subjects during exercise, and 11 patients with coronary artery disease during
cardiac catheterisation. The rebreathe value for cardiac output exhibited an almost
linear relationship with VOz (r=0.9), and correlated well with the cardiac output
measured using the thermodilution method during rest (r=0.87) (Wilmore et al.,
1982).
Reybrouck et al compared the Defares method with the invasive Fick method in 16
hypertensive patients at rest and during exercise. There was a good overall
correlation (r=0.96, p<0.001). However, at rest the cardiac output was overestimated
using the rebreathing method by an average 0.5 I/min, (p<0.05). During exercise the
mean difference was negligible (p>0.25) and the limits of agreement were
substantially improved. It was thus concluded that the Defares rebreathing
measurement of cardiac output was acceptable during exercise, but not at rest
(Reybrouck and Fagard, 1990).
Russell et al measured the cardiac output at rest in 25 patients with valvular heart
disease or dilated cardiomyopathy. Duplicate recordings were made by three
techniques; the Collier rebreathing, invasive dye-dilution and invasive
thermodilution. The reproducibility of measurements in individual patients was
satisfactory with dye-dilution but was poor with Collier rebreathing and
thermodilution, only 50% and 70% ofthe differences being within 20% of the mean
respectively. Measurements ofcardiac output by the Collier rebreathing method were
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not significantly different from those obtained with dye-dilution (mean difference —
0.3 I/min). Unfortunately correlation coefficients were not calculated on the available
data. Thermodilution significantly overestimated cardiac output by a mean of 2.2
l/min (p<0.001) compared with rebreathing and by a mean of 1.9 I/min (p<0.001)
compared with dye-dilution. It was concluded that the Collier method of measuring
cardiac output was acceptable at rest, providing duplicate recordings were made in
order to correct for the inherent variability. The commercially available
thermodilution method of measuring cardiac output was found to be unsatisfactory
because of variable results and overestimation compared with dye-dilution (Russell
et al., 1990).
Nugentet al compared the Collier rebreathing method of measuring cardiac outputat
rest with the direct Fick and thermodilution techniques in 11 patients under
investigation for suspected coronary artery disease. The rebreathing results were
consistently lower than the other two methods (mean difference —0.73, 95%
confidence interval —0.95 to —0.5 l/min with the direct Fick, and -0.72, 95%
confidence interval —1.19 to —0.26 I/min with thermodilution). In the same study 11
healthy subjects underwent Collier rebreathing cardiac output measurements at rest
and during two levels of steady state exercise, on three consecutive days.
Reproducibility of results between replicates at rest (coefficient of variation 9.1%)
improved with exertion (coefficients of variation 5.6% and 5.4% respectively at each
exercise level) (Nugentet al., 1994).
In summary,the indirect rebreathing methods of Collier and Defares are less accurate
and less reproducible than dye dilution or direct Fick techniques for measuring
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cardiac output at rest. The Collier method although providing a slight
underestimation, is more consistent and accurate than the Defares method. During
exertion however, both methods provide acceptable and reproducible results. For
practical reasons it is simpler to perform the Defares method during maximal
exercise. It was therefore proposed to adopt the Collier method for measuring cardiac
output at rest and the Defares method during exercise testing. Numerousstudies have
now been completed with this protocol and have shownit to be a safe and effective
method of calculating cardiac output (Cooke et al., 1998;Williams et al.,
2001;Wrightet al., 2003;Schlosshanet al., 2006).
1.5 Aims and objectives
This review has highlighted the importance of obtaining objective measures in the
evaluation of cardiac resynchronisation therapy. With the development of non-
invasive techniques to assess cardiac power output, it is now possible to obtain
measurements of cardiac functional capacity using cardiopulmonary exercise testing.
This thesis applies these methods to investigate several hypotheses in patients with
chronic heart failure suitable for cardiac resynchronisation therapy, in order to
further our understanding of complex mechanisms in these disease areas and to
realise the importance of the application of these measures in clinical practice. The
hypothesestested in this thesis are:
(1) That cardiac resynchronisation therapy leads to improvements in central
haemodynamicsbuthas no effect on the peripheral effects of heart failure.
(2) That exercise training in addition to cardiac resynchronisation therapy will
improve the overall outcome by reversing skeletal muscle deconditioning.
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(3) That epicardial lead placement via a mini-thoracotomy wasa safe technique
and provided similar improvements to transvenous left ventricular lead
placement.
These hypothesis were tested using three studies. The objectives of these studies
were:
1.5.1 Study I: The longitudinal improvement in exercise haemodynamic
measuresfollowing cardiac resynchronisation therapy
1) To assess the impact of cardiac resynchronisation therapy on cardiopulmonary
indices, exercise haemodynamics, cardiac pump function and skeletal muscle
function. Morespecifically, to evaluate:
e The rate of improvement in functional class, exercise haemodynamic
measures and skeletal muscle torque.
e To identify which variables or patient characteristics predict significant
improvementin exercise capacity following technically successful CRT.
2) To assess the impact of cardiac resynchronisation therapy on symptoms and
quality of life using the Minnesota living with heart failure questionnaire
(MLWHE).
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1.5.2
1)
2)
3)
L334
1)
2)
3)
Study II. The effects of exercise rehabilitation in addition to cardiac
resynchronisation therapy
To assess whether a formal exercise rehabilitation programme in addition to
cardiac resynchronisation therapy leads to a further improvement in
functional class, exercise capacity and exercise haemodynamic measures.
To assess whether exercise rehabilitation reverses skeletal muscle
deconditioning in patients following CRT.
To assess the effect of exercise training in non responders to CRT.
Study III. The effectiveness of cardiac resynchronisation therapy
placed via a mini thoracotomy in patients with previously failed
transvenous placement
To examine the whetherleft ventricular lead placement via a mini thoracotomy
wasfeasible in patients with previously failed transvenous placement.
To assess the improvementin functional class, exercise capacity and exercise
haemodynamic measures in patients following left ventricular lead placement
via a mini thoracotomy
To compare the difference in response following lead placement via mini
thoracotomy andtransvenouslead placement
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CHAPTER 2: METHODS
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2.1 Background
The methodology using cardiopulmonary exercise testing described in this thesis is
based on work previously carried out (Cooke et al., 1998;Williams et al.,
2001;Wrightet al., 2003). A non-invasive method of evaluating cardiac power output
was developed and validated by Cookeet al (Cookeet al., 1998). Seventy subjects,
with a wide range of cardiac function (from athletes to patients with severe CHF),
were studied in the development and validation of non-invasive measurements of
various exercise parameters and CPO (Cookeetal., 1998). Using these methods I
studied the impact of CRT alone, CRT with exercise training and CRT placed
epicardially in appropriately selected patients.
2.2 Exercise testing protocol
The exercise tests were performed over two days. On the first day a transthoracic
echocardiogram wasperformed after 30 minutes rest. This was followedbytriplicate
measurements of resting cardiac output using Collier’s method (Collier, 1956).
Following this an incremental cardiopulmonary exercise test was performed and
peak cardiac output measured using Defares method (Defares, 1958). The second day
a second exercise test was performed and peak cardiac output measurement. After at
least 30 minutes rest peak lowerlimb skeletal muscle function was measured.
2.2.1 Familiarisation and standardisation
Patients were made familiar with the exercise equipment and introducedto the staff
prior to recruitment for any of the studies. The purpose of the studies and the
procedures were explained in full before written consent was obtained. All patients
performed a preliminary cardiopulmonary exercise test and non-invasive
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measurements of cardiac output were madeat rest and during exercise. The findings
from this test were discarded and not used in the final results. Familiarisation
identified patients not able to complete any part of the studies in this thesis — e.g.
patients not able to exercise maximally due to non-cardiac limitation, not willing to
give blood etc. These screened patients were notentered into the studies.
Exercise testing was conducted on the same Cosmos treadmill (Cosmos, Nussdorf-
Traustein, Germany) throughout the studies using a modified Bruce protocol. The
same supervisors (me and a sport scientists) conducted the tests throughout. All
patients were exercised after a two-hour postprandial period and were asked not to
consumealcohol or caffeine for the preceding 12 hours. The room in whichthetests
were carried out was maintained at a constant temperature of 22°C using an air
conditioning system controlled by a thermostat. Follow-up tests were performed at
the same time of day for each individual.
2.2.2 Calibration
The gas analysis system wascalibrated before each test. The pneumotach, which was
used to measure gas volumes was calibrated manually with a 3 litre syringe
(Cardiokinetics, Salford, UK) by five injections and withdrawals, representing
fluctuations in respiration, after a baseline was established (no flow). The O2 and
CO, analysers were also calibrated using bottled gases, and the manual
sphygmomanometer was checked against a standard mercury column manometer
every month.
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2.2.3 Day One — Echocardiogram
Transthoracic echocardiograms were performedprior to any testing andafterat least
30 minutes rest. All the echocardiograms were performed by myself in the same
room at John Moores University. All echocardiograms were performed using a
Acuson Cypress echocardiography system (Siemens medical solutions, Malvern,
USA). The scans were performedin the left lateral position. Parasternal long axis,
parasternal short axis and apical views were obtained. Left ventricular dimensions
were measured in systole and diastole using m-mode in the parasternal long axis.
Ejection fraction was calculated using the Simpson’s rule (Otto, 2004) from the
apical 4 chamberand apical 2 chamber views.
2.2.4 Minnesota living with heart failure questionnaire.
The Minnesota living with heart failure questionnaire was first designed in 1984. It
measures the effects of heart failure and treatments for heart failure on an
individual’s quality of life. The questionnaire assesses the impact of frequent
physical symptoms- shortness of breath, fatigue, peripheral oedema, and difficulty
sleeping - and psychological symptomsof anxiety and depression. In additionit also
measures the effects of heart failure on physical and social functioning. Since
treatments might have side effects in addition to ameliorating symptoms and
functional limitations produced by heart failure, questions about side effects of
medications, hospital stays and costs of care are also included to help measure the
overall impact of a treatment on quality of life. To measure the effects of heart
failure symptoms, functional limitations and psychological distress on an
individual’s quality of life, the MLHFQasks each personto indicate using a 6-point
76
(zero to five) scale how mucheach of 21 questions prevents them from living as they
desire (see appendix 3 for trial questionnaire).
2.2.5 Day one — Resting Cardiac Output
Resting CO was measured using the CO> re-breathing method of Collier (Collier,
1956), as previously described in section 1.4.3. Patients sat at rest for five minutes,
until respiratory values were stable, with respiratory monitoring and a 12 ECG lead
for heart rate measurement. A 5 litre anaesthetic bag was connected to the
pneumotach with a three-way tap in between. The bag wasfilled to 2 times the
resting V;, with a CO2 concentration calculated by the computer from the following
equation:
Bag CO? = (48.5 + 0.007 x VCO= 0.7 x ETpCO2) x 100 / P Bar
The bag determined concentration was attained by manual mixing of O2, CO, and
nitrogen using Bassett and Fitton’s method (Bassett, Jr. and Fitton, 1995). After
expiration, the three-way tap wasaltered so the subject breathed from the gas in the
closed anaesthetic bag. The concentration of CO2 in the bag exceededthe patient’s
concentration of COz in their venous (pulmonary capillary) blood and the diffusion
gradient between the venousbloodand alveolar space was reversed. Equilibrium was
achieved during several breaths (see figure 2.1). The computer recognised
equilibrium at the point where the difference between inspired and expired CO2 was
less than 0.1% in two successive breaths. Calculation of the partial pressure of CO.
in the venous blood was made by the computer and CO wascalculated using the
indirect Fick equation (see section 1.4.3). At least three measurements of CO were
77
madein order to calculate an average. Respiratory values were allowed to go back to
baseline between each measurement.
= 4
= 2
C0
2 %|
 
 
Oo 5 10 15
Time (sec)
Figure 2.1: Equilibrium method tocalculate cardiac outputat rest using Collier's method
2.2.6 Day one — Incremental cardiopulmonary exercise test
After the resting measurements, an incremental exercise test using a modified Bruce
protocol was performed (see table 2.1). A 12-lead electrocardiogram (ECG) was
recorded at baseline and then every 3 minutes. Blood pressure was measured using a
sphygmomanometerat baseline(first Korotkoff sound used for systolic BP andfifth
sound for diastolic BP), two minutes into each stage, at peak exercise and during
recovery. A mask attached to a counterweighted headgear was placed around the
patients head. A silicone seal gel was positioned around the mask to achieve an
airtight seal. Prior to starting the exercise the seal was checked by askingthe patient
to blow out with the pneumotach sealed. A few minutes were given before starting
the incremental test to allow the patients to get used to the mask and headgear(see
figure 2.2).
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Table 2.1 The seven stages of Bruce and Modified Bruce protocols
 Bruce Modified Bruce
Time (mins) Speed Incline Speed Incline
(mph) (%) (mph) (%)
0-3 1.7 10 1.7 0
3-6 2.5 12 1.7 5
6-9 3.4 14 1.7 10
9-12 4.2 16 2.5 12
12-15 5.0 18 3.4 14
15-18 5.5 20 4.2 16
18-21 6.0 22 5.0 18       
 
Figure 2.2: Set up for a incremental exercise test (published with the permission of the subject)
VO. (mls/min), VCO2 (mls/min), end tidal partial pressure of carbon dioxide
(PETCO2, mm Hg), tidal volume (V;, 1), and respiratory rate (RR, min'') were
recorded breath by breath using the Medgraphics CPXD analytic system (Medical
graphics corporation, St Paul, Minnesota, USA). Respiratory exchange ratio (RER =
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VCO,/VO2), minute ventilation (VE = V; x RR, L/min), and VO2/kg (VO2/weight,
mls/min/kg) were calculated from the above variables. Predicted peak VO. was
calculated by the Wasserman technique (Wasserman et al., 1994): Peak VO. =
weight x [56.36 — (0.413 x age)] — males and: weight x [44.37 — (0.413 x age)] -
females. Various ventilatory indexes were calculated from the above data: ratio of
minute ventilation to O2 consumption at peak exercise (peak VE/VOz), ratio of
minute ventilation to CO, production at peak exercise (peak VE/VCO2). The
regression slopes relating minute ventilation to O2 consumption (VE/VO>slope) and
CO,production (VE/VCO;slope) were also calculated. The V-slope method (Beaver
et al., 1986), was used to calculate anaerobic threshold (AT).
At peak exercise a peak cardiac output measurement was made. Defares method
(Defares, 1958) was used to calculate cardiac output at peak exercise, again using the
indirect Fick equation. The anaesthetic bag wasfilled with 4% CO, with the volume
being above a physiological tidal volume. The three-way tap was adjusted so the
patient breathed from the bag for 15 secondsin order for the computer to construct a
graph of end tidal points. The computer applied a best-fit exponential curve to the
points according to the technique of Heigenhauser (Heigenhauser and Jones, 1989),
rejecting the first point, and using 8 secondsofre-breathing to create an exponential
curve. End tidal points could then be manually modified to create a better fitting
curve (see figure 2.3).
Patients were encouraged to exercise to exhaustion, and their limiting symptom (e.g.
breathlessness, fatigue or chest pain) was recorded. All patients performed symptom-
limited exercise tests unless termination was indicated for safety reasons e.g.
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exercise-induced hypotension, significant cardiac arrhythmia, or other clinical end
points indicating compromised safety of continued exercise. Attainment of an age-
predicted heart rate was not usedasa criterion for stopping the test
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12
 
10) _—_—
CO
2 %
 
O | 5 | 10 | 15 | 20
Time (sec)
Figure 2.3: Exponential curve obtained at peak exercise using Defares’ method
2.2.7 Day two — Second cardiac output measurement
A repeat cardiopulmonary exercise test was performed using the same equipment,
exercise protocol and headgearas detailed in section 2.2.5. The subject was exercised
until the VO2, VCO, RER and HR weresimilar to that achieved on day one. Atthis
point a second cardiac output measurement was performed in the same fashion as
day one.
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2.2.8 Cardiac power output and Cardiac reserve
The three resting cardiac output readings were averaged as were the two separate
peak cardiac outputs. Cardiac power output was calculated at rest and peak exercise
from the equation:
Cardiac poweroutput (watts) = (CO x MBP) x K
Where MBPis the meanarterial blood pressure in mm Hg, COis the cardiac output
in L/min and the conversion factor 2.22 x 10 ~ (Tan, 1986) (see appendix 1). MBP
wascalculated from the equation:
MBP= (systolic pressure + 2 x diastolic pressure) / 3
Meanarterial blood pressure is defined as the average pressure throughout the
cardiac cycle. It has physiologic and clinical importance as it represents the tissue
perfusion pressure (Ira, 1996). Cardiac reserve is defined as the difference between
cardiac poweroutput at peak exercise andrest.
2.2.9 Day two-Lowerlimb peak skeletal muscle torque
On the second day ofeach visit, after a minimum of 30 minutes rest following the
cardiac output test, peak skeletal muscle torque was measured in each leg. Testing
was performedat the knees using a Biodex isokinetic dynamometer (Biodex medical
systems Inc, New York, USA) (see figure 2.4). Each leg was measured in full
extension and flexion to 90 degrees using a 60-degree/sec protocol. Five
measurements were taken in each leg with the peak value being taken.
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Figure 2.4: Lower limb peak skeletal muscle torque measurement using a Biodex Isokinetic
dynamometer(published with subjects permission)
2.3 Definition of non responders to CRT.
As metioned in section 1.2.7.1 there is currently no universally accepted definition
for a responder to CRT. For the purposes of this thesis we defined a responder as
someone who showed an improvement in both ejection fraction and peak VO>
following CRT. The mechanism of CRT implies that there will be a more co-
ordinated ventricular contraction and therefore an improvementin ejection fraction
should be part of any definition of positive response. However the main aim of CRT
is to improve functional capacity. The main objective marker of functional capacity
is peak VO, andtherefore this should also be incorporated into any definition of
positive response.
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2.4 Study I: The longitudinal improvement in exercise haemodynamic
measures following Cardiac Resynchronisation Therapy
2.4.1 Patient population and study design
Forty patients were prospectively recruited from the CRT referral clinic at the
Cardiothoracic Centre in Liverpool between July 2004 and November 2005. Patients
werenoteligible if they had contraindications to exercise testing, or had non-cardiac
conditions that would limit their exercise capacity e.g. chronic pulmonary disease,
neurological or rheumatological disabilities. All patients were given an information
sheet and provided informed consent (illustrated in appendix 2). The study was
approved bythe Liverpool adult research ethics committee.
Following a preliminary familiarisation test, all patients performed cardiopulmonary
exercise testing, with non-invasive measurements of cardiac output before, 2 weeks,
6 weeks and 3 months after successful CRT. No alteration in treatment occurred as a
result of this study. At 6 months the subjects wereclassified as either a responder or
non responder, as defined in section 2.3, and the baseline parameters were assessed
to look for predictors of response.
2.4.2 Cardiopulmonary exercise testing
All patients performed cardiopulmonary tests, with assessment of cardiac output and
cardiac power output as described previously in section 2.2. All patients exercised
according to the modified Bruce protocol. The same supervisors carried out the tests
(AYP, PW)throughoutthe study.
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2.4.3. Echocardiography
Transthoracic echocardiography was performedin all patients at each visit on day
one as per the methodsdescribedin section 2.2.3
2.4.4 Peak skeletal muscle torque
On the second day of each visit peak skeletal muscle torque was measured in the
quadriceps and hamstring muscles as per the methods described in section 2.2.8
2.4.5 Quality of life and symptom assessment
The New Yorkheart association functional classification (NYHA criteria committee,
1964) and the Minnesota living with heart failure (Minnesota, USA) (see appendix 3)
were assessed whenthepatients attended for each visit.
2.4.6 Statistical analysis
Linear regression analysis was used to look for relationships between the baseline
cardiopulmonary data and peak skeletal muscle function. A goodnessoffit value (1°)
was calculated for all the regression analysis. A p value of <0.05 was considered as
showinga significant coorelation between two variables. Group data for continuous
variables was expressed as mean + standard error of the mean (SEM).
Haemodynamic data and cardiopulmonary exercise test results (continuous data)
before and after CRT were compared using the repeated measures ANOVA with a
Bonferroni post-hoc test. Discrete data was expressed as modes and compared using
the Chi-square (7°) test. Baseline variables were assessed for the ability to predict
response to CRT using logistic regression with a univariate analysis. A responder
wasdefinedas persection 2.3.
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2.5 Study II. The effects of exercise rehabilitation in addition to cardiac
resynchronisation therapy
2.5.1 Patient population and study design
Fifty patients referred for CRT between June 2004 and August 2005 wererecruited.
Exclusion criteria included inability to perform an exercise test, reduced exercise
tolerance due to non-cardiac causes (e.g. chronic obstructive airways disease,
neurological or orthopaedic disability) and recent or planned revascularisation. All
patients received a written information sheet and gave informed consent (see appendix
2). The study was approvedbythe Liverpool adult research ethics committee.
2.5.2 Study protocol
All patients underwent cardiopulmonary exercise testing, a resting transthoracic
echocardiogram, quality of life assessment using the Minnesota living with heart
failure questionnaire and measurement of peak skeletal muscle torque. All
measurements were taken at baseline and repeated 3 months and 6 monthsafter
CRT.Prior to the study a separate familiarisation test was performed andthe results
discarded.
After the 3 month assessment patients were randomised (as described in section
2.5.3) into either an exercise group (n=25) or a control group (n=25). The exercise
group underwent a programmeof physician supervised exercise training consisting
of three 30 minutes visits per week. Each session consisted of 10 minutes treadmill
walking followed by 10 minutes cycling and then a further 10 minutes treadmill
walking. The intensity was 80% of the peak heart rate achieved at the 3 month test
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for the first four weeks, 85% for the next four weeks and 90% for the final four
weeks. This was performed at a non-clinical setting (Liverpool John Moores
University) away from the base hospital. Patients were supervised by an advanced
life support trained physician not involved in the CRT implant or follow up at the
base hospital (Liverpool heart and chest hospital). Clinical follow up was organised
at the base hospital for both groups. The exercise group were not provided with any
specific instruction or guidance to perform exercise outside the study. The control
group were given no specific advice on exercise training and underwent no
supervised training. No change in cardiac medication occurred as part of the study
protocol.
2.5.3 Randomisation
Randomisation occurred at 3 months. It was not performed at baseline to eliminate
the potential for bias due to pre-emptive training in the exercise group.
Randomisation was performed using a simple sealed envelope method. Fifty sealed
envelopes, 25 with exercise training and 25 with control were placed into a box.
After the 3 month assessment for each patient an envelope was picked by a person
not involvedin the study.
2.5.4 Cardiopulmonary exercise testing
The patients performed an incremental cardiopulmonary exercise test on each
occasion, as previously described in section 2.2. All patients were exercised
according to a modified Bruce protocol. The same supervisors carried out all tests
(AYP, PW), on the same equipment.
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2.5.5 Echocardiography
Transthoracic echocardiography was performedin all patients at each visit on day
oneas per the methods describedin section 2.2.3
2.5.6 Peak Skeletal Muscle Torque
On the second day of each visit peak skeletal muscle torque was measured in the
quadriceps and hamstring muscles as per the methods describedin section 2.2.8.
2.5.7 Statistical analysis
Group data for continuous variables was expressed as mean + standard error.
Discrete data was expressed as modes. For in-group analyses paired samplest-tests
were usedto look forstatistical significance in continuous variables and Chi-square
(x?) tests were used for discrete variables. To look for differences between the
exercise and control groups at 6 months, change scores were calculated and
independent sample t-tests were used. Analyses were carried out using SPSS version
12.0.1 for Windows(SPSS Inc, Chicago,Illinois). Statistical significance wasset at
the 5% level.
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2.6 Study III. The effectiveness of left ventricular lead placement via a mini
thoracotomy to achieve cardiac resynchronisation therapy in patients with
previously failed transvenous placement.
2.6.1 Patient population and study design
Twenty-three patients with previously unsuccessful transvenous placement(5 (22%)
with failure to cannulate coronary sinus, 12 (52%) with excessive thresholds at all
positions attained, 4 (17%) with diaphragmatic twitching and 2 (9%) with recurrent
displacements) were recruited. The control group was made up ofthirty-five
consecutive patients who had received CRT via the transvenous route. Standard
clinical guidelines (NationalInstitute for Clinical Excellence, 2003;Huntet al., 2005)
were used to assess suitability for CRT. All patients were in New York heart
association (NYHA)functional class III, had a QRS width >120 ms on their surface
ECG anda left ventricular ejection fraction (EF) <35%. Exclusion criteria for the
study included non-cardiac physical limitation e.g. arthritis, pulmonary disease,
myocardial infarction within the last 3 months, coronary artery bypass grafting or
percutaneoustransluminal coronary angioplasty within the last 3 months, or planned
for the future andsignificant untreated valvular heart disease. All patients received a
written information sheet and gave informed consent(see appendix 2). The study was
approvedbythe Liverpool adult research ethics committee.
2.6.2 Study protocol
All patients were assessed at baseline, 3 and at 6 months post CRT with
echocardiography, NYHA classification, Minnesota living with heart failure
(MLWHF) scoring and cardiopulmonary exercise testing with measurement of
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cardiac function. Prior to the baseline test a separate familiarisation test was
performed, the results of which were discarded. Pacemakers were set at manufacture
default settings and optimisation of pacemaker intervals was not performed during
the study period. Pacemaker follow up was performedat the implanting centre at 6
weeksand 6 months post CRT implantation.
2.6.3 Cardiopulmonary exercise testing
The patients performed an incremental cardiopulmonary exercise test on each
occasion, as previously described in section 2.2. All patients were exercised
according to a modified Bruce protocol. The same supervisors carried out all tests
(AYP, PW), on the same equipment.
2.6.4 Echocardiography
Transthoracic echocardiography was performed in all patients at each visit on day
one as per the methodsdescribed in section 2.2.3
2.6.5 Implantation and programming of cardiac resynchronisation therapy
device
2.6.5.1 Mini thoracotomy group:
This group had right ventricular and right atrial leads placed via the transvenous
route and the CRT pacemakerplaced in a subcutaneouspre pectoral pocket using the
standard technique. The LV lead was implantedusing left lateral mini thoracotomy
under a generalanesthetic. A 3cm incision was madethrough the left 5th intercostal
space and the left lung wasretracted. A Medtronic (model 5071) epicardial lead was
implanted using the Medtronic (model 10626) implantation tool. The lead was
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positionedin the posterolateral portion of the LV epicardium, using anactive fixation
screw. Standard testing of R wave sensing, impedance and pacing threshold were
undertaken. The epicardial lead was then tunnelled back to the previously implanted
pacemaker box.
2.6.5.2 Transvenous group
Implantation was performed using the standard technique of transvenous lead
insertion. Local anesthetic was delivered with the patient awake but sedated where
necessary. Lead testing and antibiotic prophylaxis were identical to the epicardial
group.
In both groups the pacemaker was programmedto a base rate of 60 bpm and upper
limit 85% of the age-gender maximumpredicted heart rate. Atrio-Ventricular delays
were programmedto standard settings (120ms paced, 100mssensed). No V-V offset
was utilised during this study. Patients in atrial fibrillation received biventricular
VVIR pacemakers. For this study patients received CRT-P and CRT-D devices as
appropriate and no distinction was made between them.
2.6.6 Statistical analysis
All continuous variables are presented as mean + standard error. Analyses were
carried out using SPSS version 12.0.1 for Windows (SPSSInc, Chicago,Illinois). A
repeated measures ANOVAwith a Bonferroni post hoc test was used to look for
intra-group differences between the baseline and post CRT results. All discrete
variables are presented as modes and analysed using Chi-Square (2) test. To assess
intergroup differences mean change scores were calculated and an independent
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samples t-test was used. A p value of <0.05 was considered to be statistically
significant.
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CHAPTER3: RESULTS
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3.1 Study I: The longitudinal improvement in exercise haemodynamic
measures following cardiac resynchronisation therapy
3.1.1 Baseline data
3.1.1.1 Baseline characteristics of study population
Baseline characteristics of the patients are shown in table 3.1. Mean (t SEM) age
was 65.3 + 1.6 (range: 38-80) years and 36 (90%) patients were male. The mean and
mode NYHAclass was3 and there was evidenceofa dilated cardiomypoathy with a
LV end diastolic dimension of 7.01 cm + 0.15 and a ejection fraction of 21.7 % +
1.5. Thirty (75%) of the patients were in sinus rhythm at baseline, the rest (25%)
were in atrial fibrillation. The primary cause of the dilated cardiomypathy was
ischaemic in 29 (72.5%), valvular heart disease in 4 (10%) and idiopathic in 7
(17.5%).
3.1.1.2 Baseline cardiopulmonary haemodynamic data
The baseline cardiopulmonary haemodynamic data are shown in table 3.2. Resting
heart rate was 79 + 3/min and increased to 124 + 4/min at peak exercise. This was
coupled with a increase in meanarterial pressure from 88.7 + 1.9 mmHgto 106.0 +
1.8 mmHg.Total exercise duration was 322 + 27 secondsandpatients did achieve a
true maximal cardiopulmonary exercise test manifest by a peak RERgreater than 1.0
(1.04 + 0.02). The subjects were significantly impaired in their cardiopulmonary
exercise capacity with a peak VO> of 15.51 + 0.54 mls/kg/min, which was 66.9 + 2.8
% of their predicted peak VO». Cardiac power output increased from a resting value
of 0.65 + 0.02 watts to a peak value of 2.53 + 0.10 watts, therefore giving a cardiac
reserve of 1.89 + 0.09 watts.
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Table 3.1: Baseline characteristics of study population
 
Male, n (%)
Female, n (%)
Age(yrs, range)
NYHAclass
Height (cm, range)
Weight(kg, range)
BMI (kg/m’, range)
QRSduration (msec, range)
Sinus rhythm, n(%)
Atrial Fibrillation, n(%)
Left ventricular end diastolic dimensions (cm)
Ejection fraction (%)
Aetiology
Ischaemic
Valvular
Idiopathic
Medication
ACEinhibitors/ARB
Diuretics
Beta-blockers
Digoxin
Spironolactone
36 (90%)
4 (10%)
65.3 + 1.6 (38-80)
3
171.2 + 1.2 (154-186)
84.5 + 2.8 (58-139)
28.7 + 0.8 (20-44)
158.0 + 2.9 (124-192)
30 (75%)
10 (25%)
7.01 £0.15
21.71 41.5
29 (72.5%)
4 (10%)
7 (17.5%)
39 (97.5%)
40 (100%)
33 (82.4%)
17 (42.5%)
18 (45%)
 
All continuousvalues are expressed as mean + SEM
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Table 3.2: Baseline cardiopulmonary haemodynamicsand skeletal muscle measurements of
study population
 
Resting HR (min)
Resting MBP (mm Hg)
Resting SBP (mmHg)
Resting VO2 (mls/kg/min)
Resting CO (L/min)
Resting CPO (watts)
Resting VE (L/min)
Exercise duration (secs)
AT(mls/kg/min)
AT % peak VO? (%)
Peak RER
Peak HR (min‘')
Peak MBP (mm Hg)
Peak SBP (mm Hg)
Peak VO» (mls/kg/min)
% predicted peak VO. (%)
Peak CO (L/min)
Peak CPO (watts)
Cardiac reserve (watts)
Peak VE (L/min)
Peak VE/VCO>,
Peak VE/VO>2
VE/VCOzslope
VE/VOz;slope
Right extension (N-M)
Right flexion (N-M)
Left extension (N-M)
Left flexion (N-M)
79 +3
88.7 + 1.9
116.9 + 2.3
5.18 £0.19
3.30+0.11
0.65 + 0.02
14.5 + 0.7
322 +27
10.76 + 0.55
68.1 +2.8
1.04 + 0.02
124+4
106.0 + 1.8
154.5 + 3.2
15.51 + 0.54
66.9 + 2.8
10.75 + 0.35
2.53 0.10
1.89 + 0.09
54.0 + 2.2
41.6+1.4
43.6 +2.1
40.8 + 1.6
45.9+2.5
119.8 + 9.0
63.5 + 4.7
123.2+9.8
64.2 +5.5
All values expressed as mean + SEM.
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3.1.1.3 Relationship between cardiopulmonary andskeletal muscle parameters
at baseline
Full relationship betweenall of the baseline parameters are given in table 3.3.
3.1.1.3.1 Baseline relationship to exercise duration
Atbaseline there wasa significant correlation between overall exercise duration and
peak VO (R’=0.45, p<0.001), peak CPO (R°=0.25, p=0.001), cardiac reserve
(R?=0.35, p<0.001) and the ventilatory equivalents for oxygen uptake (peak VE/VO>
(R?=0.13, p=0.024), VE/ VO>slope (R°=0.22, p=0.002)) and carbon dioxide output
(peak VE/VCO> (R?=0.20, p=0.04), VE/ VCOslope (R*=0.24, p=0.001)) see figure
3.1.
There was no signficant correlation with peak RER (R°=0.00 p=0.895), the
percentage of peak VO at the anaerobic threshold (R°=0.09 p=0.066), LV end
diastolic dimension (R?=0.01 p=0.676), ejection fraction (R’=0.10 p=0.073),
Minnesota living with heart failure scores (R°=0.01 p=0.518) and peak skeletal
muscle torque in extension (right: R°=0.07 p=0.104, left: R°=0.01 p=0.484) or
flexion (right: R?=0.04 p=0.21, left: R’=0.03 p=0.292)
3.1.1.3.2 Baseline relationship to peak VO»
At baseline there was a significant correlation between peak VO» and exercise
duration (see section 3.1.1.3.1), peak CPO (R°=0.24 p=0.002), cardiac reserve
(R°=0.27 p=0.001) and the ventilatory equivalents for oxygen uptake (peak VE/VO2
(R7=0.36 p<0.001), VE/ VOslope (R’=0.35 p<0.001)) and carbon dioxide output
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(peak VE/VCO> (R7=0.44 p<0.001), VE/ VCO>slope (R7=0.48 p<0.001)) see figure
3.2
There was no signficant correlation with peak RER (R7=0.05 p=0.161), the
percentage of peak VO, at the anaerobic threshold (R°=0.00 p=0.739), LV end
diastolic dimension (R’=0.01 p=0.599), ejection fraction (R’=0.05 p=0.213),
Minnesota living with heart failure scores (R’=0.00 p=0.993) and peak skeletal
muscle torque in extension (right: R’=0.02 p=0.459, left: R’=0.02 p=0.426) or
flexion (right: R?=0.07 p=0.116,left: R?=0.02 p=0.358).
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Figure 3.1(a-g) Significant correlelations with exercise duration for peak VO, (a), peak
CPO (b), CR (c), peak VE/VCO,(d), peak VE/VO,(e), VE/VCO, slope (f) and VE/VO,
slope (g).
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3.1.1.3.3. Baseline relationship to peak cardiac power output
At baseline there was a significant correlation between peak CPO and exercise
duration (see section 3.1.1.3.1) and peak VO> (see section 3.1.1.3.2). There was also
signficant correleation between peak cardiac power output and cardiac reserve
(R°=0.94 p<0.001), ejection fraction (R’=0.23 p=0.004), peak skeletal muscle torque
in extension (right: R°=0.29 p<0.001, left: R°=0.23 p=0.002) and flexion (right:
100
 
R°=0.19 p=0.006,left: R’=0.11 p=0.036), and the ventilatory equivalents for oxygen
uptake (peak VE/VO2 (R?=0.33 p<0.001), VE/ VOz slope (R°=0.33 p<0.001)) and
carbon dioxide output (peak VE/VCO, (R?=0.45 p<0.001), VE/VCO. slope
(R°=0.45 p<0.001)) see figure 3.3. There was no signficant correlation with peak
RER (R?=0.03 p=0.333), the percentage of peak VO. at the anaerobic threshold
(R7=0.06 p=0.140), LV end diastolic dimension (R’=0.01 p=0.570), Minnesotaliving
with heart failure scores (R°=0.04 p=0.233)
3.1.1.3.4 Baseline relationship to cardiac reserve
At baseline there was a significant correlation between cardiac reserve and exercise
duration (see section 3.1.1.3.1), peak VOp2(see section 3.1.1.3.2) and peak CPO (see
section 3.1.1.3.2). There wasalso signficant correleation between cardiac reserve and
ejection fraction (R°=0.20 p=0.009), peak skeletal muscle torque in extension (right:
R°=0.27p=0.001, left: R’=0.20 p=0.004) andright sided flexion (R°=0.17 p=0.009).
There was a trend towards a correlation in left sided flexion but this did not reach
statistical significance (R7=0.10 p=0.052). Cardiac reserve also showedsignificant
correlation with the ventilatory equivalents for oxygen uptake (peak VE/VO,
(R°=0.33 p<0.001), VE/ VO> slope (R?=0.38 p<0.001)) and carbon dioxide output
(peak VE/VCO; (R7=0.47 p<0.001), VE/ VCO; slope (R’=0.50p<0.001)) see figure
3.4. There was no signficant correlation with peak RER (R?=0.02 p=0.401), the
percentage of peak VO, at the anaerobic threshold (R°=0.04 p=0.240), LV end
diastolic dimension (R*=0.00 p=0.768), Minnesota living with heart failure scores
(R°=0.05 p=0.184).
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3.1.1.3.5 Baseline relationships for ejection fraction and left ventricular end
diastolic dimension.
Ejection fraction showed a signficant correlation with peak CPO (see section
3.1.1.3.3 ), cardiac reserve (see section 3.1.1.3.4), peak skeletal muscle torque during
extension (right: R°=0.16 p=0.013, left: R°=0.13 p=0.027) and flexion on the right
side (R’=0.14 p=0.018). There was a trend towards a signficant correlation with left
sided flexion but this failed to reach statistical signifcance (R’=0.09 p=0.057) see
figure 3.5.
Ejection fraction showed no signficant correlation with peak VOz (see section
3.1.1.3.2) or any of the ventilatory equivalents for oxygen uptake (peak VE/VO2
(R°=0.02 p=0.360), VE/VO> slope (R’=0.04 p=0.192)) and carbon dioxide output
(peak VE/VCO2 (R°=0.02 p=0.344), VE/ VCOz slope (R°=0.03 p=0.320)). There
was no signficant correlation between the left ventricular end-diastolic dimension
and ejection fraction (R’*=0.03 p=0.307). Left ventricular end-diastolic dimension
showed nosignficant correlation with any variable (see table 3.3
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3.1.1.3.6 Baseline relationships for ventilatory equivalents, peak RER and the
percentage of peak VO,at the anaerobic threshold
The ventilatory equivalents for oxygen uptake and carbon dioxide production
showed signficant correlation with exercise duration (see section 3.1.1.3.1), peak
VOz(see section 3.1.1.3.2), peak CPO (see section 3.1.1.3.3) and cardiac reserve
(see section 3.1.1.3.4). There was significant correlation between peak RER and the
ventilatory equivalents for oxygen uptake (peak VE/VO, (R7=0.56 p<0.001),
VE/VO, slope (R7=0.42 p<0.001)) and carbon dioxide output (peak VE/VCO,
(R7=0.23 p=0.002), VE/VCO> slope (R?=0.27 p=0.001)) (see figure 3.6). Peak RER
did not show anycorrelation with any other parameter(seetable 3.3).
At baseline there was no significant correlation between the percentage of peak VO
at the anaerobic threshold and anyvariable (see table 3.3).
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Figure 3.6(a-d) Correlelations with peak respiratory exchange ratio for peak VE/VCO,(a),
peak VE/VO,(b), VE/VCO,slope (c), VE/VO,slope (d).
3.1.1.3.7_ Baseline relationship for Minnesota living with heart failure scores
At baseline there was no signficant correlation with Minnesota living with heart
failure scores and exercise duration (see section 3.1.1.3.1), peak VO» (see section
3.1.1.3.2), peak CPO (see section 3.1.1.3.3), CR (see section 3.1.1.3.4),
echocardiographic parameters (see section 3.1.1.3.5) and any measure of skeletal
muscle function (right extension (R7=0.05 p=0.176), right flexion (R?=0.04
p=0.244), left extension (R7=0.06 p=0.139) andleft flexion (R°=0.01 p=0.630)).
The only parameter that MLWHF showed a mild correlation with was the peak
ventilatory equivalents for carbon dioxide production (R°=0.10 p=0.045
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3.1.2 Longitudinalresults from baseline to 3 months
3.1.2.1 Functional measures and exercise duration
At baseline the mode New York heart association classification was 3. This showed a
signficant improvement to 2 at 2 weeks post (x p<0.001). The mode NYHA was
maintained at 2 between 2 and 6 weekspost (x” p=0.360). Between 6 weeks and 12
weeks post the mode NYHA class stayed at 2 however there was a significant
improvement during that time using the chi squared test (x° p<0.001) (see figure
3.7).
Exercise duration increased from a baseline of 323 + 27 seconds to 477 + 33 seconds
(p<0.001). The improvement in exercise duration was maintained at 6 weeks with no
further signficant improvement in exercise duration between 2 and 6 weeks post (2
weeks: 477 + 33, 6 weeks: 527 + 33 seconds, p=0.396). Between 6 and 12 weeks the
mean exercise duration showed no further change (6 weeks: 527 + 33, 12 weeks: 558
+ 36, p=1.0) (see figure 3.8)
Minnesota living with heart failures also showed a significant improvement from
baseline at the 2 weeks post stage (baseline: 61.6 + 3.7, 2 weeks: 37.3 + 4.0,
p<0.001). The improvement seen was maintained but not increased at the 6 weeks
stage (2 weeks: 37.3 + 4.0, 6 weeks: 33.1 + 4.0 p=1.0). At 12 weeks postthe initial
improvement has been maintained but again no further improvement was seen
compared to the 6 weeksposttest (6 weeks: 33.1 + 4.0, 12 weeks: 32.3 + 3.6 p=1.0)
(see figure 3.9).
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Figure 3.7: Longitudinal change in New Yorkheart associationclass.
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Figure 3.8: Longitudinal improvementin exercise duration
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Figure 3.9: Longitudinal improvement in Minnesotaliving with heartfailure.
3.1.2.2 Peak VO,
There wasa signficant increase in the peak VOz at the 2 weeks post test (baseline:
15.51 + 0.54, 2 weeks: 17.76 + 0.55 p=0.003). This improvement was maintained but
not increased at 6 weeks (2 weeks: 17.76 + 0.55, 6 weeks: 17.54 + 0.56 p=1.0).
Between 6 and 12 weeks postthe initial improvement was maintined but no further
improvement wasseen (6 weeks: 17.54 + 0.57, 12 weeks: 18.48 + 0.62 p=0.177) (see
figure 3.10).
3.1.2.3 Ventilatory equivalents for oxygen and carbon dioxide
There was no significant change in the ventilatory equivalents for oxygen or carbon
dioxide between baseline and 2 weeks (peak VE/VCOnz: baseline 41.6 + 1.4, 2
weeks: 39.4 + 1.2 p=0.163, VE/VCOzslope: baseline 40.8 + 1.6, 2 weeks: 37.4 + 1.2
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p=0.082, peak VE/VOz: baseline 43.6 + 2.1, 2 weeks: 41.4 + 1.6 p=0.758, VE/VO>
slope: baseline 45.9 + 2.5, 2 weeks: 41.8 + 1.9 p=0.323).
Between the 2 and 6 weeks test there was no signficant change (peak VE/VCO): 2
weeks: 39.4 + 1.2, 6 weeks: 39.2 + 1.3 p=1.0, VE/VCO)>slope: 2 weeks: 37.4 + 1.2,
6 weeks: 37.4 + 1.3 p=1.0, peak VE/VO2: 2 weeks: 41.4 + 1.6, 6 weeks: 42.2 + 1.6
p=1.0, VE/VOzslope: 2 weeks: 41.8 + 1.9, 6 weeks: 43.0 + 1.9 p=1.0).
Between the 6 and 12 weektest there were also no significant changes in any of the
ventilatory equivalents for oxygen (peak VE/VO>: 6 weeks: 42.2 + 1.6, 12 weeks:
41.3 + 1.4 p=1.0, VE/VOzslope: 6 weeks: 43.0 + 1.9, 12 weeks: 42.5 + 1.8 p=1.0) or
for carbon dioxide (peak VE/VCO2: 6 weeks: 39.2 + 1.3, 12 weeks: 38.3 + 1.2
p=1.0, VE/VCO;slope: 6 weeks: 37.4 + 1.3, 12 weeks: 37.1 + 1.3 p=1.0).
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Figure 3.10: Longitudinal improvement in peak VO,
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3.1.2.4 Peak cardiac output and cardiac reserve
There wasa signficant increase in peak cardiac poweroutputand cardiacreserve at 2
weeks post CRT (peak CPO:baseline: 2.53 + 0.10, 2 weeks: 2.96 + 0.13 p=0.001,
cardiac reserve: baseline: 1.89 + 0.09, 2 weeks: 2.27 + 0.11 p=0.004). There was no
further increase between 2 and 6 weeks for either peak cardiac power output (2
weeks: 2.96 + 0.13, 6 weeks: 3.07 + 0.13 p=0.636) or cardiac reserve (2 weeks: 2.27
+ 0.11, 6 weeks: 2.41 + 0.12 p=0.338). At 12 weeks post CRT there was no
significant increase compared to the 6 week post stage in either peak cardiac power
output (6 weeks: 3.07 + 0.13, 12 weeks: 3.23 + 0.15 p=0.492)or cardiac reserve (6
weeks: 2.41 + 0.12, 12 weeks: 2.58 + 0.14 p=0.438), however the 3 month results
were signficantly improved compared to the 2 weeks post results (peak CPO: 2
week: 2.96 + 0.13, 12 weeks: 3.23 + 0.15 p=0.014, cardiac reserve: 2 weeks: 2.27 +
0.11, 2 weeks: 2.58 + 0.14 p=0.005)(see figure 3.11)
3.1.2.5 Peak RERand percentage of peak VO,at the anaerobic threshold.
There wasnosignficant change in either peak RERorthe percentage of peak VO; at
the anaerobic threshold between the baseline and 2 weekstests (peak RER:baseline:
1.04 + 0.02 2 weeks: 1.05 + 0.02 p=1.0, peak VO. at the anaerobic threshold:
baseline: 78.9 + 11.7, 2 weeks: 69.1 + 2.1 p=1.0). Between 2 and 6 weeks there was
no change in peak RER (2 weeks: 1.05 + 0.02, 6 weeks: 1.08 + 0.02, p=1.0) and the
percentage of peak VO» at the anaerobic threshold (2 weeks: 69.1 + 2.1, 6 weeks:
70.1 + 2.5, p=1.0).
Between the 6 and 12 weektest there were also no significant changes in either RER
(6 weeks: 1.08 + 0.02, 12 weeks: 1.08 + 0.01, p=1.0) or the percentage of peak VO,
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at the anaerobic threshold (6 weeks: 70.1 + 2.5, 12 weeks: 68.9 + 1.6, p=1.0) (see
 
 
 
 
 
table 3.4)
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Figure 3.11 The longitudinal improvement in peak cardiac power output (CPO)(a) and cardiac
reserve (CR) (b)
113
 
3.1.2.6 Echocardiographic parameters
Following cardiac resynchronisation therapy there was a trend towards an
improvement in ejection fraction at 2 weeks howeverthis failed to reach statistical
significance (baseline: 21.71 + 1.50, 2 weeks: 28.74 + 1.97, p=0.068). There was
however a significant change in ejection fraction at 6 weeks compared to baseline
(baseline: 21.71 + 1.50, 6 weeks: 30.72 + 1.16 p=0.002). There was nosignficant
change betweenthe 2 and 6 weektests (2 weeks: 28.74 + 1.97, 6 weeks: 30.72 + 1.16
p=1.0). Between 6 and 12 weeks the improvement in ejection fraction was
maintained but not increased further (6 weeks: 30.72 + 1.16, 12 weeks: 32.01 + 1.43
p=1.0) (see figure 3.12a).
There was a small reduction in left ventricular end-diastolic dimension between
baseline and 2 weeks however this just failed to reach statistical significance
(baseline: 7.01 + 0.15, 2 weeks: 6.60 + 0.15 p=0.055). The change between baseline
and 6 weeksalso just failed to reach statistical signficance (6 weeks: 6.46 + 0.15
p=0.052). There was nostatistically signficant difference between baseline and 12
weeks (12 weeks: 6.67 + 0.16 p=0.366). Between 2 and 6 weeks there was no
signficant changein left ventricular end-diastolic dimension (2 weeks: 6.60 + 0.15, 6
weeks: 6.46 + 0.15 p=1.0). Between 6 and 12 weeks there was no change in left
ventricular end-diastolic dimension (6 weeks: 6.46 + 0.15, 12 weeks: 6.67 + 0.16
p=1.0) (see figure 3.12b)
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3.1.2.7 Skeletal muscle function
At 2 weeks post cardiac resynchronisation therapy there was no significant
improvement in peak skeletal muscle torque in flexion or extension on the right
(extension: baseline: 119.8 + 9.0, 2 weeks: 128.8 + 11.5 p=1.0, flexion: baseline:
63.5 + 4.7, 2 weeks: 70.3 + 4.5 p=0.292) or on the left (extension: baseline: 123.2 +
9.8, 2 weeks: 130.5 + 11.9 p=1.0, flexion: baseline: 64.2 + 5.5, 2 weeks: 70.7 + 4.5
p=0.708).
Between 2 and 6 week post cardiac resynchronisation therapy no significant change
in peak muscle torque on the right (extension: 2 weeks: 128.8 + 11.5, 6 weeks: 127.6
+ 10.7 p=1.0, flexion: 2 weeks: 70.3 + 4.5, 6 weeks: 70.7 + 5.3 p=1.0) or on theleft
(extension: 2 weeks: 130.5 + 11. 9, 6 weeks: 131.3 + 11.1 p=1.0, flexion: 2 weeks:
70.7 + 4.5, 6 weeks: 72.3 + 5.2 p=1.0).
There was also no significant improvement between 6 and 12 weeks post cardiac
resynchronisation therapy on the right (extension: 6 weeks: 127.6 + 10.5, 12 weeks:
123.5 + 10.0 p=1.0, flexion: 6 weeks: 70.7 + 5.3, 12 weeks: 71.1 + 4.8 p=1.0) or on
the left (extension: 6 weeks: 131.3 + 11. 1, 12 weeks: 126.3 + 9.9 p=0.882, flexion: 6
weeks: 72.3 + 5.2, 12 weeks: 71.6 + 4.3 p=1.0) (see table 3.4)
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Figure 3.12: The longitudinal improvementin ejection fraction (a) and left ventricular end
diastolic dimension (b)
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Table 3.4: Longitudinal improvementfollowing CRT
 
 
 
     
Baseline 2 weeks 6 weeks 3 months
NYHA 3 2* 2* 2 tty
MLWHF 61.6 (3.7) 37.3 (4.0) * 33.1 (4.0) * 32.3 (3.6) *
Exercise * x *Duration 322 (27) 478 (33) 527 (33) 558 (36)
Peak VO; 15.51 (0.54) eR bie) 18.48(0.62)
RER 1.04 (0.02) 1.05 (0.02) 1.08 (0.02) 1.08 (0.01)
Percentage of
peak VO,at 78.9 (11.7) 69.1 (2.1) 70.1 (2.5) 68.9 (1.6)
AT
PeakCPO 2.53(0.10) 2.96(0.13)* 3.07 (0.13) * ee
CR 1.89 (0.09) 2.27(0.11)* 2.41 (0.12) * a
LVEDD 7.01 (0.15) 6.60 (0.15) 6.46 (0.15) 6.67 (0.16)
EF 21.71 (1.5) 28.74 (1.97) 30.72(1.16) 32.01(1.43)
RightExtension 119.8 (9.0) 128.8 (11.5) 127.6(10.7) 123.5 (10.0)
Left Extension 123.2 (9.8) 130.5 (11.9) 131.3 (11.1) 126.3 (9.9)
Right Flexion 63.5 (4.7) 70.3 (4.5) 70.7 (5.3) 71.1 (4.8)
Left Flexion 64.2 (5.5) 70.7 (4.5) 72.3 (5.2) 71.6 (4.3)
Peak VE/VCO, 41.6 (1.4) 39.4 (1.2) 39.2 (1.3) 38.3 (1.2)
Peak VE/VO, 43.6 (2.1) 41.4 (1.6) 42.2 (1.6) 41.3 (1.4)
VE/VCO;slope 40.8 (1.6) 37.4 (1.2) 37.4 (1.3) 37.1 (1.3)
VE/VO;slope 45.9 (2.5) 41.8 (1.9) 43.0 (1.9) 42.5 (1.8)  *p<0.05 comparedto baseline +p<0.05 compared to 2 weeks
tp<0.05 compared to 6 weeks
All values expressed as mean + SEM.
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3.1.3 Predictors of response
At 3 months 27 (67.5%) out of the 40 patients were defined as responders. The
baseline parameters showed that there was no signficant difference in patients age
(responders: 66.4 + 1.8 vs. non-responders: 63.0 + 3.3 p=0.323) and baseline QRS
duration (responders: 159.3 + 3.7 vs. non-responders: 155.1 + 4.5 p=0.48). There
wasa Significant difference in the echocardiographic parameters at baseline between
responders and non-responders with responders showing a less dilated LVEDD
(responders: 6.76 + 0.14 vs. non-responders: 7.30 + 0.18 p=0.024) and a more
impaired ejection fraction (responders: 21.61 + 1.70 vs. non-responders: 29.13 + 2.22
p=0.015). Peak skeletal muscle torque during extension at baseline wassignificantly
different between the responders and non-responders(right: responders: 114.9 + 8.6
vs. non-responders: 147.8 + 12.9 p=0.032, left: responders: 113.9 + 8.8 vs. non-
responders: 144.6 + 12.8 p=0.029) but there was no significant difference during
flexion (right: responders: 61.3 + 4.2 vs. non-responders: 75.2 + 7.0 p=0.08,left:
responders: 62.6 + 5.0 vs. non-responders: 70.1 + 6.0 p=0.15). There were also
significant differences between the responders and non-responders in the baseline
ventilatory equivalents for carbon dioxide production (peak VE/VCO>: responders:
44.3 + 1.6 vs. non-responders: 38.9 + 2.4 p=0.04, left: responders: 43.7 + 1.8 vs. non-
responders: 38.0 + 2.8 p=0.035). The baseline peak ventilatory equivalents for
oxygen consumption (peak VE/VO2) did just reach signficance (responder: 46.9 +
2.3 vs. non-responders: 40.8 + 3.4 p=0.049) whilst the ventilatory equivalent slope
for oxygen consumption (VE/VO;slope) were not significantly different between the
responders and non-responders (responder: 50.1 + 3.5 vs. non-responders: 43.3 + 4.0
p=0.15).
118
There wasalso no significant difference between the responders and non-responders
in mean MLWHFscores (responders: 57.1 + 3.5 vs. non-responders: 66.6 + 5.3
p=0.16), exercise duration (responders: 344 + 31.9 vs. non-responders: 349.1 + 50.8
p=0.16), peak VOz (responders: 15.44 + 0.63 vs. non-responders: 16.41 + 1.00
p=0.39), RER (responders: 1.05 + 0.02 vs. non-responders: 1.04 + 0.02 p=0.83),
percentage of peak VOz at AT (responders: 70.6 + 3.6 vs. non-responders: 62.8 + 4.3
p=0.09), peak CPO (responders: 2.42 + 0.11 vs. non-responders: 2.79 + 0.21 p=0.27)
and cardiac reserve (responders: 1.80 + 0.11 vs. non-responders: 2.09 + 0.20 p=0.35).
Full results are shown in table 3.5
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Table 3.5: Baseline predictors of response
 Responders Non-Responders(n=27) (n=13) p-value
Age (years) 66.4 + 1.8 63.04 3.3 0.32
QRSduration (ms) 199.9 23.7 155.14 4.5 0.48
MLWHFscores 57.1+3.5 66.6 + 5.3 0.16
Exercise Duration (secs) 344 + 31.9 349.1 + 50.8 0.94
Peak VO) (mls/kg/min) 15.44 + 0.63 16.41 + 1.00 0.39
RER 105+0.02 1.04 + 0.02 0.83
Percentage of peak VO, at 70.6 + 3.6 62.8 + 4.3 0.09
AT
Peak CPO 2.42+0.11 2.79 + 0.21 0.27
Cardiac Reserve 1.80 + 0.10 2.09 + 0.20 0.35
LVEDD 6.76 + 0.14 7.30 +0.18 0.024
Ejection Fraction 21.61 + 1.70 29.13 + 2.22 0.015
Right Extension 114.9+ 8.6 147.8 + 12.9 0.032
Left Extension 113.9+ 8.8 144.6+ 12.8 0.029
Right Flexion 61.34 4.2 D270 0.08
Left Flexion 62.6 + 5.0 70.1 + 6.0 0.15
Peak VE/VC02 44.34+1.6 38.9424 0.04
Peak VE/V02 46.9 + 2.3 40.8 + 3.4 0.049
VE/VC02Slope 43.7+ 1.8 38.0+2.8 0.035
VE/V02 Slope 50.1 + 3.5 43.3+4.0 0.15
 All values expressed as mean + SEM.
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3.2 Study II. Theeffects of exercise rehabilitation in addition to cardiac
resynchronisation therapy
3.2.1 Baseline Data
Baseline characteristics of the patients are shownin table 3.6. Mean age was 64.4 +
1.5 (range: 38-80) years and 46 (92%) patients were male. The mean and mode
NYHAclass was 3 and there was evidence of a dilated cardiomypoathy with a left
ventricular end diastolic dimension of 7.07cm + 0.13 and a ejection fraction of
23.67 % + 1.32. Thirty three (66%) of the patients were in sinus rhythm atbaseline,
the rest (17(34%)) were in atrial fibrillation. The primary cause of the dilated
cardiomypathy was ischaemic in 37 (74%), valvular heart disease in 6 (12%) and
idiopathic in 7 (14%).
3.2.2 Baseline cardiopulmonary data
The baseline cardiopulmonary haemodynamic data are shown in table 3.7. Resting
heart rate was 76 + 2/min and increased to 121 + 4/min at peak exercise. This was
associated with an increase in meanarterial pressure from 87.3 + 1.2 mmHgto 104.8
+ 1.5 mmHg.Total exercise duration was 374 + 27 seconds and patients did achieve
a true maximalcardiopulmonary exercise test manifest by a peak RER of 1.0 + 0.02.
The subjects were significantly impaired in their cardiopulmonary exercise capacity
with a peak VO2 of 16.12 + 0.49 mls/kg/min which was 67.1 + 2.5 % oftheir
predicted peak VO. Cardiac poweroutput increased from a resting value of 0.63 +
0.03 watts to a peak value of 2.48 + 0.11 watts therefore giving a cardiac reserve of
1.85 + 0.1 watts.
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Table 3.6 Baseline characteristic of the study population
 
Male, n (%)
Female, n (%)
Age (yrs, range)
NYHAclass
Height (cm, range)
Weight(kg, range)
BMI (kg/m?, range)
QRSduration (msec, range)
Sinus rhythm, n(%)
Atrial Fibrillation, n(%)
Aetiology
Ischaemic
Valvular
Idiopathic
Medication
ACEinhibitors/ARB
Diuretics
Beta-blockers
Digoxin
Spironolactone
46 (92%)
4 (8%)
64.4 + 1.5 (38-80)
3
171.8 + 1.1 (154-186)
84.4 + 2.5 (55-139)
28.7 + 0.7 (20-44)
160.4 + 2.9 (124-198)
33 (66%)
17 (34%)
37 (74%)
6 (12%)
7 (14%)
49 (98%)
48 (96%)
30 (60%)
23 (46%)
27 (54%)
 All values expressed as mean + SEM.
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Table 3.7: Baseline cardiopulmonary data
 
Resting HR (min")
Resting MBP (mm Hg)
Resting VO> (mls/kg/min)
Resting CO (L/min)
Resting CPO (watts)
Resting VE (L/min)
Exercise duration (secs)
AT (mls/kg/min)
AT % peak VO(%)
Peak RER
Peak HR (min’')
Peak MBP (mm Hg)
Peak SBP (mm Hg)
Peak VO> (mls/kg/min)
% predicted peak VO2 (%)
Peak CO (L/min)
Peak CPO (watts)
Cardiac reserve (watts)
Peak VE (L/min)
Peak VE/VCO2
Peak VE/VO,
VE/VCO3}slope
VE/VO3stope
Right extension (N-M)
Right Flexion (N-M)
Left Extension (N-M)
Left Flexion (N-M)
76+ 2
88.3 + 1.6
5.35 + 0.18
3.25 + 0.13
0.63 + 0.03
15.1 +0.7
374 + 27
11.63 £0.51
71.8+2.4
1.00 + 0.02
121+4
104.8 + 1.5
152.7 +2.8
16.12 + 0.49
67.1 +2.5
10.56 + 0.41
2.48 + 0.11
1.85 +0.1
54.5 + 2.0
44.36 + 1.96
43.46 + 1.68
43.94 + 2.36
46.93 + 2.44
128.4+6.5
70.3 + 3.9
124.1 +6.5
72.8 + 3.4
 All values expressed as mean + SEM.
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3.2.3 Baseline to 3 months post CRT
Full results from baseline to 3 months post cardiac resynchronisation therapy are
shownin table 3.8.
3.2.3.1 Functional measuresand exercise duration
There was an improvement in NYHAclassification from a mode of 3 to 2 (°
p<0.001) (see figure 3.13), and in the Minnesotaliving with heart failure scores from
61.8 + 2.5 to 31.8 + 2.8 (p<0.001) (see figure 3.14). Exercise duration improved from
a baseline of 374 + 27 to 562 + 31 (p<0.001) (see figure 3.15).
3.2.3.2 Peak VO;andthe ventilatory equivalents for oxygen and carbon dioxide
Following cardiac resynchronisation therapy there was an increase in peak VO,
(mls/min/kg) from 16.12 + 0.49 to 18.41 + 0.50 (p<0.001) (see figure 3.16). There
was also an improvementin the ventilatory equivalents for carbon dioxide (peak
VE/VCO3: 44.36 + 1.96 to 38.84 + 0.98 p<0.001, VE/VCO>slope: 43.94 + 2.36 to
37.49 + 1.0 p=0.001) (see figure 3.17). There was no change in the ventilatory
equivalents for oxygen (peak VE/VO>: 43.46 + 1.68 to 41.94 + 1.10 p=0.236,
VE/VO;slope: 46.93 + 2.44 to 43.22 + 1.42 p=0.087)(see figure 3.18).
3.2.3.3 Peak Cardiac output and Cardiac Reserve
At 3 months post there was an improvement in peak cardiac power output (W) from
2.48 + 0.11 to 3.20 + 0.11 (p<0.001) (see figure 3.19) and also in cardiac reserve (W)
from 1.85 + 0.10 to 2.54 + 0.10 (p<0.001) (see figure 3.20).
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3.2.3.4 Peak RER and percentage of peak VO,at the anaerobic threshold.
The peak respiratory exchange ratios (RER) achieved improved from 1.00 + 0.02 to
1.08 + 0.01 (p<0.001), however the percentage of peak VO. at the anaerobic
threshold (%) remained unchangedatthis point (71.8 + 2.4 to 69.1 + 1.3 (p=0.319))
(see figure 3.21).
3.2.3.5 Echocardiographic parameters
Following cardiac resynchronisation therapy there was a reduction in the left
ventricular end-diastolic dimension from 7.07 + 0.13 to 6.64 + 0.11 (p<0.001). This
was coupled with an improvementin the ejection fraction from 23.7 + 1.32 to 32.4+
0.92 (p<0.001) (see figure 3.22).
3.2.3.6 Peak skeletal muscle torque
There was no improvement in peak skeletal muscle torque during extension (right:
128.3 + 6.5 to 131.3 + 6.9 p=0.272, left: 124.1 + 6.5 to 127.2 + 6.5 p=0.149) (see
figure 3.23) or during flexion (right: 70.3 + 3.9 to 72.8 + 3.5 p=0.101, left: 72.8 + 3.4
to 70.7 + 3.2 p=0.275) (see figure 3.24).
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Table 3.8: Longitudinal data baseline to 3 months
 
 
 
    
Pre CRT 3 months Post CRT
NYHAclass 3 2*
MLWHF 61.8 + 2.5 31.8+42.8*
cud} 374 +27 562 £31*
Peak VO),(mls/kg/min) 16.12 + 0.49 18.41 + 0.50*
RER 1.00 + 0.02 1.08 + 0.01 *
anofpeak VOz N&+24 69.1413
Peak CPO (W) 2.48+0.11 3.20+ 0.11*
CR (W) 1.85+0.10 2.54 + 0.10*
DiniDanentem| 7072013 eetsoute
Ejection Fraction (%) 23.1 41.32 32.4 + 0.92*
Right Extension (N-M) 128.3 + 6.5 131.3+6.9
Left Extension (N-M) 124.1+6.5 127.2+6.5
Right Flexion (N-M) 70.3 + 3.9 72.8 + 3.5
Left Flexion (N-M) 72.8434 70.7 + 3.2
Peak VE/VCO, 44.36 + 1.96 38.84 + 0.98 *
Peak VE/VO, 43.46 + 1.68 41.94+ 1.10
VE/VCO;slope 43.94 + 2.36 37.49 + 1.00 *
VE/VO;slope 46.93 + 2.44 43.22 + 1.42  
All values expressed as mean + SEM.
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3.2.4 Baseline data at randomisation
At 3 monthsthe patients were randomisedto either exercise training or control. The
2 groups were well matchedat the point of randomisation (see table 3.9). There was
similar rate of sinus rhythm in both the exercise group (16 patients (64%)) and the
control group (17 patients (68%)).
3.2.4.1 Functional measures and exercise duration
There was nosignificant difference in either NYHAclassification between the 2
groups at 3 months (exercise: 2 vs. control: 2 (7° p=0.905)), or in the Minnesota
living with heart failure scores from (exercise: 34.6 + 4.5 vs. control: 29.0 + 3.3
(p=0.325)). Exercise duration was also similar in both groups post randomisation
(exercise: 581 + 45 vs. control: 542 + 43 (p=0.527)).
3.2.4.2 Peak VO, andthe ventilatory equivalents for oxygen and carbon dioxide
Following randomisation there was no significant difference in peak VO,
(mls/min/kg) between the 2 groups (exercise: 18.74 + 0.68 vs. control: 18.08 + 0.75
(p=0.521)). There were also no significant differences in the ventilatory equivalents
for carbon dioxide (peak VE/VCOz: exercise: 37.6 + 1.1 vs. control: 40.1 + 1.6
(p=0.195), VE/VCOzslope: exercise: 36.4 + 1.1 vs. control: 38.6 + 1.7 (p=0.290)).
There was also no significant difference in the ventilatory equivalents for oxygen
(peak VE/VOnz: exercise: 41.0 + 1.2 vs. control: 42.8 + 1.8 (p=0.420), VE/VO}slope:
exercise: 42.7 + 1.6 vs. control: 43.8 + 2.4 (p=0.715)).
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3.2.4.3 Peak cardiac output and cardiac reserve
At 3 months following cardiac resynchronisation therapy there was no signficant
differences betweent the 2 groups in peak cardiac power output (w) (exercise: 3.27 +
0.16 vs. control: 3.14 + 0.15 (p=0.545)) and cardiac reserve (w) (exercise: 2.57 +
0.14 vs. control: 2.51 + 0.14 (p=0.772)).
3.2.4.4 Peak RER and percentage of peak VO, at the anaerobic threshold.
The peak respiratory exchange ratios (RER) achieved wassimilar in the 2 groupsat 3
months (exercise: 1.10 + 0.02 vs. control: 1.07 + 0.01 (p=0.246)). The percentage of
peak VO>at the anaerobic threshold (%) was also similar in both groups(exercise:
67.5 + 1.7 vs. control: 70.8 + 1.9 (p=0.200)).
3.2.4.5 Echocardiographic parameters
Following randomisation there was no signficant difference in the left ventricular
end-diastolic dimension between the 2 groups (exercise: 6.64 + 0.18 vs. control:
6.57 + 0.11 (p=0.752)). There was also no significant difference in the ejection
fraction between the 2 groupsat this stage (exercise: 32.8 + 1.2 vs. control: 32.6 +
1.4 (p=0.895)).
3.2.4.6 Peak skeletal muscle torque
There was no significant difference between the 2 groups in peak skeletal muscle
torque during extension (right: exercise: 135.0 + 10.1 vs. control: 127.7 + 9.6
(p=0.603), left: exercise: 135.0 + 10.1 vs. control: 119.4 + 8.0 (p=0.233)) or during
flexion (right: exercise: 73.7 + 5.1 vs. control: 71.9 + 4.9 (p=0.805), left: exercise:
72.5 + 4.5 vs. control: 68.8 + 4.5 (p=0.567)).
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3.2.5 Results at 6 months post cardiac resynchronisation therapy.
No patients in the exercise group had any complications from the exercise training
and there were no problems with cardiac arrhythmias. Full results following
randomisation are shownin table 3.9.
3.2.5.1 Functional measures and exercise duration
Following the period of exercise training the exercise group showed a further
significant improvement in New York heart association class (2 vs. 1 Ca p<0.001))
(see figure 3.13) and Minnesota living with heart failure score (34.6 + 4.5 vs. 26.2 +
4.1 (p=0.013)) (see figure 3.14). The exercise group also showed a significant
increase in exercise duration (seconds) (581 + 45 vs. 752 + 36 (p<0.001)) (see figure
3.15). The control group showed significant improvement in exercise duration
(seconds) (542 + 43 vs. 572 + 44 (p=0.028)) but no improvements in NYHAclass(2
vs. 2 (x2 p=0.607) and MLWHFscore(29.0 + 3.3 vs. 29.5 + 3.6 (p=0.949).
Inter-group analyses confirmedthat the improvements in NYHAclass (mean change
exercise: 1 vs. control: 0 (p=0.001)), exercise duration (seconds) (mean change
exercise: 171 + 35 vs. control: 30 + 13 (p<0.001)), and MLWHFscores (mean
change exercise: -8.4 + 3.1 vs. control: 1.6 + 3.1 (p=0.026)) were significantly better
in the exercise group.
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Figure 3.15: Exercise Duration
3.2.5.2 Peak VO> and the ventilatory equivalents for oxygen and carbon dioxide
There was a signficant increase in the peak VO> (mls/kg/min) following exercise
training (18.74 + 0.68 vs. 20.10 + 0.77 (p=0.011)) (see figure 3.16). This
improvement was not matched in the control group (18.08 + 0.75 vs. 18.07 + 0.78
(p=0.977)). There was no significant improvement in either group in the ventilatory
equivalents for carbon dioxide production (peak VE/VCOz: exercise: 37.6 + 1.1 vs.
37.9 + 1.3 (p=0.746) control: 40.1 + 1.6 vs. 39.0 + 1.6 (p=0.177), VE/VCO;}slope:
exercise: 36.4 + 1.1 vs. 35.7 + 1.2 (p=0.427) control: 38.6 + 1.7 vs. 37.1 + 1.8
(p=0.224)) (see figure 3.17) and for oxygen consumption (peak VE/VO3: exercise:
41.0 + 1.2 vs. 43.1 + 1.6 (p=0.096) control: 42.8 + 1.8 vs. 41.3 + 2.0 (p=0.068),
VE/VOy>slope: exercise: 42.7 + 1.6 vs. 43.4 + 1.7 (p=0.610) control: 43.8 + 2.4 vs.
41.9 + 2.5 (p=0.285)) (see figure 3.18).
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Inter-group analyses confirmed that the improvement in peak VO, (mls/kg/min)
(mean change exercise: 1.37 + 0.5 vs. control: -0.01 + 0.30 (p=0.022)) was
significantly better in the exercise group. There wasalso a difference between the 2
groupsin the change in peak VE/VO> (mean changeexercise: 2.1 + 1.2 vs. control: -
1.5 + 0.8 (p=0.016)). The inter-group analyses showed no difference between the 2
groups in peak VE/VCO> (mean change exercise: 0.3 + 1.0 vs. control: -1.1 + 0.8
(p=0.266)), VE/VCOz slope (mean changeexercise: -0.7 + 0.8 vs. control: -1.5 + 1.2
(p=0.585)) and VE/VO> slope (mean change exercise: 0.6 + 1.3 vs. control: -1.8 +
1.7 (p=0.241).
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3.2.5.3 Peak cardiac output and cardiac reserve
The exercise group showeda further significant improvementin peak cardiac power
output (w) (3.27 + 0.16 vs. 3.76 + 0.20 (p<0.001)) (see figure 3.19) and in cardiac
reserve (w) (2.57 + 0.14 vs. 3.05 + 0.19 (p<0.001)) (see figure 3.20). This was not
matched by the control group who showed nosignificant improvement in peak
cardiac power output (w) (3.14 + 0.15 vs. 3.20 + 0.19 (p=0.633)) and in cardiac
reserve (w) (2.51 + 0.14 vs. 2.52 + 0.18 (p=0.968)).
Inter-group analysis confirmed that the improvement in peak cardiac power output
(w) (mean change exercise: 0.49 + 0.12 vs. control: 0.06 + 0.13 (p=0.019)) and
cardiac reserve (w) (mean change exercise: 0.48 + 0.11 vs. control: 0.01 + 0.13
(p=0.008)).
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Figure 3.19: Peak cardiac power output
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3.2.5.4 Peak respiratory exchange ratio and the percentage of peak VO) at the
anaerobic threshold.
The maximum RERachievable was significantly increased in the exercise group
(1.10 + 0.02 vs. 1.14 + 0.02 (p=0.001)) and there was a significant reduction in the
percentage of peak VO>at the anaerobic threshold (%) (67.5 + 1.7 vs. 62.1 + 2.0
(p=0.010)) (see figure 3.21). The control group showed nosignificant change in the
peak RER (1.07 + 0.01 vs. 1.06 + 0.02 (p=0.571)) and in the percentage of peak VO,
at the anaerobic threshold (%) (70.8 + 1.9 vs. 70.0 + 2.3 (p=0.703)).
Inter-group analysis confirmed that the improvement in peak RER (mean change
exercise: 0.04 + 0.01 vs. control: -0.01 + 0.01 (p=0.008)) was significantly greater in
the exercise group. There was also a trend towards a difference between the two
groups when assessing the change in the percentage of peak VO» at the anaerobic
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threshold (%) but this did not reach significance (mean change exercise: -5.4 + 1.9
vs. control: -0.8 + 2.1 (p=0.109)).
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Figure 3.21: Peak respiratory exchange ratio (a) and the percentage of percentage of peak VO,
at the anaerobic threshold (b)
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3.2.5.5 Echocardiographic parameters
At 6 months the exercise group showed a trend towards an improvement in left
ventricular end diastolic dimensions (cm) but this did not to reach statistical
significance (6.64 + 0.18 vs. 6.40 + 0.11 (p=0.164)). The improvementin the control
group did achieve significance (6.57 + 0.11 vs. 6.34 + 0.11 (p=0.006)). Conversely
the ejection fraction (%) significantly improved in the exercise group (32.8 + 1.2 vs.
37.4 + 1.1 (p=0.010)) but not in the control group (32.6 + 1.4 vs. 35.0 + 14
(p=0.132)) (see figure 3.22).
Inter-group analyses of the changes showed nosignificant difference between the 2
groups in either left ventricular end diastolic dimensions (cm) (mean change
exercise: -0.24 + 0.17 vs. control: -0.23 + 0.08 (p=0.963)) or ejection fraction (%)
(mean change exercise: 4.5 + 1.6 vs. control: 2.5 + 1.6 (p=0.371)).
3.2.5.6 Peak skeletal muscle torque
After the period of exercise training the peak skeletal muscle torque during extension
(N-M) wassignificantly improved in the exercise group (right: 135.0 + 10.1 vs.
144.8 + 11.5 (p=0.009)), left: 135.0 + 10.1 vs. 143.6 + 10.6 (p=0.004)) (see figure
3.23), during flexion there was an trend towards improvementbutthis did not reach
significance (right: 73.7 + 5.1 vs. 76.8 + 5.6 (p=0.120), left: 72.5 + 4.5 vs. 76.3 +5.4
(p=0.076)) (see figure 3.24). The control group showed a trend towards an
improvementin the peak skeletal muscle torque during extension but this failed to
reach significance (right: 127.7 + 9.6 vs. 131.5 + 9.9 (p=0.064), left: 119.4 + 8.0 vs.
124.3 + 8.2 (p=0.060)) and no significant change during flexion (right: 71.9 + 4.9 vs.
71.0 + 5.0 (p=0.680), left: 68.8 + 4.5 vs. 71.2 + 4.6 (p=0.334)).
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Inter-group analyses showednosignificant difference between the 2 groupsin either
extension (right: exercise: 9.8 + 3.4 vs. control: 3.8 + 2.0 (p=0.133)), left: exercise:
8.7 + 2.8 vs. control: 5.0 + 2.4 (p=0.309)) or flexion (right: exercise: 3.2 + 2.0 vs.
control: -0.9 + 2.1 (p=0.168)), left: exercise: 3.9 + 2.1 vs. control: 2.3 + 2.4
(p=0.635)).
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Table 3.9: Results from 3 to 6 months
 
 
 
       
Exercise Group Control Group
3 months 6 months A change 3 months 6 months A change
NYHAclass 2 1* 1+ 2 2 0
MLWHF
|
34.6445 [262441 *| -8443.1+|] 290433 295436 16431
ExerciseDuration
|
581445 752436* 171435+
|
542443 s72444* 30413
(seconds)
Peak VO2 1974 + 0.68 120.10 + 0.774| 1.37 + 0.5+| {18.08 + 0.75 18.07 + 0.78 -0.01 + 0.30(mls/kg/min)
RER 1.10+0.02 }1.14+0.02 *]0.04 + 0.014] |1.0740.01 1.06+0.02 |-0.01+0.01
Percentage ofpeak VO, at 67.5+1.7 62.1420*| -54+19 708+19 700423 08421the AT (%)
ae 3.27£0.16 |3.76 + 0.20 *|0.49+0.12 413.14+0.15 3.20+0.19 0.06+0.13
CR(W) 2.5740.14 3.05 + 0.19 *10.48+0.11 442.5140.14 2.52+0.18 0.01+0.13
LVEDD (cm) 6.64+0.18 6.40+0.11 |-0.24+40.17]16.57+0.11 16.34+0.11 *| -0.23 40.08
EF%) 328412 |374411*] 45416 |]32641.4 350414 25416
RightExtension (N-} 135.0+ 10.1]144.84 11.5*] 9843.4 ||127.7496 131.5499 3.8420
M)
tae 135.0 10.1 ]143.6+ 10.64] 8.7428 }]119.44£80 1243482] 5.0424
Right Flexion! 77451 768456 32+20 719449 710250 09421(N-M)
Left Flexion 72.544.5 763454 3.9421 |]oss+45 712446 23424
Peak 37.64£1.1 37.9413 0341.0 401416 390416 -11408VHVEO: Get I, 91. Bt 1: Vel. O+1. 1+0.
Peak VE/VO,| 41.0+12 43.1416 2.1412 428+18 413420 -1.5+£08
VECO? 364211 35.7412 -0.7+08 386+1.7 371418 15412slope
VE/VO,slope} 42.7+1.6 43.441.7 0.6413 43.8424 419425 18417   All values expressed as mean + SEM.
* p<0.05 compared to 3 months, + p<0.05 compared to control group A change
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3.2.6 Percentage change at 6 months
Full results for the percentage change between baseline and 6 months are shown in
table 3.10 and figure 3.25.
3.2.6.1 Functional measures and exercise duration
The exercise group showed a 66.7% improvement in NYHA class and a 57.9%
reduction in Minnesota living with heart failure scores. The improvement in the
control group was 33.3% in NYHAclass and 52.6% in Minnesota living with heart
failure scores. There was a 101.3% improvementin exercise duration in the exercise
group whilst the control group had a 53.0% improvement.
3.2.6.2 Peak VO» and the ventilatory equivalents for oxygen and carbon dioxide
There was a 24.7% improvement in peak VO> in the exercise group, the control
group showed a 12.1% improvement. The exercise group showed a 14.6% reduction
in the peak VE/VCO)and an 18.8% reduction in the VE/VCO, slope. The control
group showed a 12.1% reduction in the peak VE/VCO, and a 15.6% reduction in the
VE/VCO>;slope.
There was a 0.8% overall reduction in the peak VE/VO> and a 7.5% reduction in the
VE/VO)slopein the exercise group. The control group showed a 5.0% reduction in
the peak VE/VO;and a 10.7% reduction in the VE/VO;slope.
3.2.6.3 Peak Cardiac output and Cardiac Reserve
The exercise group showed a 51.7% improvementin peak cardiac poweroutput with
a 64.8% improvement in cardiac reserve. The control group showed a 28.9%
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improvement in peak cardiac power output and a 36% improvement in cardiac
reserve.
3.2.6.4 Peak RERandpercentage of peak VO,at the anaerobic threshold
The peak respiratory exhange ratio showed a 14.5% increase in the exercise group
and a 6.6% increase in the control group. The exercise group showed a 13.4%
reduction in the the percentange of peak VO,at the anaerobic threshold. The control
group showeda 2.5% reduction at 6 months
3.2.6.5 Echocardiographic parameters
There was a 9.4% reduction in the left ventricular end diastolic dimensions in the
exercise group, whilst the control group showed a 10.2% reduction. This was
coupled with an increasein the ejection fraction of 57.8% in the exercise group and
48.1% increase in the control group.
3.2.6.6 Peak skeletal muscle torque
The exercise group showed a 12.8% increase in right sided extension and a 15.8%
increase in left sided extension. The control group showed a 2.4% increase in right
sided extension and 0.2% increasein left sided extension.
The exercise group showed a 9.2% increase in right sided flexion and a 4.8%
increase in left sided flexion. The control group showed a 1.0% increasein right
sided flexion and a 2.2% reductionin left sided flexion.
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Table 3.10: Percentage change at 6 months
 
 
 
   
Exercise group Control group
NYHAclass 66.7 33.3
MLWHF 57.9 52.6
Exercise Duration 101.3 53.0
Peak VO, 24.7 121
Peak VE/VCO, 14.6 12.1
VE/VCO;slope 18.8 15.6
Peak VE/VO, 0.8 5.0
VE/VO;slope ta 10.7
Peak RER 14.5 6.6
Percentage of peak VO),at the anaerobic 13.4 25
threshold , .
Peak cardiac poweroutput 51.7 28.9
Cardiac Reserve 64.8 36.0
Left ventricular end diastolic dimensions 9.4 10.2
Ejection Fraction 57.8 48.1
Right Extension 12.8 2.4
Left Extension 15.8 0.2
Right Flexion 9.2 1.0
Left Flexion 4.8 2.2  
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146
 
3.2.7 Effect of exercise training in non responders
At 3 months post cardiac resynchronisation therapy there were 17 non responders
(34%). After randomisation 9 of the non responders were randomised to the
exercise group and 8 were randomised to the control group. At the 6 monthtest in
the exercise group 6 (67%)of the 9 non responders at 3 months were now classified
as responders. In the control group 2 (25%) of the 8 non responders at 3 months
were now classified as responders. This difference was highly statistically
significant (p=0.002).
147
3.3 Study III. The effectiveness of left ventricular lead placement via a mini
thoracotomy to achieve cardiac resynchronisation therapy in patients with
previously failed transvenous placement.
3.3.1 Baseline Data
Baseline characteristics for both groups are shown in Table 3.11. There was no
significant difference in the mean age (mini thoracotomy: 66.4 + 2.0 (range: 47-80
years) vs. transvenous: 64.5 + 1.8 (range: 38-80 years) (p=0.48)) and gender
distribution (mini thoracotomy: 86% male vs. transvenous: 78% male (p=0.053))
between the two groupsat baseline. The mean and mode NYHAclass was3 in both
groups and there was evidence of a similar cardiomypoathy in both groups with a
dilated left ventricular end diastolic dimension (mini thoracotomy: 7.14 + 0.94 vs.
transvenous: 6.79+0.67 (p=0.14)) and an severely impaired ejection fraction (mini
thoracotomy: 23.1 + 7.8 vs. transvenous: 27.4 + 8.1 (p=0.061)).
In the mini thoracotomy group 71% of the patients were in sinus rhythm at baseline
whilst in the transevenous group 74% were in sinus rhythm (p=0.58). The cause of
the dilated cardiomypathy was predominantly ischaemic in both groups (mini
thoracotomy: 71% vs. transvenous: 74% (p=0.47)). Patients were well medicated in
both groups with similar levels of usage of ACE inhibitors (mini thoracotomy:
100% vs. transvenous: 100% (p=1.0)), Beta blockers (mini thoracotomy: 57% vs.
transvenous: 65% (p=0.093)), Digoxin (mini thoracotomy: 52% vs. transvenous:
44% (p=0.11)), Spironolactone (mini thoracotomy: 59% vs. transvenous: 59%
(p=1.0)) and loop diuretics (mini thoracotomy: 94% vs. transvenous: 94% (p=1.0)).
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Table 3.11: Baseline characteristics of the study population
 Mini Transvenous p value
thoracotomy Group (n=35)
Group(n-23)
Age (years) 66 .4+2.0 64.54 1.8 p=0.48
Sex (% male) 78 86 p=0.053
NYHA class 3 3 p=0.54
Peak VO) (mls/kg/min) 16.06 + 0.79 15.59 + 0.62 p=0.87
IschaemicAetiology of 73.9 71.4 p=0.47
CardiacFailure (%)
QRSwidth (ms) 159+ 18 161 +21 p=0.74
Left Ventricular End Diastolic 6.79 + 0.15 7.14+40.17 p=0.14
Diameter (cm)
Ejection Fraction (%) 27.4+41.9 23.14 1.3 p=0.061
Sinus Rhythm (%) 73.9 71.4 p=0.58
Atrial Fibrillation (%) 26.1 28.6 p=0.58
ACEInhibitors or ARBs (%) 100 100 p=1.0
B-Blockers (“%) 65 57 p=0.093
Digoxin (%) 44 52 p=0.11
Spironolactone (%) 59 59 p=1.0
Loop Diuretic (%) 94 94 p=1.0
 All values expressed as mean + SEM’
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3.3.2 Baseline cardiopulmonary data
The baseline cardiopulmonary haemodynamic data are shown in table 3.12. There
was no significant difference between the two groups in any baseline
cardiopulmonary measure. The mini thoracotomy groupresting heart rate was 74 +
3/min and increased to 119 + 6/min at peak exercise. This was a coupled with a
increase in mean arterial pressure from 87.5 + 2.4 mmHg to 104.2 + 2.3 mmHg.
The transvenous group showeda simliar increase in heart rate from a resting value
of 80+ 3 to 116 + 4 at peak exercise. This was again coupled to a increase in mean
arterial pressure from 89.6 + 1.8 to 105.4 + 1.8.
Total exercise duration was similar in both groups (mini thoracotomy: 344 + 42 vs.
transvenous: 357 + 33 seconds (p=0.797)) and patients did acheive a true maximal
cardiopulmonary exercise test manifiest by a peak RER greater than 1 (mini
thoracotomy: 1.02 + 0.02 vs. transvenous: 1.01+ 0.02 (p=0.703)). The subjects in
both groups were significantly impaired in their cardiopulmonary exercise capacity
with a reduced peak VO> (mini thoracotomy: 16.06 + 0.79 vs. transvenous: 15.59 +
0.62 mls/kg/min (p=0.638)). Both the groups showed a similar resting cardiac
power output (mini thoracotomy: 0.61 + 0.04 vs. transvenous: 0.64 + 0.03
(p=0.521)) which increased at peak exercise (mini thoracotomy: 2.42 + 0.19 vs.
transvenous: 2.46 + 0.13 p=0.852). Therefore the cardiac reserve for both groups
wassimilar at baseline (mini thoracotomy: 1.80 + 0.17 vs. transvenous: 1.81 + 0.11
(p=0.969)).
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Table 3.12: Baseline cardiopulmonary data
 
paid Transvenous p valuethoracotomyGroup Group
Resting HR (min) 74+ 3 80+ 3 p=0.181
Resting MBP (mm Hg) 87.5 +2.4 89.6+ 1.8 p=0.478
Resting SBP (mmHg) 151.7+4.1 153.2 + 3.3 p=0.420
Resting VO> (mls/kg/min) 5.36 + 0.37 5.43 + 0.21 p=0.867
Resting CO (L/min) 3.20 + 0.22 3.26+0.14 p=0.806
Resting CPO (watts) 0.61 + 0.04 0.64 + 0.03 p=0.521
Resting VE (L/min) 14.5+ 1.0 15.1+0.8 p=0.683
Exercise duration (secs) 344 + 42 357 + 33 p=0.797
AT (mls/kg/min) 11.04 + 0.82 11.22 + 0.83 p=0.911
AT % peak VO2 (%) 71.1444 70.6 + 2.9 p=0.914
Peak RER 1.02 + 0.02 1.01+ 0.02 p=0.703
Peak HR (min) 119+6 116+4 p=0.734
Peak MBP (mm Hg) 104.2 +2.3 105.4 + 1.8 p=0.673
Peak SBP (mm Hg) 151.7+4.1 152.9 +3.4 p=0.773
Peak VO, (mls/kg/min) 16.06 + 0.79 15.59 + 0.62 p=0.638
Peak CO (L/min) 10.34 + 0.72 10.40 + 0.44 p=0.940
Peak CPO (watts) 2.42 + 0.19 2.46 + 0.13 p=0.852
Cardiac reserve (watts) 1.80 + 0.17 1.81 +0.11 p=0.969
Peak VE (L/min) 54.6 + 3.1 52.1 +2.5 p=0.542
Peak VE/VCO, 45.37 + 3.57 44.05 + 1.72 p=0.713
Peak VE/VO, 43.34 + 2.84 44.25+1.91 p=0.784
VE/VCO>2siope 45.77 + 4.53 43.28 + 1.80 p=0.563
VE/VO>2slope 48.70 + 4.50 47.20 + 2.30 p=0.746
 All values expressed as mean + SEM.
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3.3.3 Post CRT exercise and haemodynamic measures
Full results from baseline to 6 months post cardiac resynchronisation therapy are
shownin table 3.13
3.3.3.1 Functional measures and exercise duration
NYHAclass was improved in both groups at 3 months (transvenous: 3 vs. 2 7°
p<0.001, mini thoracotomy: 3 vs. 2 C p<0.001). Between 3 and 6 months NYHA
stayed at 2 in both groups, although there was a further significant improvement
using the 7° test (transvenous: p=0.003, mini thoracotomy: p<0.001). Inter-group
analysis of the change at 6 months showed no difference (transvenous: 1, mini
thoracotomy: 1 p=0.548) (see figure 3.26).
Both groups showed an improvement in exercise duration (seconds) at 3 months
(transvenous: 357 + 33 vs. 571 + 41 p<0.001, mini thoracotomy: 344 + 41 vs. 439 +
49 p=0.007). A further improvement occurred in both groups between 3 and 6
months (transvenous: 571 + 41 vs. 666 + 41 p=0.014, mini thoracotomy: 439 + 49
vs. 576 + 51 p=0.001). Inter-group analysis of the change at 6 months showed no
difference (transvenous: 288 + 35, mini thoracotomy: 218 + 45 p=0.215)(see figure
3.27).
Minnesotaliving with heart failure (MLWHF)scores improved at 3 months in both
groups (transvenous: 60.3 + 3.0 vs. 29.7 + 3.1 p<0.001, mini thoracotomy: 61.0 +
3.7 vs. 36.8 + 4.5 p=0.001). No further improvements were seen between 3 and 6
months in either group (transvenous: 29.7 + 3.1 vs. 25.7 + 3.2, mini thoracotomy:
36.8 + 4.5 vs. 33.5 + 4.5 p=0.83 p=0.16). Inter-group analysis of the change at 6
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months showed no difference (transvenous:-34.8 + 3.4, mini thoracotomy: -28.0 +
5.2 p=0.252) (see figure 3.28).
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Figure 3.27: Exercise duration
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Figure 3.28: Minnesota living with heart failure
3.3.3.2 Peak VO, and peakrespiratory exchange ratio
Both groups showed a significant improvement in peak VO. (mls/min/kg) at 3
months. The improvement seen in the mini thoracotomy group was of a smaller
magnitude than that of the transvenous group at this stage (transvenous: 15.59 +
0.62 vs. 18.42 + 0.62 p<0.001, mini thoracotomy: 15.43 + 0.79 vs. 16.91 + 0.91
p=0.015). Between 3 and 6 months peak VO. was maintained in the transvenous
group without further significant improvement (18.42 + 0.62 vs. 18.98 + 0.63
p=1.0). Whereas the mini thoracotomy group demonstrated a further significant
improvement (16.91 + 0.91 vs. 18.30 + 1.05 p=0.021) to achieve a comparable
overall level of peak VO> to the transvenous group at 6 months(see figure 3.29).
Inter-group analysis of the change at 6 months showed no difference (transvenous:
3.04 + 0.53, mini thoracotomy: 2.33 + 0.73 p=0.423).
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There were also significant improvements in the maximum respiratory exchange
ratios (RER) achievable in the transvenous group at 3 months (1.01 + 0.01 vs. 1.07
+ 0.01 p=0.045). No further change in RER occurred at the 6 monthsstage (1.07 +
0.01 vs. 1.09 + 0.02 p=0.569). In the mini thoracotomy group there was no
significant improvement in the RER at 3 months (1.02 + 0.02 vs. 1.07 + 0.02
p=0.11) and between 3 and 6 months (1.07 + 0.02 vs. 1.10 + 0.02 p=0.34). However
the overall improvement between baseline and 6 months wassignificant (1.02 +
0.02 vs. 1.02 + 0.10 p=0.020). Therefore inter-group analysis of the change at 6
months showed no difference (transvenous: 0.07 + 0.02, mini thoracotomy: 0.08 +
0.0 p=0.809) (see figure 3.30).
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3.3.3.3 Peak cardiac power output and cardiac reserve
Haemodynamic assessment showed significant improvements at 3 months (peak
CPO (watts) (transvenous: 2.46 + 0.13 vs. 3.14 + 0.15 p<0.001, mini thoracotomy:
2.42 + 0.19 vs. 3.06 + 0.18 p<0.001) and cardiac reserve (CR) (watts) (transvenous:
1.81 + 0.11 vs. 2.49 + 0.13 p<0.001, mini thoracotomy: 1.80 + 0.17 vs. 2.41 + 0.16
p<0.001)). Between the 3 and 6 months stage peak CPO andcardiac reserve showed
further significant improvements in the transvenous group (peak CPO: 3.14 + 0.15
vs. 3.39 + 0.16 p=0.007, CR: 2.49 + 0.13 vs. 2.75 + 0.15 p=0.005) but not in the
mini thoracotomy group (peak CPO:3.06 + 0.18 vs. 3.36 + 0.28 p=0.55, CR: 2.41 +
0.16 vs. 2.60 + 0.25 p=1.0). Inter-group analysis of the change at 6 months showed
no difference in peak CPO (transvenous: 0.90 + 0.12, mini thoracotomy: 0.90 +
0.19 p=0.972) and cardiac reserve (transvenous: 0.90 + 0.11, mini thoracotomy:
0.76 + 0.20 p=0.503) (see figure 3.31).
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Figure 3.31: Peak cardiac power output(a) and cardiac reserve(b).
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3.3.3.4 Echocardiographic parameters
At 3 months both groups showeda significant improvementin ejection fraction (%)
(transvenous: 23.1 + 1.3 vs. 32.3 + 1.0 p<0.001, mini thoracotomy: 27.4 + 1.9 vs.
34.5 + 1.5 p=0.006). There were no further significant improvements at 6 months
(transvenous: 32.3 + 1.0 vs. 36.1 + 1.2 p=0.061, mini thoracotomy: 34.5 + 1.5 vs.
36.9 + 1.3 p=0.66).
At 3 months the left ventricular end diastolic dimension (LVEDD) (cm) was
significantly improved in the mini thoracotomy group (6.79 + 0.15 vs. 6.38 + 0.14
p=0.003) and a trend towards improvementin the transvenous group wasseen (7.14
+ 0.17 vs. 6.72 + 0.14 p=0.09). Between 3 and 6 months the transvenous group had
a further trend towards improvement in LVEDD (6.72 + 0.14 vs. 6.40 + 0.09
p=0.08), and demonstrated a significant overall improvement at 6 months(pre: 7.14
+ 0.17 vs. 6 months: 6.40 + 0.09 p<0.001). The mini thoracotomy group showed no
further improvement in LVEDD between 3 and 6 months (6.38 + 0.14 vs. 6.29 +
0.13 p=1.0). Inter-group analysis of the change at 6 months showed no difference in
ejection fraction (transvenous: 12.4 + 1.5, mini thoracotomy: 8.4 + 2.2 p=0.118) and
LVEDD(transvenous: -0.56 + 0.13, mini thoracotomy: -0.60 + 0.14, p=0.823) (see
figure 3.32).
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Table 3.13: Post cardiac resynchronisation therapy results
 
Transvenous Group Mini thoracotomy Group
 
           
Pre 3 6 A Pre 3 6 A
CRT months| months |Change| CRT months| months Change
NYHA . . * *ve 3 2 2% 4 3 2 2% 1
Exercise 357 571 666 288 344 439 576 218Duration] (33) (41)* |(41) *t}] (5) 1) @9* ott 45)
18.30Peak VO,| 1559 18.42 18.98 3.04 15.43 16.91 (55) 2.33*] (0.62) (0.62) * (0.63) *| (0.53) (0.79) }@.91)*| “a,” 0.73)
246 3.14 339 0.90 242 3.06 336 0.90Peak CPO] (913) |(0.15) *|(0.16)*t| (0.12) (0.19) |(0.18) *] (0.28) *| (0.19)
2.75cr 18t 249 ops| 0:90 180 241 2.60 0.76(0.11) {(0.13)*} “QP? (11) 0.17) [0.16* (0.25) *| (0.20)
rer 10l 1.07 1.09 0.07 1.02 1.07 1.10 0.08(0.01) |(0.01) *| (0.02) *| (0.02) (0.02) (0.02) (0.02) *| (0.03)
603 29.7 25.7 -348 61.0 368 33.5 -28.0MLWHF? (30) 3.1)* 3.2)* G4) 3.7) 4.5)* 4.5)* (6.2)
bewane 714 672 640 -0.56 679 638 629 -0.60
* * *peastobe (0.17) (0.14) (0.09) (0.13) (0.15) (0.14) 0.13) 0.14)
Ejection 23.1 323 36.1 124 274 345 369 8.4Fraction (1.3) (1.0)* |.2)* (5) a9) as)* a3)* (2.2)
Given as mean (SE) for continuous data and modefor discrete data (NYHA)
*p<0.05 compared to Pre, tp<0.05 compared to 3 months,
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3.3.2 Percentage improvement at 6 months
At 6 months significant improvements were seen in all variables in both groups.
Functional measures showed an overall 33.3% reduction in NYHA class in both
groups and an increase in exercise duration (transvenous: 80.6%, mini thoracotomy:
63.5%). Peak VO, showed a 19.5% improvement in the transvenous group and a
14.5% improvement in the mini thoracotomy group. Haemodynamic measures during
exercise showed an increase in peak CPO (transvenous: 36.6%, mini thoracotomy:
37.3%) and an increase in cardiac reserve (transvenous: 49.7%, mini thoracotomy:
42.1%). There was only a small improvement in RER (transvenous: 7.9%, mini
thoracotomy: 6.9%). Echocardiographic measures showed a reduction in LVEDD
(transvenous: 8.4%, mini thoracotomy: 8.2%) and an increase in ejection fraction
(transvenous: 53.7%, mini thoracotomy: 30.7%). MLWHFscores showeda reduction
of 57.7% in the transvenous group and 45.9% in the mini thoracotomy group (see
 
           
figure 3.33).
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Figure 3.33: Percentage change at 6 months
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3.3.5 Pacing parameters
In the transvenous group there was no significant increase in any pacing parameter
(R wave sensed, LV lead impedance andthreshold) at either 3 or 6 months. The
mini thoracotomy group showed no changein either R wave or lead impedancebut
there was a significant increase in the threshold at 6 months (1.1 + 0.2 vs. 2.3 + 0.3,
p=0.02). The percentage of ventricular pacing was >95% in both groups at each
test. When comparing the transvenous and mini thoracotomy group measurements,
the only significant difference was lower impedancein the mini thoracotomy group
(implant: p=0.038, 3 months: p=0.02, 6 months: p=0.003). Full details of pacing
parameters are given in table 3.14.
Table 3.14: Pacing parameters
 
  
Transvenous Mini thoracotomy
Pre 3 months 6 months Pre 3 months 6 months
R wave 11.3 11.9(mv) (1.4) 12.2 (1.5) 12.6 (1.7) (1.9) 8.2 (1.3) 8.3 (1.1)
Impedance 877.9 869.5 858.1 582.7 446.0 471.3
(Q) (93.9) (80.0) (91.6) (87.0) + (43.4) Tf (52.1) ¢
Threshold 2.3 (0.3)
(my) at 1.1 (0.2) 1.5 (0.3) 2.9 (0.7) 1.1 (0.2) 1.7 (0.3) 2
0.4ms
Ventricularpacing (%) N/A 97 (1.0) 98 (0.7) N/A 96 (0.9) 97 (0.9)     Values give as mean (SE), *p<0.05 compared to 3 months, ¢ p<0.05 compared to transvenous group
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3.3.6 Complication rate
Overall complications rates were low in both groups. During the peri-operative
period the mini thoracotomy group had statistically higher rate of renal
impairment (mini thoracotomy: 13% vs. transvenous: 3% p<0.001), lower
respiratory tract infection (mini thoracotomy: 9% vs. transvenous: 3% p<0.001) and
pericardial effusions (mini thoracotomy: 4% vs. transvenous: 0% p=0.003). There
were no complications due to the general anaesthetic or any evidence of
cerebrovascular accidents, myocardial infarctions or unstable angina. The median
length of stay was higher in the mini thoracotomy group (mini thoracotomy: 5.5 +
0.6 days vs. transvenous: 3.0 + 0.4 days, p=0.001).
During the 6 monthsofthe study there wasno significant difference in LV lead exit
block (Mini thoracotomy: 4% vs. Transvenous: 3% p=0.558) or pocket haematoma
(Mini thoracotomy: 9% vs. Transvenous: 6% p=0.207). There were no lead
displacements or system infections and no patients required re-operation or system
extractions during the study period.
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Discussion
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4.1 Study I: The longitudinal improvement in exercise haemodynamic
measures following cardiac resynchronisation therapy.
This study explored the baseline characteristics of a group of patients being
considered for cardiac resynchronisation therapy and the longitudinal improvement
following CRT. Unlike the majority of trials looking at CRT which have
traditionally used a pre and post design we were seeking to describe the rate of
change that occurs following CRT. In addition to the standard functional class and
quality of life assessments, I also assessed the effect of CRT on non-invasively
measured cardiac ouput and skeletal muscle function. The effect of CRT on skeletal
muscle has not previously been described.
From previous studies it has been shownthat patients suitable for CRT are severly
limited in terms of exercise capacity and functional status. It has been assumedthat
this limitation is due to dyssynchronous cardiac contraction leading to a reduced
cardiac output. The majority of trials have not assessed the response of CRT to
cardiac output and have instead used either peak VO2 or exercise duration as
surrogate marker of cardiac function. The disadvantage of this approach is that both
peak VO, and exercise duration are measures that are affected by a variety of
external factors including cardiac output. Therefore when wetry to assess the
difference in response in patients following CRT, a more detailed understanding of
the changes following CRT would be neededto try to better predict the likelihood
of response following CRT.
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4.1.1 Baseline data
Thebaseline data shownin section 3.1.1 showed that the group was typical group
to be considered for cardiac resynchronisation therapy with a mean age of 65 years
and a male preponderance. There was evidence of a severe dilated cardiomyopathy
with signficant functional and quality of life impairment. All haemodynamic
measures showed significant impairment and the results were very similar to data
publishedin all the majortrials (see table 4.1) (MIRACLE (Abrahametal., 2002),
MIRACLE-ICD (Young et al., 2003), CARE-HF (Cleland et al., 2005a),
COMPANION(Bristow et al., 2004)) and therefore could be considered a typical
group prior to cardiac resynchronisation therapy.
Table 4.1: Baseline characteristics compared to other majortrials
 
 
    
Longitudinal Miracle Miracle- Conwanion Care-study ICD P HF
Mean age 65 64 67 67 65(years)
Men (%) 90 90 77 67 73
Women (%) 10 10 23 33 21
NYHA III (%)_ 100 90 89 86 94
Peak VO,(mls/min/kg) 15.5 14.0 13.3 NA NA
MLWHIEscores| 62 59 57 NA 45
LVEF(%) 22 22 24 22 26
LVEDD(cm) 7.0 7.0 7.6 6.7 7.2
QRS(ms) 158 166 164 160 165
Resting Heart a9 14 1 12 70rate (bpm)
Systolic BP(mm Hg) 116 115 114 111 117
Diuretics (%) 100 94 94 95 99
Digoxin (%) 43 79 NA NA 43
ARB/ACEi (%) 98 92 91 89 95
Beta-blockers 68 72(%) 82 59 60
Spironolactone 45 NA NA 54 56   
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4.1.2 Baseline relationships between cardiopulmonary variables
The correlations between baseline cardiopulmonary variable and skeletal muscle
function were assessed using linear regressions. Whilst linear regression is a useful
method of assessing relationship between 2 variables it should be noted that a
significant correlation does not necessarily mean there is a significant realtionship
between the variables. If linear regression is used haphazardly then there would be a
risk of a chance relationship occurring between 2 variables with no real relationship. To
use linear regression accurately it is important to assess 2 variables that have the
possibility of a relationship rather than assessing any randomvariables. In this study
wehaveassessed the exercise cardiopulmonary, the functioncalclass, quality oflife
scores and skeletal muscle function. It is reasonable to expect these variables to
have a possible linear relationship and therefore linear regression is valid. However
this data is only being used as a means of exploring the baseline data and the
limitations of linear regression mean that the results should be reviewed with
caution.
The baseline exercise duration wasclosely related to the peak cardiac poweroutput,
cardiac reserve, peak VOand the respiratory equivalents for oxygen and carbon
dioxide. The baseline peak VO, wasalso closely related to peak cardiac power
output, cardiac reserve and the respiratory equivalents for oxygen and carbon
dioxide. Interestingly the variables that showed the most consistent correlations
with other measures were peak cardiac poweroutput and cardiac reserve. These two
variables not only correlated with exercise duration, peak VO2, the respiratory
equivalents for oxygen and carbon dioxide but also with ejection fraction and peak
skeletal muscle function in both legs. Therefore peak cardiac power output and
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cardiac reserve provide a more comprehensive evaluation of a patient’s overall
physiology than either peak VO>or exercise duration. The majority of trials looking
at cardiac resynchronisation therapy have solely focussed on peak VO>andexercise
duration. Howeverthere is evidence from previoustrials that peak cardiac power
output is a superior predictor of mortality in patients with chronic heart failure
(Williams et al., 2005) and this study confirms that peak cardiac power output
correlates better than any other variable at baseline.
The fact that the baseline peak VO does not correlate with peak skeletal muscle
torque is suprising. When looking at different exercise protocols it has been shown
that a treadmill based exercise protocol leads to a 10-15% higher peak VO> than a
bicycle based protocol. The explantation given for this difference is that a treadmill
based protocol uses more skeletal muscle compared to a bicycle explaning the
higher peak VO2. Hence one would expect peak VO. and peak skeletal muscle
torque to be closely related. The lack of relationship between peak VO>andskeletal
muscle function in this study may reflect that patients suitable for CRT are at the
severe end of the spectrum ofheart failure. They are likely to suffer from chronic
skeletal muscle dysfunction and therefore by the time they are sympotmatic enough
to be considered for CRT the skeletal muscle may well be so deconditionedthatat
this point it is no longer contributing in any meaningful way to the patients’ peak
VO>, hence the lack of correlation. The reasons why a skeletal muscle myopathy
occurs in chronic heart failure are not well described. It is hypothesised that in part
it is a disuse myopathy due to a reduction in exercise capacity and also that the
reduced cardiac output leads to a reduced skeletal muscle perfusion (Drexler etal.,
1992). Therefore it is not suprising that there is a postive correlation between
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skeletal muscle function and peak cardiac power output and cardiac reserve. This is
further enforced by the fact that the only variables that correlated with skeletal
muscle function were measures of cardiac output whether measured by rebreathing
techniques (peak cardiac poweroutput and cardiac reserve) or by echocardiographic
methods (ejection fraction). These results provide some evidence for the muscle
hypothesis of heart failure as described by Clark et al (see section 1.2.3.1) (Clark et
al., 1996).
It is interesting to note that left ventricular end diastolic dimension did not correlate
with any other measure. This can be explained by basic cardiac physiology. In vivo
there are multiple mechanisms regulating cardiac output including cardiac
contractility, heart rate, preload, after load, ventricular geometry and
neurohormonal regulation. The force of contraction and stroke volume can be
altered by the Frank-Starling mechanism (Starling, 1918;Frank, 1959). This states
that the length and tension of the muscle at the time of stimulation determined the
magnitude of its contractile response. Therefore increasing preload increasing the
pre systolic tension and dilation of the left ventricle leading to an increase in
sarcomere length would increase contractility. This mechanism is used as a
compensatory mechanism for the heart, however whilst these mechanismsare very
successful in the short term the long term effects of a chronically increased preload
and left ventricular dilation lead to the clinical syndrome of heart failure
(Braunwald and Ross, 1964). There is now good evidencethat in patients with heart
failure the Frank-Starling mechanism has been exhausted and therefore any further
left ventricular dilation that occurs does not lead to any increase in cardiac function.
Therefore when looking at a cross section of patients prior to CRT the left
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ventricular end diastolic dimension of any one patient simply relates to the time
spent with a chronically increased preload. As the Frank-Starling mechanism has
been exhausted it is not surprising that the left ventricular end diastolic dimension
does not correlate with any other haemodynamic measure.
There is no significant correlation between a person’s quality oflife, as measured
by Minnesota living with heart failure, and almost any haemodynamicor functional
measures. The only slight correlation was with the peak respiratory ventilatory
equivalents for carbon dioxide which showed a small correlation which just reached
signficance (R’=0.10 p=0.045). This lack of correlation is interesting as it would
seem reasonable to assume that a person with severe heart failure would be mainly
impaired due to the cardiac disease and therefore there would be somecorrelation
with measures of cardiac function. It should be remembered however that whilst
heart failure starts as a one organ disease by the time a person has become
symptomatic enough to be considered for CRT it is now a disease involving the
whole body. Thus a person’s MLWHFscorewill be dependent on more than simply
their cardiac function and will include other organ dysfunction, psychological and
social issues. Thereofore it is not suprising that a persons baseline MLWHFscore
does not correlate with other haeodynamic measure. Where MLWHF maybe of
more useis in the longitudinal response to CRT. In a longitudinal study the fact the
quality of life scores are being assessed in the same indviduals and that the only
signficant treatment donein that time is CRT. Therefore any changesseen are likely
to be due to the CRTasthe other organ dysfunction, psychological and social issue
should not be altered. MLWHFscores were the most commonly used marker of
quality of life at the time our studies were performed. The results from our study
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have been recently corberated by Athanasopoulos et al who also showed that
MLWHF showedpoorcorrelation with cardiopulmonary variables and plasma NT-
proBNP levels (Athanasopoulos et al., 2010). As mentioned in section 2.2.4
MLWHEF incorporates physical, emotional, social and mental dimensions of quality
of life. Whilst all these different dimensions are measured by MLWHF,it was never
designed to measure any one dimension separately. Therefore when assessing the
physical response to cardiac resynchronisation therapy it is not adequate to simply
rely on quality of life scores as assessed by MLWHF.Theonly accurate objective
measurementofphysical response remains cardiopulmonary exercise testing.
4.1.3 Longitudinal response to cardiac resynchronisation therapy
Cardiac resynchronisation therapy is now a widely accepted treatment for suitable
patients. The majortrials to date have randomised almost 4000 patients and shown
that by 6 months there are improvements in functional class, exercise duration and
peak VO (Bristow etal., 2004;Cleland et al., 2005b)). Howeverthese studies have
only really focussed on a pre and post design. In this study we assessed how earlyit
waspossible to see signficant change following CRT.In our study at 3 months post
CRT there were signficant improvements in NYHAclass, Minnesota living with
heart failure scores, exercise duration, peak VO2, peak CPO, cardiac reserve, and
ejection fraction. During the trial there was a gradual improvement in the
ventilatory equivalents for oxygen consumption and carbon dioxide but these trends
failed to reachstatistical significance. The improvements in NYHA class, MLWHF,
exercise duration, peak VO2, and ejection fraction are in keeping with the data
published in the majorclinical trials (Bristow et al., 2004;Cleland et al., 2005b).
Thereis very little data currently published on the effects of CRT on peak CPO and
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CR. The only trial to date by Schlosshan et al showed that CRTledto a significant
improvement in both peak CPO and cardiac reserve at 8 weeks post CRT
(Schlosshanet al., 2006). In this study there wasa similar significant improvement
in NYHAclass and peak VO2 when compared to our study. Both studies also
showed no significant change in RER. Interestingly whilst both confirmed a
significant improvement in exercise duration, peak CPO and cardiac reserve the
magnitude observed in our study does appear to be smaller than that reported by
Schlosshan et al. This may be explained by the fact the patient population in the
Schlosshan et al study appears to be more impaired than in our study. This is
evident by the patients in our study having a higher baseline peak VO2, peak CPO,
CR and a lower VE/VCO, slope and VE/VOslope (see table 4.2). When
comparingstudies it is important to rememberthat different exercise protocols and
different cardiopulmonary analysis systems may well give slightly different results.
The difference between the 2 studies can also be explained by the relatively small
numbers in both groups especially the study by Schlosshan et al. When working
with small numbersthe possibility of some outliers affecting the overall data set
increase and therefore it is possible that in the Schlosshan study the larger
percentage increases in some measures is related to a small number of people
showing above normal improvements. With a signficantly larger population in our
study and longer follow up (12 versus 8 weeks) this effect should have been
reduced to give a more accurate data set.
172
Table 4.2: Comparisons to study by Schlosshanetal.
 
  
Longitudinal study Schlosshanetal
Pre CRT Post CRT % change Pre CRT Post CRT % change
NYHA 3 2* -33.3 3 2* -33.3
EACRG 75 558 * B23 374 531 * 42duration
Peak VO2 15.51 18.48 * 19.1 13.9 16.81 * 20.9
RER 1.04 1.08 3.8 1.09 1.09 0
VECO?|" :408 37.1 9.1 46.9 37.5 * 20slope
WEVO? G55 42.5 TA 57.7 42.6 * 26.2slope
Peak * *CPO 2.53 3.23 27.7 1.92 2.63 37
CR 1.89 2.58 * 36.5 1.18 1.83 * 55.1      
In our study there was no significant improvement in either peak RER orthe
percentage of peak VOpat the anaerobic threshold. This suggests that the overall
improvement seen at maximum exercise is made up of a combination of an
improved aerobic and anaerobic capacity. The fact that the peak RER is not
different pre and post provides reassurance that the exercise tests were truly
maximal and similar levels of exertion were achievedatall tests.
Echocardiographic parameters showed a significant improvement in ejection
fraction that becamesignificant at 6 weeks post CRT. The 2 week test did show a
trend towards an improvementin ejection fraction from 21.7% to 28.7% but this
just failed to reach statistical significance (p=0.068). Cardiac resynchronisation
therapy provides a more co-ordinated ventricular contractions and therefore it
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would be expected that there would be a significant improvement seen immediately.
In keeping with ourresults none of the major trials to date have reported on an acute
response in ejection fraction. The earliest reported improvement was at | month
(Gras et al., 2002) . In the current study the improvementat 2 weeks was very close
to beingstatistically signficant and we feel that the fact it failed to reach signficance
is mostlikely to be related to the relatively small numbers involvedin this study.
Left ventricular end diastolic dimension showed a trend towards improvements
throughoutthe study but this just failed to reach signficance at both 2 weeks and 6
weeks post CRT. This can be explained by the fact that reverse remodelling will
take some time andtherefore it would not be too suprising that improvements are
delayed. Howeverit is also possible that the lack of significance mayin part be due
to the relatively small samplesize.
It has already been appreciated that patients with cardiac failure have signficant
skeletal muscle dysfunction which is responsible for at least part of the symptoms
that patients suffer (Clark et al., 1996). However the effect of cardiac
resynchronisation therapy on skeletal muscle function has not previously been
described. In this study despite improvements in functioncal class, exercise capacity
and haemodynamic measures there were no significant improvement in peak
skeletal muscle torque in either leg. Therefore cardiac resynchronisation therapy by
itself does not improve skeletal muscle function at 3 months, and thus a major cause
of symptomsis left untreated despite CRT. Patients suitable for CRT have been
gradually deconditioning over a long period of time and CRT byitself doesn’t
resolve this deconditioning. The cardiopulmonary data show that the patients have
had a significant improvement in the ability to exercise. However this does not
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necessarily equate to an increased amount of regular exercise in day to daylife. By
the time patients have reached a level of symptoms severe enough to make them
suitable for CRT their confidence in performing unsupervised exerciseis likely to
have been significantly reduced. Therefore to improve a patients confidence to
perform regular exercise a structured supervised exercise programme may well be
required to achieve a higher level of exercise in the long term andstart to reverse
the skeletal muscle deconditioning.
4.1.4 Predictors of response
Cardiac resynchronisation therapy has been shownto improve both morbidity and
mortality in suitable patients. However each of the majortrials have shown around a
30% non responderrate. Implantation of a CRT device does carry some risk of
complication and in a health care system with a limited budget it is obviously
important to try and target the patients who are mostlikely to benefit to minimise
cost and complications. Currently QRS duration is the most commonly used marker
for ventricular dyssynchrony (Bristow et al., 2004;Cleland et al., 2005b). However
as these trials have shown a 30% non responderrate there has been a large amount
ofinterest recently into finding more accurate predictors of response.
Alternative predictors of response have ranged from basic echocardiographic
parameters (Clelandet al., 2005b) to complex tissue Doppler echocardiography and
nuclear imaging (Ascione et al., 2008;Trimble et al., 2008). In the published
literature to date no single measure has been shown to be a good reproducible
predictor of response. In the largest trial to date looking at predictors of response
(the PROSPECTtrial) a multitude of echocardiographic parameters were assessed
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in an international multi centre trial. No single measure showeda reliable degree of
accuracy in predicting response (Chungetal., 2008).
In our study we assessed the variables that were significantly different between
responders and non responders. As shown in previous studies QRS duration,
baseline exercise duration and peak VO» were not goodpredictors of response. The
strongest predictors of response were the baseline ejection fraction and the left
ventricular end diastolic dimensions. Responders had a significantly lower ejection
fraction anda less dilated left ventricular end diastolic dimension. Non responders
had a significantly higher peak skeletal muscle torque during extension in both sides
and significantly better ventilatory equivalents for oxygen consumption (peak
VE/VO2) and carbon dioxide production (VE/VCO2 slope and peak VE/VCOz).
The overall picture therefore is that a responder was generally in a more impaired
state than a non responder. This is shown by a worse ejection fraction more
impaired skeletal muscle function and worse ventilatory equivalents in the
responder group. In the REVERSEtrial it was shown that CRTis of benefit in
patients with mild heart failure, however due to the patients only having mild
impairmentthe differences did not achieve significance until 12 months post CRT.
This does raise the possibility that the non responder group is simply less impaired
and therefore longer term follow up would be needed to see if they achieve a
delayed response.
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4.1.5 Limitations of this study
This study is a non randomised prospective study without a control group. Whilst
having a control group would have shownthe benefits of CRT in more detail it was
felt that the large scale multi centre trials have already described this adequately.
The main reason for this study was to assess the relationships in variables at
baseline in patients suitable for CRT andassess the effects of CRT on peak CPO,
CR and skeletal muscle torque. As the numbers in this trial are fairly smallit is
important to take account of this when reviewing the results. We have shown
statistically significant improvements in some variables which are in keeping with
previously published data, however a longer term follow up anda larger cohort may
have provided some moreinformation.
4.1.6 Conclusions
This study showsthat CRT leads to signficant improvementin functional class and
exercise haemodynamicsas early as 2 weeks following CRT. This is significantly
earlier than has previously been reported. At baseline peak CPO wasthe single best
variable when lookingat correlation with the patients other variables. QRS duration
wasa poor predictor of response and it is shownin this study that the more severe
the heart failure the better the chance of response within 3 months of CRT. CRT by
itself does not improve skeletal muscle function and therefore a structured exercise
programme mayhelp to improvethe benefit.
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4.2 Study II. The effects of exercise rehabilitation in addition to cardiac
resynchronisation therapy
In this study the baseline characteristics and haemodynamic measurements were
very similar to those of the longitudinal study and in keeping with previously
published data (Schlosshanet al., 2006). The initial stage of the study was a three
month longitudinal follow up with simple CRT. This allowed us to again see the
longitudinal response of CRT. Similar to study I at three months after CRT we
demonstrated significant improvements in all functional and haemodynamic
measures. These improvements were of a similar magnitude and overa similar time
scale to those seen in other multicentre trials (Cleland et al., 2005b;Abraham, 2006)
. At 3 months there was a 14% improvementin the peak VO» and approximately a
30% improvement in the peak cardiac power output and cardiac reserve. Ejection
fraction also showed a 37% improvement. In addition to these improvements the
MLWHF score improved by almost 50%. The baseline peak VO2 was
16.12mls/kg/min whichis slightly higher than has previously been reported in CRT
trials (Abraham et al., 2002;Schlosshan et al., 2006). However, the correlation
between peak VOand NYHAclass is knownto be poor (Genthet al., 1996) andit
is important to remember that the measured peak VO, can vary depending on the
testing method andprotocolutilised.
Peak VO, showed significant improvement at 3 months without a significant
change in the percentage of VO> at the anaerobic threshold. This suggests that the
improvement in peak VO. was due to an equal improvementin the capacity to
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perform aerobic and anaerobic exercise. Following CRT the increased RERreflects
an ability to exercise to a greater level of physiological stress. In the longitudinal
study described in study I there was a trend towards an increased peak RERat 3
months but this was notstatistically significant. The most likely reason that this
reached significance in this study but not study I is the larger study population in
this study. The increase in peak RER was not a familiarisation response as a
separate exercise test had been performed prior to the study and the results
discarded. The results at 3 months support the theory that CRT improves function
due to enhanced central cardiac function alone. This study again confirms the
absenceofany peripheral skeletal muscle changes 3 months after CRT alone.
At the point of randomisation there were no significant differences between the 2
groups. Randomisation was delayed until the 3 month stage in order to limit bias.
Had patients been awareat an earlier stage that they were goingto bein the exercise
group there would have been the potential for them to self-train. This would have
influenced the 3 month results and made any comparison between the 2 groupsless
reliable. The exercise training group underwent a graduated intensity exercise
programme over 3 months whilst the control group were given no specific advice
relating to exercise. We recognise that this exercise training programme was more
intensive, frequent and prolonged than the usual cardiac rehabilitation offered to
patients following myocardial infarction or coronary revascularisation. The
provision of cardiac rehabilitation post revascularisation is very varied throughout
the UK. Wrightet al showed that the average programmeof once a weeksessions
for 6 weeks led to no significant improvement in objective cardiopulmonary
measurements (Wrightet al., 2002). Previoustrials looking at exercise in CHF have
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had varying intensity and frequency. In the Extra Match meta analyses thetrials
varied from 2 to 7 times a week and 50% to 80% of the peak heart rate (Piepoli et
al., 2004) and in HF-Action the exercise programme was 30 minutes 3 times a week
for 3 months at 60-70% of heart rate reserve in the supervised stage. This was then
followed by home unsupervised exercise programme of 40 minutes 5 times a week
for a minimum of | year again at 60-70% heart rate reserve (O'Connoret al., 2009).
However, by the end of the trial the average duration of exercise was only 50
minutes per week (O'Connoret al., 2008). As ourtrial was based over a 3 month
training period but did not have an extended home unsupervised programmelike
HF-Action, we felt it appropriate to have a higher intensity of exercise. Hence we
started at 80% and went up to 90% of peak heart rate. Despite the high intensity it
was welltolerated and nopatients in the exercise group had any complications from
the exercise training. Attendance at the exercise programme was extremely high
with the average being 98.5% attendance for the study. Thisis likely to have been
influenced by the fact that the visits were physician supervised andit is debateable
whether this level of attendance would occur in a non-trial setting. However this
high level of attendanceis similar to that in other supervised programmes such as
HF-Action and we hypothesise that if patients and clinical staff were made fully
aware of the extent of improvements possible with a structured exercise programme
then attendance figures may well be close to those achievedin this study.
At six months, those patients undertaking exercise training demonstrated further
significant improvements in NYHAclass, exercise time, peak VO2, peak CPO, CR,
RER and MLWHEFscore which were not mirrored in the control group. Although
in-group analysis showed a significant improvement in skeletal muscle function
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with exercise training this was not supported by significant inter-group changes
compared to the control group. This may reflect the relatively small number of
patients in each group. Equally it may be due to the frequency or duration of the
training programme. Had the patients exercised more frequently or for a longer
period the differences in improvement in peak skeletal muscle function may have
achieved significance. Nevertheless the overall changes at the end of the study were
greater in the exercise group for most variables. The overall improvement in
exercise duration seen in the control group (53%) was comparable to previously
published data (Schlosshan et al., 2006). However, the introduction of exercise
training increased the improvement to 101%. This level of improvement has never
been described following CRT alone. Peak VO2, known as a powerful predictor of
prognosis (Mancini et al., 1991), was improved by 12% in the control group
compared with 25% in the exercise group. Again this level of improvement has
never previously been reported. In all haemodynamic measures the addition of
exercise training doubled the percentage improvement at 6 months when compared
to the control group. The exercise group also showed more substantial
improvements in both right (13%) and left sided (16%) peak skeletal muscle
function. The control group showed only a 2.4% improvementin right sided and a
0.2% improvement in left sided extension during the same period. The likely
explanation behind these overall changes is that CRT alone improves functional
capacity and QOL by enhancing cardiac function and exercise training improves
functional capacity further by enhancing skeletal muscle and cardiac function.
After 3 months of cardiac resynchronisation therapy 17 out of the 50 (34%) patients
were classified as non-responders. This rate is comparable with the major clinical
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trials which have shown a non responder rate of approximately 30% (Abraham et
al., 2002;Younget al., 2003). Recently there has been increasing focus in trying to
predict responders to cardiac resynchronisation therapy. In this study there were
similar numbers of non responders in both groups with 9 in the exercise group and 8
in the control group at 3 months, howeverthe addition of exercise duration lead to a
dramatic reduction in the numberof patients being classified as non responders
from 9 to 3, an improvement of 67%. This improvement in responderrate at 6
months cannot be simply explained by a delayed response to cardiac
resynchronisation therapy as the changes were not matched in the control group
where the reduction was only from 8 non responders at 3 months to 6 at 6 months,
an improvement 25%. The difference between the reduction in non responders in
the exercise and control group was highly significant. Therefore the addition of
exercise training not only doubles the improvement seen following CRT it can also
help to transform non responders to responders. It has been previously described
that exercise training is useful in patients with heart failure and it is therefore not
surprising that there is an improvement in responder’s rates with exercise training.
However the major trials have focussed on patients with mild cardiac failure
(NYHAclass 1-2). Patients with more advanced heart failure are usually less
physically and psychological able to perform an exercise programme. The
mechanism behind the improvements seen in this study may be that CRT improves
the patient from severe to mild heart failure. Exercise training then builds on the
newly improved physically and psychological level to lead to even further
improvements.
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4.2.1 Limitations of this study
This study used a randomised controlled protocol. A further control group who
were suitable for CRT but who were randomised to exercise training alone would
have improved the methodology. Howeverin view of the CARE-HFstudy (Cleland
et al., 2005b) which showed a mortality benefit from CRT it was considered
unethical to withhold CRT even temporarily. Overall the data set was relatively
small and therefore some caution should be exerted when interpreting the results.
However,all the principal measures achieved highly significant improvements. In
view of the relatively small number of patients involved in this study it was not
appropriate to look for benefits in mortality or CHF hospitalisation. These endpoints
could only accurately be assessedbylargerscaletrials.
By the very nature of exercise training it is impossible to blind the patient to
whether they are in the exercise or control group. We attempted to limit any
potential impact by delaying randomisation until the 3 month stage. Wealsotried to
minimise bias from actual training visits in the exercise training group by
performing the exercise training in a non clinical setting and by utilising a physician
not involved in the pacemakerimplant or follow up.
4.2.2 Clinical implicationsof this study
In view of the significantly improved outcomes in the exercise group it would be
reasonable to suggest that exercise training should be offered to all patients
following CRT. This would ensure the best possible outcome from CRT. The
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exercise programmeused in this study wasa practical regime which could be used
in clinical practice.
4.2.3 Conclusions
Cardiac resynchronisation therapy is an effective treatment for suitable patients.
The addition of exercise training significantly enhances the benefits seen by
improving both the central cardiac function and the peripheral skeletal muscle
function. Exercise training would provide only a small additional cost to the overall
cost of CRT, and we therefore feel that it would be justified to offer this to all
patients following CRT.
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4.3 Study III. The effectiveness of left ventricular lead placement via a mini
thoracotomy to achieve cardiac resynchronisation therapy in patients with
previously failed transvenous placement.
This study is the first to directly compare functional and clinical improvements
following lead placement via a mini thoracotomy with transvenous placement of
CRT. Surgical placement of the LV lead is well recognised and was used in the
initial evaluation of CRT (Auricchio et al., 1999b;Auricchio et al., 2002). These
studies placed the LV epicardial lead via a full thoracotomy. This did carry some
risk in the peri-operative period with a prolonged recovery time and high
complication rate (2.4% wound complications and 9.8% atrial fibrillation)
(Auricchio et al., 2002). In the longer term 7.3% developed lead exit block at 12
months (Auricchio et al., 2002) which led to the development of transvenous
placement via the coronary sinus (Linde et al., 2002). Transvenous placement is
now the standard method of implantation (Bristow et al., 2004;Cleland et al.,
2005b) although there are limitations. Firstly the implantation success rate is
approximately 90% with a significant operator learning curve (Abraham etal.,
2002;Bristow et al., 2004;Cleland et al., 2005b). Also the final site of LV lead can
be compromised due to inadequate venous anatomy, stimulation of adjacent
structures or high thresholds. These problems mayin part be responsible for the
30% non-responderrate seen in trials (Bristow et al., 2004;Cleland etal., 2005b).
Improvementsin surgical epicardial lead technology, new implanting tools and new
surgical techniques including mini-thoracotomy (Mair et al., 2005;Shah et al.,
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2006;Doll et al., 2008) and robotic/thoracosopic implantation (Jansenset al., 2003)
reflect a resurgence of interest in the option of surgical epicardial LV lead
positioning. Such advances mean it is now possible to place an epicardial lead in
any position on the LV (Mairet al., 2005;Shah etal., 2006;Doll et al., 2008). These
methods of implantation have been proposedas potential alternatives for patients
with failed transvenous lead implantation. Initial case studies and small case series
have shownsuccessful delivery of CRT. To date there has been trials directly
comparing surgical epicardial LV lead placement via a mini thoracotomy versus
transvenous lead placement. In the first trial to report Mair et al compared 70
patients who received transvenous LV lead placement to 16 patients who hadtheir
LV lead placed mini thoracotomy. In this study they purely assessed pacing
parameters at follow up of 16 months. There wasno significant increase in surgical
epicardial lead threshold during this study, which suggests that long term surgical
epicardial lead performance is reasonable. Interestingly the transvenous group in
this study had an exceptionally high complication rate with 25 (36%) LV lead
related complications (failed implantation, CS-dissection, loss of pacing capture,
diaphragm stimulation or lead dislodgment). This rate of complications would be
considered excessively high and mayreflect a lack of experience in transvenous LV
lead placement. The study also did not assess any objective exercise or functional
measures to see if similar improvements were achieved between mini thoracotomy
and transvenous LV lead placement (Mairet al., 2005). Shah et al reported data on
11 patients receiving surgical epicardial LV lead placement and in keeping with our
study showed a higher peri-operative morbidity but significant improvements in
functional class following surgical epicardial LV lead placement. Howeverthere
was no assessment of exercise capacity or cardiopulmonary measures in this study
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to compare surgical epicardial and transvenouslead placement. (Shahetal., 2006).
Both the trials by Mair et al and Shah et al were prospective and non-randomised.
The only randomised trial to data was reported by Doll et al. In this study they
randomised 80 patients in a | to | basis to either surgical epicardial or transvenous
LV lead placement. The transvenousgroup had a shorter inpatient stay but a higher
exposure to radiation. At 6 months there was no significant difference in LV lead
pacing parameters (Doll et al., 2008). These three studies therefore confirmed that
surgical epicardial lead placement was a technically viable procedure. However
none of these studies had actually assessed any functional or cardiopulmonary
improvement following surgical epicardial lead placement. Therefore concerns
persisted regarding peri-operative morbidity, long recovery times and
improvements in cardiopulmonary measures following surgical placements of the
left ventricular lead. In our study there were no major adverse events (death,
myocardial infarction or stroke) in either group. There were howeversignificantly
higher rates of post operative respiratory tract infections, transient renal dysfunction
and pericardial effusions in the mini thoracotomy group. This higher complication
rate combined with the recovery from a general anaesthetic, led to an increased
length of stay when comparedto the transvenous group. Pacing complications such
as exit block and pocket haematoma were similar in both groups for the study
duration and were comparable with other studies (Shah et al., 2006;Doll et al.,
2008). However, our period of follow up was limited to six months and exit block
has been reported as a late occurring phenomenonafter mini thoracotomy pacing. In
this study there was a sub acute rise in LV lead threshold of the mini thoracotomy
group. This does raise the possibility of long term exit block and longer term
analysis is planned in due course.
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The benefits of CRT have been extensively described with significant
improvementsin functional class, haemodynamic measures and mortality (Abraham
et al., 2002;Bristow et al., 2004;Cleland et al., 2005b). In this study peak VOz,
exercise time and NYHA class all improved significantly in both groups at three
months, but to a lesser extent in the mini thoracotomy group. Thereafter peak VO>
only increased significantly in the mini thoracotomy group between 3 and 6 months,
although there were further improvements in both groups in exercise time and
NYHAclassification. Regarding peak VO, alone, as the most reliable objective
marker of functional capacity and considering its use as a selection criteria for
cardiac transplantation (Mancini et al., 1991), it is possible to conclude that the
significant improvement in functional capacity with transvenous CRT was seen
over a shorter time scale. The improvement in the mini thoracotomy group was
madeovertwostages whilst the transvenous group managed a similar improvement
in one.It is likely that the longer hospital stay and higher complication rate delayed
the improvements in patients receiving mini thoracotomy placementof the LV lead.
This has an important impact on deciding the ideal time to assess responderstatus
following CRT whenachieved using transvenous or mini thoracotomy approaches.
Interestingly both groups demonstrated highly comparable values for RER atall
stages of the study with all significant increases only seen between the baseline and
3 month assessments. This confirms comparable levels of physiologic exertion
throughout the study and excludes any possibility of motivationalbias.
Evaluation of left ventricular function showed significant increases in EF in both
groups at 3 months, which was maintained at 6 months. These overall
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improvements were comparable to previous studies (Auricchio et al.,
1999b;Bristow et al., 2004;Cleland et al., 2005b). Reduction in LVEDD wasonly
significant at 3 months in the mini thoracotomy group but had reachedstatistical
significance in both groups at 6 months. We are unable to explain this delayed
remodelling in the transvenous group. It may possibly be due to the fact that
ventricular size was non-statistically greater and EF lowerat baseline in this group
indicating a greater degree of disease. Supporting this theory is the fact that
dynamic left ventricular function in the form of CPO and CR also increased
significantly in a two stage process in the transvenous group. There were no
significant improvements in the mini thoracotomy group between the 3 and 6 month
assessments.
When comparing the overall improvements between the groups at 6 monthsthere
was no significant difference in any variable. This therefore shows that similar
improvements can be attained using mini thoracotomy implantation comparedto the
transvenous. Despite the improvements in lead technology and implantation tools
mini thoracotomy lead placement is more invasive than transvenous. The longer
recovery time and increased peri-operative complications in conjunction with the
associated cost increases mean that transvenous lead placement should remain the
first choice for patients requiring CRT.
This study has focussed on mini thoracotomy placement of the LV lead as an
alternative for patients with failed transvenous leads. Another possible indication
for mini thoracotomy placement of the LV lead would be for non-responders to
CRT. One major limitation of transvenous leads is that placement is dictated by
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venous anatomy and doesnotnecessarily correlate with the ideal site of LV pacing.
Surgical epicardial leads have the advantage that they can be placed anywhere on
the left ventricular wall. It is therefore potentially possible to map the LV and pace
the most appropriate site for maximum synchrony. This indication was outside the
remit for this study and would need furthertrials.
4.3.1 Conclusions
This is the first prospective controlled study to show that epicardial lead placement
via a mini lateral thoracotomy is a safe and viable procedure compared to
transvenous placement. We confirm a longer in patient stay, increased complication
rate and a sub acute threshold rise in the mini thoracotomy group. This leads to a
delay in the rate of improvement in peak VO> in the mini thoracotomy group.
Howeverdespite this there are comparable improvementsin all measures following
mini thoracotomy achieved CRT albeit over a longer timescale. Hence mini
thoracotomy placement of the LV lead is an acceptable alternative approach but
should remain a second-line procedure.
4.3.2 Limitations
This study is a prospective controlled trial rather than a randomised controlled one.
In view of the wide clinical evidence for transvenous lead placement wefelt it was
not possible to have a randomisedprotocol. The results have to be viewed withthis
in mind. Thetrial has relatively small patient numbers and follow up is 6 months.
Whilst this group has been large enough to showstatistically significance it is
possible that longer follow up might have highlighted some differences between the
two groups not seen in this study. As exercise tests were performed prior to CRT
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implantation it was only possible to enrol patients in NYHAIII. Patients with more
severe heart failure may potentially have more risk from a surgical placement of an
epicardial lead than the groupstudiedin thistrial.
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Conclusions
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5.1 General Conclusions
Cardiac resynchronisation therapy is a widely accepted treatment for patients with
symptomatic heart failure and evidence of electromechanical dyssynchrony. There
is now a wide body ofclinical experience with CRT which showsthat in selected
cases there are significant improvements. Howeverthere is consistently a small but
significant non responder rate which implies that our understanding of patient
selection is still limited. Detailed study of the changes following CRT is important
to understand the mechanism of action of CRT which mayassist in better patient
selection. In the first longitudinal study we showedthat patients suitable for CRT
were significantly limited. At baseline the patients’ clinical condition correlated
best with peak cardiac power output and cardiac reserve suggesting that the main
impairment is in cardiac performance. Thepatients’ perceived quality oflife scores,
as assessed by the Minnesota living with heart failure, showed surprisingly poor
correlation with any cardiopulmonary or skeletal muscle parameters. This highlights
the importance in obtaining objective functional exercise testing in patients as a
patient’s own perceived symptom level could be misleading.
Following cardiac resynchronisation therapy there were significant improvements
seen within two weeks, which were maintained for the rest of the study. This rapid
improvement suggests that the main improvement is due to a more co-ordinated
efficient ventricular contraction leading to improvements in exercise
cardiopulmonary variables and quality oflife scores. However CRTbyitself had no
impact on skeletal muscle function which has become deconditioned due to
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impaired perfusion and disuse. Skeletal muscle deconditioning is an important
cause of impaired exercise capacity in patients with heart failure. Therefore we
conclude that CRT has no effect on a major cause of symptomsin heart failure.
In the second study we confirmed that even at 6 months CRTbyitself has no effect
on skeletal muscle function and did not provide further improvementin functional
or exercise cardiopulmonary measure after the initial improvements. The addition
of exercise training 3 months after CRT lead to an improvementin peak skeletal
muscle function which was associated with further increases in functional class,
exercise duration, quality of life scores and exercise cardiopulmonary
haemodynamics. The addition of exercise training led to a near doubling of the
improvement seen in exercise duration and haemodynamic measures at 6 months
compared to CRT alone. Never before have such improvements been reported
following cardiac resynchronisation therapy.
Exercise training in addition to CRTalso helped to transform patients who had been
classified as non responders at 3 months to responders by 6 months. Thus we can
not only enhance the improvements seen following CRT but also improve the
number of patients who benefit. In the exercise group only 3 out of 25 (12%)
patients werestill non responders following CRT andexercise training. This level
of non respondersis significantly lower then has previously been described in any
major CRTtrials.
In the third study we showedthat in patients in whom transvenousleft ventricular
lead placement had been unsuccessful surgical epicardial placement of the left
194
ventricular lead placement was a viable alternative. Surgical epicardial placement
led to similar improvements to transvenous placement but in somevariables the
improvement was delayed compared to the transvenous approach. The mini
thoracotomy group also had a higher peri-operative complication rate. Therefore
form this study it has to be concluded that CRT via the transvenousroute is still is
the gold standard and that the mini thoracotomyroute is an alternative in patients
where the coronary sinus anatomyis unsuitable.
These three studies have improved our knowledge of the mechanism behind the
improvements seen following cardiac resynchronisation therapy and how to
maximise the improvements. They have provided valuable insight in to method to
approach difficult patient groups such as non responders and patients with
inappropriate coronary sinus anatomy. This information will enable physicians to
individualise therapy for patients requiring cardiac resynchronisation therapy and
therefore ensure we achieve the maximum benefit.
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Appendix 1
Methodology behind the forumale for Cardiac Power Output.
In systems with fluid flow, poweris related to pressure and the flow rate. In
the cardiovascular system the pressure is measured using the meanarterial
pressure (measured in mmHg), andthe flow rate by the cardiac output
(measured in L/min). Hence when considering the cardiac system the
formulae would be
Cardiac Power Output = Mean Arterial Pressure x Cardiac Output x K
WhereK is the conversion factor to convert the product of meanarterial
pressure and cardiac output to watts. The calculation of the conversion factor
is as follows:
CPO = 1 mmHgx | L/min
Power: 1 W=1 J/s=1 N.m/sBP: 1 mmHg = 133 N/m”
Volume: 1 L= 10° m*
Therefore
CPO = 1 mmHg x | L/min
= 133 N/m’ x 10° m*/min
= 133 x10° N.m/min
= 0.133 N.m/min
= 0.133 N.m/ 60s
= 0.133/60 N.m/s
= 0.00222 N.m/s
= 0.00222 J/s
= 2.22x10° W
Hencethe conversion factor to convert CPO from (BP mmHgx CO L/min) to CPO
in watts is
CPO W = MAP mm Hg x CO L/min x K, where K = 2.22x10°.
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iThe Cardiothoracic Centre-Liverpool s/i'/a)
aaa ease
Thomas Drive
Liverpool
L14 3PE
CONSENTFORM (Version 2, Jan 52004)
RESEARCH INTO BIVENTRICULAR PACING
AT THE CARDIOTHORACIC CENTRE
Pleaseinitial box
. Iconsent to the use ofmy “blood”for the purpose of this research.
. I confirm that I have read and understand the information sheet dated for
the above study and have had the opportunity to ask questions.
. Lunderstand that my participation is voluntary and that I am free to withdraw at
any
time,without giving any reason, without my medicalor legal rights being
affected.
. Iunderstandthat sections of any medical notes may be lookedat by responsible
Individuals from the Cardiothoracic Centre or from regulatory authorities
whereit is relevant to my takingpart in research. I give permission for
these individuals to have access to myrecords.
. Lagree to take part in the abovestudy.
 
(J
)
|
 
NameofPatient Date Signature
Nameofperson taking consent Date Signature
(if different from researcher)
1 for patient; 1 to be kept in hospital notes; 1 copy to the research labs
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Appendix 3
Minnesota Living with Heart Failure Questionnaire.
Visit Date:
Patient Name:
Baselinetest [ ], 1 week post test [ ], 6week post test [ ], 3months post test [ ],
6monthsposttest [ ].
These questions concern how yourheart failure (heart condition) has prevented you
from living as you wanted during the last month. The items listed below describe
different ways some peopleare affected. If you are sure an item does not apply to
you oris not related to your heart failure, then circle 0 (No) and go onto the next
item. If an item does apply to you,circle the numberrating how muchit prevented
you from living as you wanted. Rememberto think about ONLY THE LAST
MONTH.Didyourheartfailure preventyoufrom living as you wanted during the
last month by:
No Very Very
Little Much
1 Causing swelling in your ankles, legs, etc.? 0 1 2 3 4 5
2 Makingthe work around yourhouseoryard difficult? 0 1 2 3 4 5
3. Makingyourrelating to or doing things with your friends or 0 1 3. 4 5
family difficult?
4 Makingyousit or lie downto rest during the day? 0 1 2 3 4 5
5 Makingyoutired, fatigued, or low on energy? 0 1 2 3 4 5
6 Making your workingto earn a living difficult? 0 1 2 3 4 5
7 Making your walking aboutor climbingstairs difficult? 0 1 2 3 4 5
8 Making youshort of breath? 0 1 2 3 4 5
9 Making yoursleeping well at night difficult? 0 1 2 3 4 5
10 Making youeatless of the foods you like? 0 1 2 3 4 5
11. Making your going places away from homedifficult? 0 1 2 3 4 5
12 Making your sexualactivities difficult? 0 1 2 3 4 5
13. Makingyourrecreational pastimes, sports, or hobbies 0 1 2 3 4 5
difficult?
14 Makingit difficult for you to concentrate or remember 0 1 2 3 4 5
things?
15 Giving youside effects from medications? 0 1 2 3 4 5
16 Making you worry? 0 1 2 3 4 5
17. Making you feel depressed? 0 1 2 3 4 5
18 Costing you money on medical care? 0 1 2 3 4 5
19 Making youfeela loss of self-control in yourlife? 0 1 2 3 4 5
20 Making youstay in a hospital? 0 1 2 3 4 5
21. Making youfeel you are a burden to your familyor friends? 0 1 2 3 4 5
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